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ABSTRACT

DISEASED THYROCYTES
HAVE ABERRANT COMMUNICATION
AND TNF RECEPTOR SECRETION

by
Mary LaBue

Autoimmune diseases are a world-wide health concern and are an intense area of
investigation. However, one area of research has been largely ignored. This involves
the contribution of the target tissue to the disease process. We hypothesized that cell
cell communication is disrupted by lymphocytic infiltration and advancing fibrosis and
this disruption results in altered target cell responses to immune components produced
at the site of inflammation, including Tumor Necrosis Factor-a/p/ia (TNF-a).
We have used thyroiditis as our model of autoimmunity and have documented the
development of spontaneous thyroiditis in MRL-lpr/lpr mice. We have found aberrant
connexin expression in thyroid tissue from these mice. The abnormal gap junction
assembly persisted when the cells were removed from the inflammation site and
cultured in vitro. Primary thyrocyte cultures from these mice were also functionally
uncoupled, as indicated by decreased Lucifer Yellow dye transfer. This indicated that
mechanisms other than physical disruption were influencing intercellular
communication in diseased thyrocytes.

Protein kinase C (pKC) decreases connexin 43-mediated communication and
regulates numerous cellular properties. We found increased pKC activity in diseased
thyrocytes. This enhanced pKC activity was found to be responsible for their
decreased cell-cell communication. Furthermore, pKC also decreased T4 release from
murine thyrocytes and this decrease was partially mediated through the effect of pKC
on intercellular communication.
TNF-a did not cause cytotoxic damage to the diseased thyrocytes. We did find,
however, that the enhanced pKC activity in the diseased thyrocytes caused an increase
in soluble TNF-a receptor production. The production of soluble TNF-a receptors
was not the result of proteolytic cleavage of the cell-surface receptor. Instead, the
diseased thyrocytes may be secreting soluble receptors. We are the first to report this
mode of production for soluble TNF-a receptors.

2

UNIVERSITY LIBRARY
1©MA LINDA, CALIFORNTA
LOMA LINDA UNIVERSITY
Graduate School

DISEASED THYROCYTES
HAVE ABERRANT COMMUNICATION
AND TNF RECEPTOR SECRETION
By
Mary LaBue

A Dissertation in Partial Fulfillment
of the Requirements for the Degree Doctor of
Philosophy in Microbiology and Molecular Genetics

December 1996

Each person whose signature appears below certifies that this dissertation in their
opinion is adequate, in scope and quality, as a dissertation for the degree Doctor of
Philosophy.

Lora

Chairperson
^ Green, Associate Professor of Microbiology & Molecular Genetics

James (p. Kettering, Professor of Microbiokfgj4& Molecular Genetics

>aila S. Gridley, Professor of Microbio]

& Molecular Genetics

^ohn^T Lewis, Professor of Microbiology & Molecular Genetics

Kenneth Dorshkind, Professor of Biomedical Sciences, UCR

ACKNOWLEDGEMENTS

There were many people whose help has made this dissertation possible. I would
first like to thank Dr. Lora Green. Without her expert advice this work would not
have been possible. My thanks to my coworker Joyce Lazarus; together we made
some very stubborn primary cells grow.
I would also like to thank George Asberry and Dr. Resa Chase for their expert
tissue handling, Dr. William Fletcher, Dorothy LaJon, Judy Folz, Bill Thomas, Lisa
Kinne, Dr. Robert Stagg, Dr. Keith Colburn, Dr. John Jennings, Marilyn Malto and
Angela Godwin for their technical assistance and Jerry Bohn, Scott Hathaway,
Elizabeth Price, Valencia Taylor and Robert Pedersen for photographic processing.
Several antibodies and reagents were donated to help complete this work. My
thanks is extended to Dr. Giuseppe Molinaro (for anti-Iak monoclonal antibodies), Dr.
Kenneth Dorshkind (for anti-CD3-epsilon antisera), Dr. Carl Ware (for murine anti
human TNF-a monoclonal antibody and rabbit anti-human TNF-a antisera), Dr.
Gerald Nelson (for Grave's patient sera) and Genentec (for anti-murine TNF-R55
antisera). I am grateful to Dr. Daniel Goodenough, Dr. David Paul, Dr. Eric Beyer,
Dr. Bruce Nicholson, Dr. Dale Laird, Dr. J.P. Revel, Dr. Otto Traube and Dr. Klaus
Willecke for the gift of connexin cDNAs and antisera.
This work was financially supported by the Department of Veterans Affairs (RDIS
Green-001).

iii

TABLE OF CONTENTS

LIST OF TABLES.............
LIST OF FIGURES............
LIST OF ABREVIATIONS

x
xi

xiv

CHAPTER 1
I.

INTRODUCTION
A.
B.
C.
D.

E.
F.
G.

H.
I.

J.
K.

1

Prologue..................................................................................
Statement of Hypothesis.........................................................
Protein Kinase C.....................................................................
The Thyroid ............................................................................
1. T3 and T4 Synthesis......................................................
2. Thyroid Stimulating Hormone.....................................
Autoimmune Thyroiditis.......................................... .............
Cell - Cell Communication.......................................................
Regulation of Cell-Cell Communication by Phosphorylation
1. Regulation by PKA.......................................................
2. Regulation by PKC.......................................................
Cell-Cell Communication in the Thyroid..............................
Tumor Necrosis Factor............................................................
1. TNF -a Receptors........................................................
2. Soluble TNF-a Receptors.......................................... .
Tumor Necrosis Factor and the Thyroid.................................
Objectives ...............................................................................

1
4
4

10
11
12
14
17
21
22
22
23
23
24

25
26
27

CHAPTER 2
H.

MATERIALS AND METHODS
A.

29

Characterization of Autoimmune Thyroiditis in
MRL-lpr/lpr Mice......................................................................
1. MRL-lpr/lpr mice...................................................................
2. Tissue and serum samples.......................................................
3. Hematoxylin and Eosin (H&E) staining procedure..............
4. Immunocytochemistry............................................................ .
5. Free Thyroxine (Free T4) fluorometric
enzyme immunoassay..................................................... .
6. Enzyme-linked immunosorbent assay for the detection of
thyroid stimulating hormone in mouse sera....................
7. Enzyme-linked immunosorbent assay for the detection of
anti-dsDNA antibody in serum.......................................
iv

29
29
29
30
30

31
31
32

B.

C.

D.

8. Enzyme-linked immunosorbent assay for the detection of
anti-thyroglobulin antibodies in serum.............................
9. Enzyme-linked immunosorbent assay for the detection of
anti-microsome (Thyroperoxidase) antibodies
in MRL mouse serum.........................................................
Mechanisms Regulating Cx43-Mediated Cell-Cell Communication
in a Fetal Rat Lung Cell Line.........................................................
1. Culture of FRL cells...................................................................
2. RNA extraction from FRL cells................................................
3. ConnexincDNA probes.............................................................
4. Northern procedure for connexin mRNA from FRL cells......
5. TPA/OAG activation of pKC in FRL cells..............................
6. Electrophysiology on FRL cells................................................
7. cAMP-dependent protein kinase A (pKA) &
protein kinase C (pKC) activity assays on TPA
and OAG treated FRL cell lysates.....................................
8. Alkaline phosphatase procedure on FRL cells.........................
9. Protein Kinase C........................................................................
10. Immunocytochemistry for connexins in FRL cells.................
11. Protein extraction and Western blotting of
Cx43inFRLcells...............................................................
12. Immunoprecipitation of Cx43 in the cytosol
of FRL cells......................................................................
13. Treatment of FRL cells with transcription and
translation inhibitors ...........................................................
Reduced Cell-Cell Communication in a Spontaneous Murine
Model of Autoimmune Thyroid Disease (MRL-lpr/lpr Mice)....
1. Immunocytochemistry on murine thyrocytes and
thyroidtissue......................................................................
2. Molecular Biology........................................... ..........................
(1.) RNA extraction from murine thyroids..............................
(2.) Northern blot analysis........................................................
3. Primary culture of thyroid epithelial cells................................
4. Microinjection of murine thyrocytes.........................................
Elevated PKC Activity Can Explain the Decrease in
Cx43-Mediated Cell-Cell Communication in Thyrocytes from
Mice with Autoimmune Thyroiditis...............................................
1. Reagents.....................................................................................
2. Primary culture of thyroid epithelial cells for
inducement of follicle formation.......................................
3. Treatment to alter pKC activity in primary
thyrocytecultures...............................................................
4. Microinjections of treated and untreated
cultured thyrocytes............................................................

v

33
33
34
34
35
35
36
36
37
37
39
40
40
41
42
43
44
44
44
44
45
45
46
47
47
47
48
48

E.

5. Immunocytochemistry on treated and untreated
49
culturedthrocytes.............................................................
6. Protein kinase C activity assay on isolated thyroid cells......
49
50
7. Protein kinase A activity assay on isolated thyroid cells......
51
8. Determination of cultured thyrocyte density by MTS...........
9. Free Thyroxine (T4) assessment in culture supernatants
from non-diseased thyrocytes treated with either
51
TP A, OAG and heptanol..................................................
Thyrocytes from Mice with Spontaneous Autoimmune Thyroiditis
53
Produce the Soluble Form of the 55Kd TNF-a Receptor..........
53
1. Protein kinase C activitors and inhibitor................................
53
2. Tumor Necrosis Factor-tf/p/t<z.................................................
53
3. Antibodies................................................................................
54
4. Collagenase digestion of thyroids...........................................
5. Enzyme-linked immunosorbent assay for detection of
54
Tumor Necrosis Factor-a in sera.....................................
6. Membrane-bound TNF-a receptor sample preparation
55
for Western blotting......................................................... .
7. Soluble TNF-a receptor sample preparation for
56
Westemblotting...............................................................
8. Polyacrylamide gel electrophoresis and
57
western blotting ...............................................................
9. Sample preparation for determination of the presence of
the soluble form of TNF-R55 within intracellular membranes
58
of diseased cells.....................................................
10. Incubation of isolated thyroid ceils with modulators
58
ofpKCactivity.......................................................
59
11. Fluorescent flow cytometry..........................................
60
12. Kolmogorov-Smimov statistics..................................
60
13. Protein kinase C activity assay.....................................
61
14. Determination of relative cell density by MTS...........
61
15. Determination of TNF-a cytotoxicy...........................

CHAPTER 3
HI.

63

Results
A.

Characterization of Autoimmune Thyroiditis in
MRL-lpr/lpr Mice.................................................
1. Comparative histology of thyroid tissue
from MRL mice........................................
2. Serological findings from MRL mice used in
this study....................................................

vi

63
63
73

B.

C.

D.

Mechanisms Regulating Cx43-Mediated Cell-Cell Communication
in a Fetal Rat Lung Cell Line.......................................................... 79
1. Northern analysis of connexin mRNA....................................... 79
2. Intercellular transfer of Lucifer Yellow dye in TPA
treated FRLcells.................................................................. 79
3. Protein kinase A and protein kinase C activity induced
in FRL cells in response to TPA and OAG........................ 82
4. Effects of pKC on alkaline phosphatase treated
FRL cells ........................................................................... 88
5. i Cx43 protein localization and changes induced by activation
of pKC ............................................................................... 91
6. Post-translational processing induced by
pKC activation................................................................... 94
7. Relative levels of Cx43 mRNA in FRL cells following
treatment with TPA and OAG............................................. 97
8. Cx43 mRNA half-life............................................................... 100
9. Relative levels of Cx43 mRNA in FRL cells treated with
TPA or OAG in the presence of cycloheximide.................. 103
Reduced Cell-Cell Communication in a Spontaneous Murine Model
of Autoimmune Thyroid Disease.................................................... 106
1. Comparative histology of thyroid tissue from diseased and
control MRL mice............................................................... 107
2. Immunocytochemical detection of connexin protein
expresion in fresh thyroid tissue cryosection
from MRL mice.................................................. ................. 107
3. Connexin mRNA expression in MRL-+/+ and MRL-lpr/lpr
thyroid tissue...................................................................... 112
4. Basal state intercellular transfer of Lucifer Yellow dye in
primary thyrocytes cultures from MRL mice...................... 112
5. Immunocytochemical detection of connexin protein expression
in thyroid cultures from diseased and
non-diseased mice............................................................. 115
Elevated PKC Activity can Explain the Decrease in Cx43-Mediated
Cell-Cell Communication in Thyrocytes from
MRL-lpr/lpr Mice.......................................................................... 123
1. Basal pKC activity levels in thyroid cells from diseased and
non-dieased mice................................................................ 124
2. Immunocytochemical labeling of Tg in cultured cells from
murine thyroids................................................................... 124
3. Intercellular dye transfer in primary thyrocyte monolayers
from non-diseased mice after increasing pKC activity
with TPA or OAG............................................................... 128
4. Immunocytochemical detection of Cx43 protein expression in
cultured non-diseased thyrocytes after activation of pKC
with TPA or OAG............................................................... 132

vii

5. Intercellular dye transfer in primary thyrocyte monolayers
from diseased mice after decreasing pKC activity.......... .

E.

132

6. Immunocytochemical detection of Cx43 protein expression in
cultured diseased thyrocytes after decreasing
pKC activity........................................................................ 135
7. Effect of pKC activity on X4 release by non-diseased
thyrocytes............................................................................ 138
8. Effect of heptanol-mediated reduction of intercellular
communication on T4 release by thyrocytes from
non-diseased mice............................................................. 141
9. Effect of heptanol on protein kinase activity in isolated
non-diseased thyrocytes ...................................................... 145
Thyrocytes from Mice with Spontaneous Autoimmune Thyroiditis
Produce the Soluble Form of the 55Kd TNF-a Receptor.............. 145
1. TNF-a in non-diseased and diseased mouse sera.................... 145
2. TNF-a receptor identification and cell-surface levels in
non-diseased and diseased thyrocytes................................. 148
3. Lymphocyte and thyrocyte populations in diseased thyroids
as detected by fluorescent flow cytometry........................... 153
4. TNF-R55 levels in the plasma membrane of non-diseased
and diseased thyrocytes as detected by fluorescent
flow cytometry.................................................................... 156
5. Soluble TNF-R55 production by non-diseased and
diseased thyrocytes............................................................. 159
6. Effect of increasing pKC activity on soluble TNF-R55
production by non-diseased thyrocytes............................... 162
7. Effect of decreasing pKC activity on soluble TNF-R55
production by diseased thyrocytes....................................... 165
8. TNF-R55 plasma membrane levels after modulating pKC
activity in non-diseased and diseased thyrocytes................ 168
9. Determination by fluorescent flow cytometry of TNF-R55
levels in the plasma membrane of diseased thyrocytes
after reduction of pKC activity............................................ 171
10. Secretion of soluble TNF-R55 by diseased thyrocytes............ 171
11. Activation of pKC in non-diseased thyrocytes after
treatment with TPA and OAG............................................. 177
12. Effect of TNF-a on non-diseased and diseased
thyrocyte survival............................................................... 177

viii

CHAPTER 4
IV.

DISCUSSION
A.
B.

C.

D.

E.

183

Characterization of Autoimmune Thyroiditis in
MRL-lpr/lpr Mice........................................... ........................
Mechanisms Regulating Cx43-Mediated Cell-Cell
Communication in a Fetal Rat Lung Cell Line.........................
1. Effect of pKC on Cx43-mediated dye transfer...................
2. Immunocytochemical localization and post-translational
processing induced by pKC activation.........................
3. Effect of pKC on transcription of Cx43...............................
4. Conclusions........................................................................
Reduced Cell-Cell Communication in a Spontaneous
Murine Model of Autoimmune Thyroid
Disease (MRL-lpr/lpr Mice)...................................................
Elevated PKC Activity Can Explain the Decrease in
Cx43-Mediated Cell-Cell Communication in Thyrocytes
from Mice with Autoimmune Thyroiditis................................
Thyrocytes from Mice with Spontaneous Autoimmune
Thyroiditis Produce the Soluble Form of the
55Kd TNF-a Receptor............................................................

183
187
187
190
194
195

196

201

207

CHAPTER 5
V.

CONCLUSIONS
A.
B.

VI.

215

Significance............
Future Investigations

218
219

LTTURATURE CITED

221

ix

LIST OF TABLES

Page

Table
1.

Serological Findings of MRL Mice Examined in This Study

2.

Intercellular Dye Transfer in Primary Thyrocytes from
Autoimmune Diseased and Non-Diseased Mice......

120

PKC Activity Levels in Thyrocytes from Non-Diseased and
Autoimmune Diseased Mice..............................................

125

Intercellular LY Dye Transfer in Primary Thyrocytes from
Non-Diseased and Autoimmune Diseased Mice After
Modulations of PKC Activity.........................................

131

3.

4.

x

74

LIST OF FIGURES

Page

Figure
1.

Schematic representation of the three families of pKC isoforms

6

2.

Schematic representation of pKC activation

9

3.

Diagram representing a gap junction

19

4.

Comparative histology of thyroid tissue from MRL mice

65

5.

Immunocytochemical determination of Iak expression and B- and
T-lymphocyte distribution in MRL thyroid cryosections..........

68

Immunocytochemical localization of thyroglobulin in thyroid
cryosections from MRL mice...............................................

72

Enzyme-linked immunosorbent assay for the detection of
microsomal anti-thyroperoxidase antibodies in serum from
MRL mice ..............................................................................

77

Northern analysis of connexin mRNA expression in fetal
ratlungcells....................................................................

81

Intercellular transfer of Lucifer Yellow dye in TPA treated fetal
rat lung cells ............................................................................

84

Protein kinase A activity induced in fetal rat lung cells in
response to TPA or OAG.................................................

86

Alkaline phosphatase-mediated down-regulation of intercellular
dye transfer and reversal by microinjection of pKC................ .

90

Immunocytochemical localization of Connexin 43 protein in fetal
rat lung cells following TPA treatment.......................................

93

Western blots of Connexin 43 from microsomal/membrane and
cytosolic fractions from fetal rat lung cells following
OAG treatment ......................................................................

96

Relative levels of Connexin 43 mRNA in fetal rat lung cells
following treatment with TPA or OAG...............................

99

6.

7.

8.

9.

10.

11.

12.

13.

14.

xi

15.

Connexin 43 message half-life in response to TPA, OAG and
8Br-cAMP treatment............................................................

102

Relative levels of Connexin 43 mRNA in fetal rat lung cells
treated with TPA or OAG in the
presence of cycloheximide.................................................

105

17.

Comparative histology of thyroid tissue from MRL mice

109

18.

Immunocytochemical detection of connexin protein expression in
MRL thyroid cryosections ..........................................................

Ill

Northern analysis for connexin expression in MRL-lpr
thyroid tissue............................................................

114

Immunocytochemical labelling of thyroglobulin in cultured
thyroid cells.....................................................................

117

Basal state intercellular transfer of Lucifer Yellow dye in primary
thyrocyte monolayers from MRL mice........................................

119

Immunocytochemical detection of connexin-43 protein expression in
thyroid cultures from MRL mice.....................................................

122

23.

Immunocytochemical labeling of Tg in cultured thyroid cells

127

24.

Intercellular dye transfer in primary thyrocyte monolayers from
non-diseased mice after treatments with TPA,
OAG or heptanol.....................................................................

130

Immunocytochemical detection of Cx43 protein expression in
cultured non-diseased thyrocytes after treatments TPA,
OAG or heptanol.................................................................

134

Intercellular dye transfer in primary thyrocyte monolayers from
diseased mice after decreasing pKC activity with Calphostin C

137

Immunocytochemical detection of Cx43 protein expression in
cultured diseased thyrocytes after decreasing pKC
activity with Calphostin C....................................................

140

Effects of pKC activation and heptanol-mediated reduction of
intercellular communication on T4 release by
non-diseased thyrocytes........................................................

143

16.

19.

20.

21.

22.

25.

26.

27.

28.

xii

29.

Effect of heptanol on protein kinase activity in isolated
non-diseased thyrocytes ............................................

147

30.

TNF-a levels in non-diseased and diseased mouse sera

150

31.

TNF-a receptor identification and cell-surface levels in
non-diseased and diseased thyrocytes.........................

152

Lymphocyte and thyrocyte populations in diseased thyroids as
detectedby fluorescent flow cytometry...................................

155

TNF-R55 levels in the plasma membrane of non-diseased and
diseased thyrocytes as detected by fluorescent flow cytometry

158

Soluble TNF-R5 production by non-diseased and
diseased thyrocytes ...........................................

161

Effects of increasing pKC activity on soluble TNF-R55
production by non-diseased thyrocytes ......................

164

Effect of decreasing pKC activity on soluble TNF-R55 productin
by diseased thyrocytes................................................................

167

TNF-R55 plasma membrane levels after modulating pKC activity
in non-diseased and diseased thyrocytes.....................................

170

Determination by fluorescent flow cytometry of TNF-R55 levels
in the plasma membrane of diseased thyrocytes after reduction
of pKC activity.............................................................................

173

39.

Secretion of soluble TNF-R55 by diseased thyrocytes

176

40.

Activation of pKC in non-diseased thyrocytes after treatment
with TPA and OAG.............................................................

176

Effect of TNF-a on non-diseased and diseased thyrocyte survival

182

32.
33.
34.

35.

36.

37.

38.

41.

1

xiii

LIST OF ABBREVIATIONS

Abs

Antibodies

Ac-MBP

Acetylated myelin basic protein

AT

Autoimmune thyroiditis

BCS

Bovine calf serum

BME

Betamercaptoethanol

cAMP

Cyclic AMP

CD3

Cluster designation 3

CD45R

Cluster designation 45 receptor

CHX

Cycloheximide

CKI

PKC inhibitor protein

Cx

Connexin

DAG

Diacylglycerol

DCGs

Dense core granules

DMEM

Dulbeco's Modified Eagles Medium

DMSO

Dimethylsulfoxide

DRB

5,6-Dichloro-1 -ribo-furanosyl-benzimidazol

ds-DNA

Double stranded DNA

EAT

Experimental autoimmune thyroiditis

EDTA

Ethylenediaminetetraacetate

EGTA

Ethylene glycol-bis (p-aminoethyl ether)-N,N,N',N-tetracetic acid

FBS

Fetal bovine serum

xiv

FITC

Fluoroscein isothiocyanate

FRL

Fetal rat lung cell line

FRTL-5

Fischer rat thyroid cell line - 5

err

Guanidine thiocyanate

HBSS

Hank's balanced salt solution

H & E

Hematoxylin and Eosin

H2Iak

Murine equivalent of HLA Class II

HLA

Human leukocyte antigen

Iak

Murine equivalent of HLA

IFN

Interferon

ig

Immunoglobulin

IL

Interleukin

IL-6

Interleukin-6

ip.

Inositol-1,4,5-triphosphate

kDa

Kilodaltons

Ipr

Lymphoproliferative gene

LY

Lucifer yellow dye

MTS

3-(4-5-dimethylthiozol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium

MTT

3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide

NK

Natural killer

OAG

Octyl-2-acetyl-glycerol

PBS

Phosphate buffered saline

xv

PBST

Tween PBS

PC

Phosphatidycholine

PIP2

Phosphatidylinositol 4,5-biphosphate

pKA

cAMP-dependent protein kinase A

pKC

Protein kinase C

PL

Phospholipase

PIA2

Phospholipase A2

PLD

Phospholipase D

PMS

Phenazine methosulfate

SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SLE

Systemic lupus erythematosus

T,

Triiodothyronine

t4

Thyroxine

TBI

Anti-TSH receptor antibody

TBS

Tris buffered saline

TCR

T-cell receptor

Tg

Thyroglobulin

TPA

12-o-tetradecanoyl phorbol- 13-acetate

TPO

Thyroperoxidase

TNF-a

Tumor necrosis factor - alpha

TNF-R55

Tumor necrosis factor receptor p55

TNF-R75

Tumor necrosis factor receptor p75

TSH

Thyroid stimulating hormone
xvi

TSHr

Thyroid stimulating hormone receptor

TTBS

Tween Tris buffered saline

xvii

CHAPTER 1
INTRODUCTION

A. Prologue

Autoimmune diseases are a world-wide health concern. The consequences of
these chronic diseases, which include systemic lupus erythematosus (SLE), rheumatoid
arthritis, diabetes and thyroiditis, can vary from minimal discomfort to extreme pain
and mortality. A general definition of autoimmune disease is: An immune response
to self antigens that evokes pathologic consequences. The majority of research into
autoimmune disease has focussed on immune/genetic susceptibility and clinical
treatments. This leaves some aspects of the disease process unexplored. For example,
it remains unclear what events lead to a break in peripheral tolerance and subsequent
immunologic responses against the target tissues. In this regard, the role of the target
tissue in the disease process has been inadequately addressed. The current model of
autoimmune disease places the impetus on the immune system and views the target
tissue as a passive victim of immune attack (Reviewed in: 1). We have demonstrated
that changes in the target tissue contribute to the loss of function associated with
diseased development. Clearly, research into the etiology and target tissue
involvement in the disease process needs to be actively pursued. The work that
comprises this dissertation is focussed on the target tissue's role in the disease process.
Current models of autoimmune disease attribute the loss of function in the target
tissue to tissue destruction mediated by inflammatory processes (Reviewed in: 1). The
tissue is infiltrated by lymphocytes and macrophages, which produce cytokines in the
1
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local area (within the site of inflammation) (Reviewed in: 1). Cytokines are typically
glycoproteins which act as chemical mediators of the immune response (2). They
have diverse biological functions ranging from inducing proliferation to cytotoxicity,
with these effects being cell type and species dependent. The pleiotropic actions of
cytokines are mediated through interaction with their specific cell surface receptors.
The cytotoxic/cytostatic cytokines thought to be most important in chronic
inflammation are Lymphotoxin (LT-alpha, TNF-beta), Tumor Necrosis Factor (TNF,
TNF-alpha), Gamma-Interferon (IFN) and the Interleukins, namely Interleukin-1 and
Interleukin-6. Of particular interest in our studies is TNF-a. TNF-a was originally
isolated from macrophages but has since been isolated from a variety of cell types,
including T-cells, monocytes, B-cells and NK cells (3). Named after its anti-tumor
activity, TNF-a can also cause stimulation of bone resorption and inhibition of bone
formation (4), inhibition of proteoglycan synthesis in cartilage (5), stimulation of
collagenase and PGE2 production in rheumatoid arthritis synovial tissue (6) and the
promotion of normal fibroblast proliferation (7). The ability of TNF-a to cause
inhibition of proteoglycan synthesis while activating collagenase and promoting
fibroblast proliferation has important implications in autoimmune tissue destruction
since these factors can disrupt tissue integrity.
Cells are organized into a contiguous tissue by contact-dependent cell-cell
communication and adhesion interactions. Contact-dependent cell-cell
communication is a process mediated through plasma membrane assembled protein
channels called gap junctions. Gap junctions are composed of connexons. Connexons

3

are a hexameric assembly of gap junctional proteins, termed connexins (Cx), that form
plasma membrane spanning hemi-channels. A complete channel is formed between
cells when two hemi-channels come into register. Gap junctions link the cytoplasm
of coupled cells, thereby allowing the exchange of ions and small molecules of less
than 1 kDa in size (8). It is logical to conclude that factors that affect communication
would also affect the ability of tissues to function in a coordinated manner. Therefore,
normal cell-cell communication would be especially crucial for endocrine/exocrine
tissue which must coordinate hormonal signals. During autoimmune disease, the
extracellular matrix is altered by lymphocytic infiltration and fibrotic disruption which
can cause a loss of cell contacts by the physical separation of cells. This could result
in the subsequent loss of cell-cell communication.
Previous studies show that in transformed cells resistance to the cytotoxic effects
of TNF-a coincides with the ability of target cells to communicate amongst
themselves via gap junction formation (9). Communication competent cells were
found to be resistant to the cytotoxic action of TNF-a while communication
incompetent cells were found to be sensitive to this cytotoxin (9). We therefore
formulated an hypothesis incorporating this information. Our hypothesis stated that
fibrotic disruption during autoimmune disease could cause a loss of cell-cell
communication which results in tissue destruction through an increased sensitivity to
the cytotoxic actions of TNF-a. To test this hypothesis, we selected a model of
inflammatory disease, thyroiditis. The thyroid is an easily accessible gland with three
principle cell types. Thyroiditis presents as lymphocytic infiltration of the gland,

4
auto-antibody production, loss of tissue functions (hypothyroidism) and ultimately
fibrosis. We have characterized an induced rat model (10) and a spontaneous murine
model of this disease (described in this dissertation). The spontaneous model of
thyroiditis was used for the work that encompasses this dissertation.

B. Statement of Hypothesis

Physical disruption of thyroid tissue during autoimmune disease could cause a loss
of cell-cell communication which could result in tissue destruction through an
increased sensitivity to the cytotoxic actions of TNF-a.
C. Protein Kinase C

Protein kinase C (pKC) is a serine and threonine-specific protein kinase
ubiquitously found in tissues and organs. This enzyme is composed of a regulatory
and a catalytic domain. The regulatory domain is the amino terminal half of the
protein. It is cysteine-rich with internal duplication (conserved region 1) and can
contain binding sites specific for phospholipid, diacylglycerol (DAG), phorbol ester
and Ca2+ (11). The catalytic domain comprises the carboxyl terminal portion of the
protein and contains the ATP-binding site (conserved region 3) (11). To date, at least
nine isoforms of PKC comprising three groups have been identified (Figure 1) (11).
These isozymes are derived from three genes and alternative splicing of mRNA (12).
The first group consists of the classical isoforms, alpha, Betaj, Betan and gamma.
This group is activated by Ca2+, DAG or phorbol esters (5). The novel isoforms,
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Figure 1. Schematic representation of the three families of pKC isoforms. Alpha
(a), Beta (£) and gamma (y) isoforms have four constant regions (Cl, C2, C3, C4) and
five variable regions (VI, V2, V3, V4, V5). The Cl region has two cysteine-rich
sequences (11). The binding sites for phospholipid (PL), diacylglycerol (DAG), Ca2+
and phorbol esters (TPA) are presumed to be in the Cl and C2 regions (11) of the
regulatory domain. The ATP-binding site is in the C3 region of the catalytic
domain (11). Epsilon (s) and theta (0) isoforms are missing the V2 and C2 regions.
The Ca2+ binding site is presumably removed. Sigma (Q is also missing the V2 and
C2 regions. This isoform has only one cysteine-rich sequence in the Cl domain (11).
Extensively modified from Nishiquka (11).
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which include delta, epsilon and theta, comprise the second group and are activated
independently of Ca2+ but are capable of being activated by phorbol esters (11). The
last group of pKC isoforms is made up of the atypical sigma isoform which has only a
single set of cysteine-rich sequences (11) and is not dependent on Ca2+ for activation.
This isoform is also not activated by phorbol esters (5).
The cascade of events that activate the classical isoforms are initiated by binding
of a ligand to a receptor linked to specific G-proteins (Gp, G12, Gn, Gq) (13). This
causes a dissociation of the G-protein alpha subunit from the Beta/gamma dimer. The
alpha subunit then activates phospholipases which cause hydrolysis of phospholipids
to yield DAG, inositol 1,4,5-triphosphate (IP3) and arachidonic acid (Figure 2). IP3
mobilizes intracellular Ca2+ stores. DAG binds and activates pKC, usually in the
presence of Ca2+ (14).
There are several phospholipases which can be G-protein activated.
Phospholipase C (PLC) hydrolyses phosphatidylinositol 4,5-biphosphate (PIP2) to
produce DAG and IP3, which activates pKC as discussed above (5). Phospholipase D
(PLD) acts on phosphatidycholine to produce phosphaditic acid. Phosphaditic acid is
further converted to DAG (15). Phospholipase A2 (PLA2) also acts on
phosphatidylcholine to yield arachidonic acid which activates pKC (5). Both PLD and
PLA2 activate pKC without Ca2+ mobilization.
The ability of different phospholipases to activate pKC through the various
pathways may reflect the production of different DAG isoforms, which may selectively
activate specific pKC isoforms. PKC isoforms vary in their ability to be activated by
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Figure 2. Schematic representation of pKC activation. PI (phosphatidylinositol),
PIP (phosphatidylinositol 3-phosphate), PIP2 (phosphatidylinositol 4,5-biphosphate),
DG (diacylglycerol), IP3 (inositol 1,4,5-triphosphate), IP (phosphoinositide), PS
(phosphatidylserine), PC (phosphatidylcholine), TPA (12-o-tetradecanoyl phorbol-13acetate). Blue arrows indicate components which activate pKC.
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the various phospholipid metabolites (9,11,16,17). For example, the alpha and gamma
isoforms are less activated by DAG in the presence of phosphatidylserine (PS) than
the Betaj and Betan isoforms (11). The Beta isoforms are activated by DAG/PS even
in the absence of Ca2+ (11). The ability to be activated by arachidonic acid also varies
in the different isoforms. The gamma isoform is activated by micromolar levels of
arachidonic acid while the Beta isoforms are poorly activated (11). The alpha isoform
is activated by arachidonic acid at high concentrations in the presence of elevated
levels of Ca2+ (11). It is postulated that different isoforms of pKC are activated by the
different phospholipid metabolites, which are produced in successive phases after
pKC-linked receptor activation, in order to mediate the variety of pKC-induced
cellular responses (11).
It is clear that further understanding of the substrate specificities and activation of
the different pKC isoforms is needed to clarify the biochemical basis of signal
transduction.

D. The Thyroid

The thyroid gland is located in the throat of mammals and consists of two lobes
connected by an isthmus. The main function of the thyroid is to produce thyroxine
(T4), triiodothyronine (T3) and calcitonin (18). In mammals, the principal biological
effects of the thyroid hormones T3 and T4 are increased oxygen consumption with heat
production, stimulation of glycolysis and regulation of normal growth and cellular
differentiation (18). Calcitonin regulates serum Ca2+ levels (18).
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The thyroid is composed of three main cell types, epithelial follicular cells (70%
of the thyroid), perifollicular cell (C-cells) and fibroblasts (18). The follicular cells
are organized into a single layer enclosing a cavity to form follicles (18). The cavity
is termed the follicle lumen which is filled with the secretory products of the follicular
cells. These products include T3, T4 and thyroglobulin (Tg) (18). The follicles are
surrounded by the perifollicular cells, which are responsible for the secretion of
calcitonin (18).

T3 and T4 Synthesis
The synthesis of T3 and T4 occurs at the lumen side of the apical membrane of the
follicular cells and is dependent upon iodide and H202 concentrations and Tg
availability (18). Iodide is first transported from the blood into the follicular cells by
active transport across the basolateral membrane (19). Once in the cell, iodide is
transported to the apical membrane and is oxidized to a higher oxidation state by H202
in the presence of thyroperoxidase (TPO) (19). Upon oxidation, iodide is bound
enzymatically by TPO to the tyrosyl residues of Tg (19). Excess iodide is stored in
the follicle lumen. The iodotyrosines within Tg are then transferred and coupled to
form T3 and T4. The Tg-bound T3 and T4 must undergo proteolysis in order to be
released from Tg, along with free iodotyrosines and iodothyronines (18). The free
iodotyrosines present in the lumen re-enter the follicular cells and are deiodinated by
deiodonase for iodide reutilization (18). Furthermore, T4 can undergo additional
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processing within the thyroid and peripheral tissues in order to be converted to T3 and
reverse T3, a compound whose biological function in unknown (Reviewed in: 18).

Thyroid Stimulating Hormone and Receptor
Thyroid stimulating hormone (TSH) is secreted by the anterior pituitary (20). It
consists of two subunits, alpha and beta, with a combined molecular weight of
28.3kDa (20). This hormone is structurally related to lutenizing hormone and follicle
stimulating hormone (20). In fact, the alpha subunits of these hormones are identical
(20). Therefore specificity of receptor binding is delegated to the beta subunit.
Secretion of TSH is regulated by T/I^ through negative feedback (20). During
hypothyroidism, plasma TSH is increased due to the corresponding low thyroid
hormone levels (21-25).
The effects of TSH on thyroid metabolism include induction of proliferation,
increased iodide organification (incorporation of iodide into protein) and thyroid
hormone secretion (Reviewed in: 20). TSH exerts its effects by binding to its cellsurface receptor. The TSH receptor (TSHr) is a G-protein coupled receptor consisting
of a seven transmembrane spanning region, a short cytoplasmic region and a large
extracellular domain (20). The TSHr can be coupled to the G-protein linked to
adenylate cyclase (Gs), which activates protein kinase A (PKA), and/or to G-proteins
linked to Ca2+/phosphatidylinositol 4,5-biphosphate (PIP2), which activates protein
kinase C (pKC) (20). Activation of the cAMP cascade appears to occur at physiologic
TSH concentrations (20). At concentrations above physiologic levels (3 to 10 times
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higher, depending on species) activation of the Ca27PIP2 cascade is favored (25-27).
The fact that both cascades can be activated by TSH has led to the question of
whether there are two different TSH receptors with different affinities. The existence
of two separate TSH receptors is possible, however, the current view favors the
existence of a single receptor. This is based on a study showing that TSH can activate
both pathways in CHO cells transfected with cDNA encoding the human THRr (26).
Furthermore, plasma membrane receptor levels on these cells determined which
pathway was activated (26).
The "switching" between the cAMP-dependent cascade and the Ca27PIP2 cascade
may involve activation of the adenosine A1 receptor. In the rat thyroid cell line
FRTL-5, adenosine receptor activation resulted in an increase in PIP2 hydrolysis (27).
Alternately, treatment of these cells with adenosine deaminase sensitized the ceils to
the cAMP-dependent pathway (27).
Activation of the cAMP-dependent cascade elicit many of the known physiologic
functions of TSH, such as protein iodination and thyroid hormone synthesis and
secretion (28). Activation of the Ca27PIP2 cascade has varying effects upon thyroid
metabolism. PKC activation has been shown to induce proliferation (5). However,
other effects tend to differ according to species. As an example, in sheep (29), dog
(30) and pig (31,32) thyroid cell activation of pKC by TPA has been shown to inhibit
iodide uptake and incorporation. In mouse the opposite situation occurs, whereas TPA
stimulated iodide incorporation in thyroid follicles (33). These species-specific
differences may be due to differences in G-protein and/or pKC isoform populations.
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The actual mechanism(s) by which pKC influences thyroid function
remains unidentified.

E. Autoimmune Thyroiditis

The development of autoimmune thyroiditis (AT) appears to be the result of a
combination of predisposing and environmental factors, but is ultimately considered to
be antigen-driven and T-cell mediated (1). AT encompasses a spectrum of clinical
changes ranging from no symptoms to severe hypothyroidism (34). The pathology is
also varied with extremes ranging from large goiters with major lymphocytic
infiltration and clearly defined lymphoid follicle centers, to fibrotic atrophic glands
(Reviewed in: 34). The infiltrating lymphocytes are usually differentially distributed
with T-cells predominantly localized in interthyroidal spaces and B-cells often
polyclonal, immunoglobulin (Ig)-positive and organized into lymphoid follicle
centers (34).
A variety of circulating anti-thyroid auto-antibodies (Abs) are present and
directed against various thyroid epitopes (35). However, disease onset or severity is
not always correlated with the presence of circulating Abs to self-reactive components
(36). This is exemplified by anti-thyroglobulin (Tg) Abs that can be detected in the
sera from non-thyroidal diseased and healthy individuals, thereby, preventing their use
as a diagnostic indicator of thyroid disease. There are other anti-thyroid component
auto-Abs that have a much higher predictive value (37). Thyroperoxidase (TPO) is a
specific microsomal enzyme which functions in the processing of Tg to the thyroid
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hormones, T3 and T4 (38). Circulating anti-TPO auto-Abs correlate with lymphocytic
infiltration of the thyroid in greater than 98% of patients with thyroid dysfunction and
is being increasingly used as a definitive serological indicator of thyroiditis (39).
Thyroid follicular cells in thyroiditis, and other cells residing at sites of
autoimmune reactivity, have an induced up-regulation of human leukocyte antigen
(HLA) Class-II on their surface (murine equivalent H2 la) (34,40). The control of
B-cell maturation and immunoglobulin (Ig) class switching largely depends on helper
T-cell function, which is, in turn, dependent on HLA Class-II expression (41). In
pathologic states, in vivo, self-reactive helper T-cells probably also exert control over
pathogenic Ab production. The ability to induce AT through the transfer of thyroidreactive T-cells, in animals, demonstrates their dominant role in the disease process
(42), and has lead to T-lymphocytes becoming a focus of experimental models.
Analysis of the T-cell receptor (TCR) polymorphism on thyroid-reactive
T-lymphocytes in humans revealed a restricted expression with respect to the number
of TCR-variable(V)-tf/p/i<2 alleles represented, with no apparent restriction of the
TCR-V-beta allelic frequency (43).
Experimental autoimmune thyroiditis (EAT) can be induced in animals by
immunization with heterologous-Tg (44). This results in the production of pathogenic
anti-Tg and anti-TPO Abs (45) which are predominantly of the IgG-class (45). In
contrast, anti-Tg/TPO Abs isolated from non-thyroidal diseased or healthy individuals
are often IgM and non-cytotoxic (46). EAT in mice has also been accomplished by
transferring T-cells derived from thyroid lesions into sub-lethally irradiated mice,
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reconstituted with selective T-cell populations (47). Analysis of the TCR on thyroid
reactive T-cells, from adoptive transfer studies (47,48) and induction with Tg (44,49),
found that there was a restriction of the number of TCR-V-beta alleles expressed.
Interpreting the restriction that occurs in EAT is hampered by the induction process,
which significantly alters the resident T-cell populations (40), and therefore prevents
direct extrapolation to human AT. Non-obese diabetic mice have an increased
incidence of spontaneous AT (50). This model is highly variable and incomplete but
does offer a closer approximation to naturally occurring AT than models in which the
disease has been induced. The thyroid-reactive T-cells isolated from these mice were
also found to be TCR-V-beta restricted (51).
MRL-lpr/lpr mice are autosomal recessive for the lymphoproliferative gene (Ipr)
associated with massive B- and T-cell hyperplasia (52-54). MRL-lpr/lpr mice
develop systemic lupus erythematosus (SLE) and are extensively studied to determine
the immunologic attributes associated with the progression of systemic disease
(53,55,56). The MRL-lpr/lpr mice have high levels of circulating auto-Abs (54,57),
the best characterized of these are the anti-nuclear Abs (58). The titer of anti-double
stranded DNA (ds-DNA) Abs often varies directly with symptoms of lupus nephritis,
the usual cause of death in the MRL-lpr/lpr mice (56,59,60). The importance of the
T-cell component, in the MRL-lpr/lpr mouse model, was demonstrated by adoptive
transfer (46) and the failure of neonatally thymectomized mice to develop SLE
(55,56). The thymus is the site of tolerization with selective apoptosis occurring
through the initiation of a surface antigen (Fas) which results in the deletion of
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potentially self-reactive T-cells (61,62). The finding of defective Fas antigen
expression associated with the Ipr gene may explain the increased number of
autoreactive clones in the MRL-lpr/lpr mice and their general failed tolerance (63).
The MRL-lpr/lpr mice have been extensively analyzed with regard to their
self-reactive T-cell repertoire (64), including TCR polymorphism, which revealed a
reduced number of W-beta TCR isotypes (65). A predominant allele (y-beta-8.3) in
the MRL-lpr/lpr mice (55,65) was also identified as one of the thyroid reactive clones
in the adoptive transfer studies (46). This suggests that MRL-lpr/lpr mice could
provide a source of information on the natural distribution of T-cell phenotypes
associated with the development of thyroid-specific autoimmunity.

F. Cell-Cell Communication

Cells are linked into a contiguous tissue by contact-dependent cell-cell
communication and the extracellular matrix (66). Cell-cell communication is
mediated through gap junctions (66). Gap junctions are composed of connexons
which are hexameric assemblies of gap junctional proteins called connexins (Cx).
Connexons form hemi-channels in the plasma membrane of one cell which aligns
coaxially with hemi-channels in the plasma membrane of a neighboring cell (67).
Aggregates of numerous channels form a gap junction (Figure 3) which is capable of
mediating the intercellular movement of ions and small molecules of about IkDa in
size (66), which include metabolites (8) and participants of second messengermediated signal transduction (68-70). Seventeen Cxs have been identified with the
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Figure 3. Diagram representing a gap junction. A complete channel is composed
of two hemi-channels called connexons. Connexons are composed of hexameric
assembled proteins called connexins (Cx). (From Advances in Second Messenger and
Phosphoprotein Research, Vol. 27:163-198, edited by Shirish Shenolikar and Angus
C. Naim. Raven Press, Ltd, New York, 1993)
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following five being the best characterized: Cx43 (isolated from heart) (71), Cx32
(isolated from liver) (72), Cx26 (isolated from liver) (73), Cx37 and Cx40 (both
isolated from lung) (74,75).
Gap junction channels show rapid transitions between open and closed states.
These transitions are termed "gating". Gap junctions can be gated by free intracellular
H+ and/or Ca2+ (76-78), voltage (79,80,81,82) and phosphorylation of the Cx protein
(83,84,85). There are differences in regulation between the different types of Cxs.
For instance, Cx43 and Cx36 can be regulated by phosphorylation while Cx26 is not
(86). Furthermore, Cx32, Cx37, Cx40 and Cx26 are sensitive to regulation by voltage
while Cx43 is completely insensitive (66,70). These differences in regulation may
indicate that various Cxs mediate distinct functions. The different gap junctions may
be adjusted to the regulatory mechanisms of different cell types. This would be
relevant in organs with heterogenous cell populations that require differential
regulation. In fact, cell-cell communication has been reported to have roles in the
regulation of growth (87-90), differentiation (91) and metabolic cooperativity
(92-94,241), all of which involve a myriad of cell types. These functions of
intercellular communication are strengthened by substantial experimental evidence
showing aberrancies in Cx expression in diseased conditions (81,89,92).
In endocrine glands, hormone receptors are often asymmetrically expressed (95).
However, functional cooperation between receptor bearing cells and receptorless cells
can be orchestrated by intercellular communication. In this way, signals can be
generated or dissipated quickly by engaging only a few (receptor bearing) cells within
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a tissue thereby allowing synchronized cellular responses. There is evidence to
support that gap junctions can regulate the secretion of hormones by endocrine tissues.
For example, in coupled rat pancreatic .Beta-cells, abolishing communication by
treatment with heptanol inhibited glucose-stimulated secretion of insulin (96). Further
studies demonstrated amylase secretion from aggregated acinar cells was markedly
increased when communication was inhibited by heptanol (97). Therefore, cell-cell
communication is implicated in the regulation of hormone receipt and response.
Furthermore, these studies suggest that altered functional properties in endocrine tissue
might be explained by deficient or aberrant gap junctional communication.

G. Regulation of Cell-Cell Communication by Phosphorylation

There are numerous reports that suggest phosphorylation and the activity of
protein kinases are controlling factors of expression and function of certain connexins
(66,95,98). Recently it has been shown that Cx43 (99,100) and Cx32 (85,101) can be
phosphorylated. Cx32 is a substrate for pKA (70) and pKC (85,101). Similarly Cx43
is serine phosphorylated into at least two post-translational products as determined by
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis (99,100).
These phosphorylated forms are a 44kDa and a 46kDa species denoted as Cx43-Pl
and Cx43-P2 (99,100). These phospho-forms are in addition to a 42kDa
nonphosphorylated species referred to as Cx43-NP (99,100). The presence of
Cx43-P2 in the plasma membrane has been consistently associated with functional gap
junctional plaques (99).
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Regulation by PKA
Activation of cyclic-AMP-dependent protein kinase A (pKA) has been
demonstrated to upregulate intercellular communication (98,102). PKA increases gap
junctional formation in the plasma membrane (98,102) as well as increases the number
of open channels (103). Recent reports have focused on peptide hormones that act
through the cAMP-mediated second messenger system (95,104-106). The most
pertinent of these is the enhancement of Cx43-mediated communication by follicle
stimulating hormone in porcine ovarian granulosa cells (95,107) and by TSH in
primary rat thyroid cells (108).

Regulation by PKC
In spite of the numerous studies that have examined the involvement of pKC in
the regulation of Cx43, questions about the precise role of this enzyme remain
unanswered. In most cases activators of pKC cause a reduction or elimination of
cell-cell communication (Reviewed in: 70). However, in rat sertoli cells (109,110),
smooth muscle of human corpus cavemosum (111) and rat myocardial cells (112)
activation of pKC can increase communication. Intriguingly, in adrenal tumor cells
(113) TPA-induced activation of pKC abolished cell-cell dye transfer but had no
effect on immunoreactive Cx43 gap junctions in membranes.
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H. Cell-Cell Communication in the Thyroid

A study of rat endocrine and exocrine tissues revealed that thyroid tissue
(follicular cells) express three of the best characterized connexins; Cx43, Cx32 and
Cx26 (114). The type of connexin(s) expressed in primary thyrocyte cultures depends
on whether the cells are organized as follicles or monolayers. Monolayer thyrocytes
predominantly express Cx43 while follicles express Cx32 and Cx26 as well as
Cx43 (114,115).
Modulation of protein kinases has been demonstrated to alter intercellular
communication in normal thyroid cells (116,117). In porcine and rat thyroid cells,
activation of pKA with cAMP analogs resulted in enhanced cell-cell communication
(116,117). However, upon treatment with the pKC activator, TPA, porcine and rat
thyroid epithelial cells showed a dramatic decrease in dye transfer (116,117).

I. Tumor Necrosis Factor

Tumor Necrosis Factor-alpha (TNF-a) is a pleiotropic cytokine produced by
activated monocytes, macrophages, B-cells, T-cells and fibroblast. Secretion of
TNF-a is induced by Ca2+ mobilization and pKC activation (93,94). During secretion,
the TNF-a propeptide is processed as a membrane-bound protein attached by a signal
anchor transmembrane domain (118). This propeptide is then processed by matrix
metalloproteinase and released as the mature protein (118). The active form of
TNF-a is a homotrimer capable of binding three receptors, which induces receptor
clustering (119).
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TNF-a mediates a variety of effects upon target cells. These effects include
inducing proliferation (7), influencing protein secretion (6) and inducing cytotoxicity
(120-124). The most described effect of TNF-a is cytotoxicity. TNF-a-induced
cytotoxicity is linked to the cell cycle but does not require DNA synthesis (125).
TNF-a damages mitochondrial functions, namely electron transport (126,127), by the
generation of superoxide anion (128). Furthermore, sensitivity to the cytotoxic activity
of TNF-a has been shown to be associated with cell-cell communication. Cells
which communicate via gap junctions have been shown to be resistant to
TNF-a-induced cytotoxicity while communication incompetent cells are sensitive (9).
TNF-a Receptors
The effects of TNF-a are mediated by binding to cell-surface receptors. Two
TNF-a receptors have been identified. The type I receptor (TNF-R55-60, p55-60)
has a molecular weight of 55-60kDa while the type II receptor (TNF-R75-80,
p75-80) has a molecular weight of 75-80kDa (3). Both are members of the nerve
growth factor family of receptors (3). These two receptors have less than 25%
homology with each other with no significant homology between the intracellular
domains (129). It is not surprising then that these two receptors are linked to different
signaling mechanisms. TNF-R75-80 has been shown to induce arachidonic acid
production (130). Also, the cytoplasmic domain of TNF-R75-80 is associated with a
novel family of molecules, TNF receptor associated factor 1 (TRAF1) and 2 (TRAF2),
which may serve as signal transducers (131). TNF-R55-60 has been shown to
stimulate the activation of pKC, sphingomylinase, phospholipase A2 as well as
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inducing production of DAGs and ceramide (132). Furthermore, TNF-R55-60
induces a yet unidentified serine protein kinase whose activity is not altered by
inhibitors of pKA and pKC (133). The presence of both receptors on a cell appears to
be required for apoptosis to occur (134). When both receptors are present, it has been
shown that each receptor can mediate apoptosis through distinct pathways (130).
Soluble TNF-a Receptors
Many cytokine receptors can be found in soluble form and are usually composed
of the extracellular domain of the cell-surface receptor. The function of soluble
cytokine receptors in vivo is not fully understood. There is evidence that soluble
receptors can act as antagonists to cytokine function by competing for the ligand with
cell-surface receptors (135-137). Alternately, soluble receptors may serve as a
reservoir by protecting the ligands from proteolysis (138-140). Soluble receptors are
derived by either proteolytic cleavage of the transmembrane region of the cell-surface
receptor resulting in release of the extracellular domain (receptor shedding) or by
secretion of truncated versions derived by alternative splicing of mRNA
transcripts (141,142).
Soluble forms of both TNF-a receptors have been reported. The soluble form of
TNF-R55-60 is approximately 30kDa while the soluble TNF-R75-80 is
approximately 40kDa (143). It has been speculated that soluble TNF-a receptors
could protect cells from the effects of TNF-a by competitive binding. In support of
this, increased serum levels of soluble TNF-a receptors are found associated with
increased serum concentrations of TNF-a (144,145). Therefore, increased levels of
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soluble TNF-a receptors are found associated with certain disease states. Serum
levels of soluble TNF-a receptors have been reported to be elevated in patients with
malignancies and rheumatoid arthritis (144,145). Soluble TNF-a receptor levels are
also elevated in the synovial fluid of rheumatoid arthritis patients (145).
In cells of lymphoid origin, soluble TNF-a receptors are produced by proteolytic
cleavage (shedding) of the extracellular domain of the cell-surface receptors. In vitro,
activation of pKC by phorbol esters induces shedding of both TNF-a receptors
(140,146-148). Furthermore, binding of TNF-a to the plasma membrane receptor can
also stimulate shedding of TNF-R75-80 in the histiocytic cell line U-937 (149).
J. Tumor Necrosis Factor and the Thyroid

Increased serum levels of TNF-a have been reported in patients with autoimmune
thyroiditis (150). Additionally, human T-cells from autoimmune diseased individuals,
including those cloned from thyroid tissue taken from patients with Hashimoto's
thyroiditis, have been demonstrated to produce TNF-a (151). Therefore, TNF-a is
most likely present within the thyroid during thyroiditis. Thyroid epithelial cells as
well as the thyroid epithelial cell line, FRTL-5, possess TNF receptors and are
therefore capable of responding to this pleiotropic cytokine (152). Indeed, TNF-a has
been shown to decrease iodide organification and thyroid hormone release (153,154).
Low thyroid hormone serum levels and diminished 131I uptake are common findings in
patients with subacute and Hashimoto's thyroiditis (34). Additionally, thyroid
epithelial cells demonstrate an increase in MHC-class I expression in response to
TNF-a (155). TNF-a also acts synergistically with interferon-gamma to increase
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expression of MHC-class II (156). Increases in MHC-class I and class II expression
may contribute to autoantigen recognition by T-cells. Direct cytotoxicity by TNF-a
on thyroid epithelial cells remains questionable. TNF-a has been reported to be
cytotoxic to FRTL-5 cells but not to thyrocytes cultured from tissue taken from
patients with thyroiditis (157,158).

K. Objectives

The objectives of this work was focused on the contribution the target tissue
imparts to the autoimmune disease process. The tissue was obtained from autoimmune
diseased thyroids. The aims of this study were divided into five phases.
Phase I describes and documents the development of spontaneous thyroiditis in
MRL-lpr/lpr mice, thereby establishing these mice as a model for thyroiditis.
Phase II explored the mechanisms that lead to reduced cell-cell communication,
chiefly the effects of pKC on Cx43-mediated intercellular communication. This part
of the study utilized a fetal rat lung cell line (FRL) derived from type II pneumocytes
(159). FRL cells are highly coupled by Cx43 gap junctions and were therefore well
suited to these studies.
Phase III was concerned with the determination of reduced cell-cell
communication in thyroid tissue and cultured thyrocytes from autoimmune
diseased mice.
Though intercellular communication was reduced in diseased thyrocytes, it became
evident that physical disruption was not the cause. Therefore, phase IV extended from
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phase III with the exploration of the intrinsic differences in the diseased thyrocytes
that led to the reduced gap junctional communication. Changes in endogenous pKC
activity and its effects on Cx43-mediated communication were examined. This phase
continued with the assessment of the contribution gap junctional communication makes
to normal thyroid function.
Sensitivity to the cytotoxic effects of TNF-a is influenced by communication
competence (9). Therefore, phase V determined the sensitivity of thyrocytes from
autoimmune-diseased mice to the cytotoxic effects of TNF-a. Soluble TNF-a
receptor production was also examined since pKC was found to be elevated in the
diseased thyrocytes. PKC has previously been shown to stimulate TNF-a receptor
shedding (146).

CHAPTER 2
MATERIALS AND METHODS

A. Characterization of Autoimmune Thyroiditis in MRL-lpr/Ipr Mice

MRL-lpr Mice
The animals used in these studies were 10 week old female MRL-lpr/lpr
(diseased) and MRL-7+ (non-diseased mice) purchased from The Jackson
Laboratories (Bar Harbor, ME). The mice were housed and aged under sterile
conditions at the J.L. Pettis Veterans Medical Center Animal Research Facility, Loma
Linda, California. All animal care and treatment procedures were in accordance with
the current animal welfare act.

Tissue and serum samples
Diseased and non-diseased mice were euthanized by C02 asphyxiation and
whole blood removed by cardiac puncture prior to surgical removal of the thyroid
gland. Serum was removed from the whole blood and stored at -70°C prior to use.
The thyroid glands were taken immediately to the pathology laboratory for
cryo-sectioning. The fresh-frozen tissue was sliced in approximately 5 micron
sections starting from the outer edge of the lobe proceeding toward the isthmus. Cut
sections were placed on poly-L-lysine coated microscope slides and stored desiccated
at -70°C.
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Hematoxylin and eosin (H&E) staining procedure
Fresh frozen cryosections previously taken from MRL-lpr/lpr and MRL-V+
mice were removed from -70°C and immediately placed in room temperature 2%
paraformaldehyde solution for 15 minutes. The fixed sections were then washed in
phosphate buffered saline (0.14 M NaCl, 8 mM Na^PO^ 1.4 mM Naf^PC^.K^O, pH
7.2) (PBS) and stained with hematoxylin and eosin using standard procedures (160).

Immunocytoch emistry
Cryosections of thyroid tissue from MRL-lpr/lpr and MRL-V+ were removed
from -70°C and fixed in 2% paraformaldehyde (as described above) or by placing
them in -20°C absolute ethanol for 15 minutes. The fixed sections were rehydrated in
PBS for 5 minutes prior to the addition of primary antisera {anti-murine IaK
(hybridoma, American Type Culture Collection), Fluorescein-IsoThioCyanate (FITC)conjugated rabbit anti-mouse IgG (Accurate Scientific, Westbury NY), FITCconjugated hamster anti-mouse CD?>-epsilon (Pharmingen, San Diego, CA), and rabbit
anti-human Tg (Biomeda, Foster City, CA)]. Cryosections that received primary
antisera that was not FITC-labelled were incubated for 16-20 hours at 4°C, washed in
PBS that contained 0.05% Tween-20 (PBST), and the appropriate affinity purified
FITC-conjugated secondary antibody (2ug/mV) (all secondary antibodies purchased
from: Accurate Scientific) added for 90 minutes at 25°C. FITC-conjugated primary
antisera were incubated for 90 minutes at 25°C. The slides were then washed with
PBST and the tissue sealed with coverslips for fluorescent microscopic analysis and
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photography. The images were taken using a computer enhanced digital video
imaging system.
Controls for the detection of species cross-reactivity and non-specific binding were
included; incubating test sections with non-immune sera followed by secondary Ab, or
with secondary Ab only.

Free Thyroxine (free TJ fluorometric enzyme immunoassay
Serum samples from MRL-7+ and MRL-lpr/lpr mice were tested for free
thyroxine (T4) concentration using a Stratus (161) fluorometric enzyme assay (Baxter
Diagnostics Inc., Deerfield, IL). All data analysis was performed by the
microprocessor linked fluorescence analyzer.

Enzyme-linked immunosorbent assay for the detection of Thyroid Stimulating
Hormone in mouse sera
Rabbit anti-mouse TSH was purchased from Accurate Scientific and was used
to develop an ELISA to determine the relative concentration of TSH in the serum
from MRL-+/+ and the MRL-lpr/lpr mice.

Serum samples were diluted 1:10 in PBS

and then titrated by 2 fold serial dilution in coating buffer (0.1M Tris, pH 9.6) and
incubated overnight at 4°C. Plates were washed in PBST and a 1:200 dilution of
rabbit anti-mouse TSH added to all wells. After a 60 minute incubation at 25°C the
plates were washed and peroxidase-conjugated goat anti-rabbit IgG (2pg/ml)
(Kirkegaard and Perry Laboratories Inc. Gaithersburg, MD) was added. An additional
60 minute incubation (25°C) was followed by washing in PBST and addition of
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substrate, SjS'SjS'-Tetramethylbenzidine (TMB). The substrate reacts with specifically
bound peroxidase Ab yielding a colored product with a measurable absorbance at
650rcm. Note; all peroxidase antisera/antibodies and the TMB substrate solution used
in our ELISA's were purchased from Kirkegaard and Perry Laboratories Inc.

Enzyme-linked immunosorbent assay for the detection of anti-ds-DNA Antibody in
serum
This enzyme-linked immunosorbent assay (ELISA) has been previously
reported (162). Briefly, 96 well microtiter plates were coated with 50pg/ml poly-Llysine (Sigma Chemical Co.) in coating buffer, followed by washing in PBST.
15fxg/ml ds-DNA was added to all wells and incubated at room temperature for
45-60 minutes after which the excess was removed by washing. Human SLE sera and
mixed normal human sera (Sigma Chemical Co.) were used as controls and standard
curves obtained from (initially diluted 1:100) 2-fold serial dilutions. Control (human)
and experimental (murine) serum samples (diluted 1:50 and 1:100) were transferred to
the coated plates and incubated for 45-60 minutes, followed by washing and the
addition of peroxidase-conjugated goat anti-human and mouse IgG secondary Ab
(2pg/ml). After washing the substrate (TMB) was added and absorbance measured at
650«m.
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Enzyme-linked immunosorbent assay for the detection of anti-thyroglobulin
antibodies in serum
Serum from the diseased and non-diseased mice were screened for anti-Tg Ab
using a solid phase ELISA that we developed. This involved the binding of bovine Tg
(Sigma Chemical Co.) to a 96-well plate at a concentration of 50ng/well in coating
buffer. The plates were incubated overnight at 4°C and washed 3 times with PBST,
prior to use. Rabbit anti-human Tg (Biomeda, Foster city, CA) and pooled normal
human sera were used as positive and negative controls, respectively. A starting
dilution of 1:50 (in PBS) was used for all sera, followed by 2-fold serial dilutions.
The plates were incubated at room temperature for 45 minutes, washed with PBST and
peroxidase-labelled goat anti-mouse, rabbit, or human IgG Ab added. The plates
were washed with PBST and lOOfil of TMB substrate added to all wells. The plates
were allowed to stand for 10 to 20 minutes for complete color development and then
read on a microplate spectrophotometer at 650nm.

Enzyme-linked immunosorbent assay for the detection of anti-microsome
(Thyroperoxidase) antibodies in MRL mouse serum
An ELISA for the detection of human Ab to TPO test kit was purchased from
General Biometrics, San Diego, California. Reagents specific for mouse anti-TPO are
not readily available, however, previous studies have shown that rat anti-TPO Ab
specifically binds to recombinant human TPO (163). Basically the kit provides
96 well microtiter plates that have been pre-coated with an unstated amount of
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recombinant human-TPO. A high titer (1:100, equivalent to 850 IU) anti-TPO human
control sera is provided along with a negative control, anti-human conjugate
(secondary Ab), wash buffer and substrate.
The kit was modified for use with mouse sera by changing the conjugate from
anti-human to peroxidase-conjugated anti-mouse IgG specific secondary Ab. The
controls were run in duplicate 2-fold serial dilutions to provide a standard curve from
which the mouse titrated values could be judged. The substrate used was TMB which
was allowed to react 10-20 minutes to insure complete color development and the
optical density read at 650/im wavelength.

B. Mechanisms Regulating Cx43-Mediated Cell-Cell Communication in a Fetal
Rat Lung Cell Line

Culture of FRL cells
The epithelial fetal rat lung (FRL) cell line was provided by Dr. G. Carpenter
(Vanderbilt University, Nashville, TN). FRL is a precursor cell to type II
pneumocytes developed by Federspiel and Haralsen (159). The cells were maintained
in Dulbeccos Modified Eagles Medium (DMEM; Gibco, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS) (J.R. Scientific). They were
routinely passaged every third day by trypsinization (0.05% trypsin (w/v), 5mM
ethylenediamine tetracetate) in phosphate buffered saline (PBS) (0.14M NaCl, 8mM
Na2HP04, 1.4mM Nat^PCVE^O pH 7.2). Cells were plated onto the appropriate size
coverslips or culture dishes for use in the various experimental procedures outlined
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below and were switched to serum free medium 16-20 hours prior to use. Cells were
grown in a humidified 5%:95% (C02:Air) incubator at 37°C and not kept longer than
20 passages after revival from frozen stock. Culture was done without antibiotics and
the cells routinely tested for mycoplasma by Hoescht dye (Sigma Chemical Co.).

RNA extraction from FRL cells
Cells from which RNA was extracted were plated at IxlO5 cells/ml to yield
confluence (IxlO7 cells/lOOmm culture dish) at the time of harvest. Three dishes per
time point of treated cells were harvested in 4M guanidine thiocyanate (GIT)
(2ml/plate). Control lung, heart, and liver tissues were immediately frozen in liquid
nitrogen, ground with a mortar and pestle and homogenized in GIT (10ml/0.5gm of
tissue). The RNA was extracted from the GIT-cell or tissue lysate by CsCl
ultracentrifugation or by bulk phenol extract, respectively, followed by alcohol
precipitation and quantitated by spectrophotometry (A^A^) (164).

Connexin cDNA probes
The connexin cDNA containing plasmids were provided by: Drs. Eric Beyer
and Dan Goodenough (Cx43), Drs. Otto Traub and Klaus Willecke (Cx40 and Cx37),
Drs. David Paul and Dan Goodenough (Cx32) and Dr. Bruce Nicholson (Cx26). The
alpha-diCXm cDNA was provided by Dr. Stephen Spindler. The plasmids were
heat-shock transformed into competent cells (164), grown for quantity, and the DNA
was extracted from the cells with phenol. The cDNA inserts were cut from the
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plasmid DNA by the appropriate restriction endonucleases. Copy DNA (50-200pg)
insert was 32P-labeled using a standard random priming technique (165).

Northern procedure for connexin mRNAfrom FRL cells
11x14cm horizontal agarose gels were loaded with approximately 25pg of
RNA per lane corresponding to different samples or experimental time points. Gels
were electrophoresed at 4°C in circulating running buffer, transferred to Hybond-N
membranes, and cross-linked to the membrane by a 4 minute exposure to 300nm
irradiation. The membranes were stained with reversible dye (methylene blue) and the
ribosomal bands were marked, photographed and quantitated densitometerically.
Membranes were hybridized at 42°C for 24 hours with alpha32P-cDNA probes. After
hybridization membranes were washed (twice with 6X SSPE:0.1% SDS at 42°C for
15 minutes/wash), placed on film and developed after 3 days of exposure. The
resulting grain densities were quantitated by densitometric scanning and corrected for
differences in the total RNA loaded per lane determined from the values of the 28S
ribosomal bands and compared to the levels of a-actin RNA.
TPA/OAG activation of pKC in FRL cells
Cell monolayers were established on the appropriate size coverslips or culture
dishes and then treated with lOOnM TPA (lOOpM stock in dimethylsulfoxide) or
lOpM octyl,2-acetyl glycerol (OAG) (lOmM stock in dimethylformamide) and
harvested at various times after treatment.
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Electrophysiology on FRL cells
Cells were cultured on 25mm diameter glass coverslips in 35mm petri dishes
and incubated at 37°C for 2 days prior to the start of the experimental protocol.
Coverslips were retrieved at various times post treatment. Cell microinjections and
electrophysiology was performed exactly as described in Godwin et.al (166). Briefly,
each coverslip culture was used for < 30 minutes, during which time pH remained
stable at 7.2-7.4. Microelectrodes were filled tip-to-shank with 2% (w/v) Lucifer
Yellow in 150 mM lithium chloride and back-filled with the same diluent. Dye was
injected with 100 ms pulses at 1 Hz for 5 seconds using standard electrometers (WPI
727) and 2.5 nA cathodal current. All observations and microinjections were done on
a Zeiss IM-405 optical base (Zeiss USA, NY) equipped with a side-port mounted
silicon intensified target (SIT) camera (Dage Model 66 Seimens Tube). The camera
was connected to a high resolution video/data recorder (A.R. Vetter Company Model
875) and to a video image processing system (Image I-AT Universal Imaging) in a
microcomputer base (Zenith AT). Fluorescence images were captured using
128-frame summation with identical contrast functions for all images
within an experiment.

cAMP-dependent protein kinase A (pKA) & protein kinase C (pKC) activity assays
on TPA and OAG treated FRL cell lysates
Cells were cultured on 35mm petri dishes and at approximately 80%
confluence were treated with either lOOnM TPA or 10pM OAG. Two dishes per time
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point in duplicate were harvested over a period of 8 hours. Monolayers were washed
with cold PBS prior to harvest, with all subsequent manipulations performed on ice.
Sample preparation for the pKA activity assay was begun by adding SOOpl/dish
of pKA extraction buffer (5mM EDTA, 50mM TRIS, pH 7.4). Cells were harvested
by scraping. The suspension was sonicated, centrifuged at maximum speed in a
microfuge for 10 minutes, and the supernatant transferred to fresh tubes. Prior to
centrifugation an aliquot was taken for protein quantitation using a Bradford assay
(167). The pKA assay was performed similarly to that previously described by
Whitehouse and Walsh (168). Briefly, each lysate was divided into four tubes, two
received lOmM cAMP and two received nothing. These samples were assayed in the
presence of substrate solution (SOpM kemptide, lOOpM ATP, lOmM MgCl2,
0.25mg/ml BSA, 50mM TRIS, pH 7.5) containing approximately 5pCi gamma-32?ATP. Incubations were done at 30°C for 5-8 minutes and the reaction terminated by
spotting 20pl of each sample onto phosphocellulose discs. Prior to scintillation
counting, discs were washed twice in 1% (v/v) phosphoric acid and twice in water
(5 minutes/wash). The activity in picomoles per minute per pg of protein (Bradford)
was calculated. Controls included; purified catalytic subunit of pKA (166), catalytic
subunit without substrate (non-specific binding) and total cpm by spotting
free gamma-32?-ATP.
Sample preparation for the pKC activity assay was begun by adding 150pl/dish
of pKC extraction buffer (20mM TRIS, pH7.5, 0.5mM EDTA, 0.5mM EGTA, lOmM
BME, 0.5% Triton-X 100, 6.25pg Leupeptin, 6.25pg Aprotinin). Cell were harvested
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by scraping. The cell suspension was then freeze/thawed in liquid N2 and sheared
with a 22-gauge needle. Lysates were incubated on ice for 30 minutes to allow
disassociation of pKC from the lipid. An aliquot was removed for protein quantitation
(Bradford analysis) prior to centrifugation at maximum speed in a microfuge for
5 minutes. Supernatants were removed to clean eppendorf tubes. The pKC assay was
performed as previously described (169). The assay tubes contained 10-20pl lysate,
20mM TRIS, 50pM acetylated myelin basic protein-(4-14)(GIBCO-BRL,
Gaithersburg, MD), 20pM ATP, 2-2.5pCi gamma-32?-NY?, ImM CaCl2, 20mM
MgCl2, 0.5pg phosphatidylserine, 0.5pg phosphatidylinositol and O.lpg diolein. A
25pi sample was spotted onto phosphocellulose disks and the disks washed and
counted as described above for the pKA assay.
Four quadruplicate sets of basal pKA and pKC activities were measured and
used to normalize values. The standard error within an assay set ranged from 2-18%,
with differences between assays varying from 8-19%. The data was graphed as
relative levels of pKA or pKC activity versus time after treatment.

Alkaline phosphatase procedure on FRL cells
Using the microinjection and imaging system previously described (166),
randomly selected FRL cell(s) within a monolayer were microinjected with alkaline
phosphatase (from calf intestine-type VII NL, Sigma Chemical Co.) and used at a
final concentration of 610U/ml in the pipet. This treatment resulted in a complete
inhibition of cell to cell LY dye transfer within 5 minutes. This procedure was used
to determine the ability of purified pKC to modulate (re-open) existing Cx43 channels
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that were closed by alkaline phosphatase dephosphorylation. Purified proteins were
stored in buffers under previously documented conditions (170-173) until just prior to
use, at which time rapid buffer exchange into 150mM KCL was accomplished with
minicolumns and centrifugation chromatography (172).

Protein kinase C
Protein kinase C was prepared from bovine brain by the method of Walton
et.al (174) and then purified further by FPLC on a mono Q HR 10/10 column as
recently described (166). This bovine brain preparation was analyzed by Western
blotting and found to be a mixture of alpha, beta and gamma, the Ca++-dependent
forms of pKC (Song and Green, unpublished observation). PKC inhibitor protein CKI
was also isolated from bovine brain according to the method described by Pearson
et.al (175).

Immunocytochemistry for connexins in FRL cells
Monolayers were established on 12x12mm sterile coverslips and at
approximately 80% confluence (usually 2 days) the experimental protocols were
started. At appropriate times after treatment, coverslips were washed in PBS, fixed
in -20°C absolute ethanol for 15 minutes and rehydrated in PBS prior to the addition
of primary antisera.
Immunoreactive Cx43 was localized with rabbit polyclonal anti-sera generated
against amino acids 360-382 of Cx43 (CT-360) (176). Coverslips were incubated
with primary antibody (1:2000 in PBS) for 16-20 hours at 4°C, after which they were
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washed in PBS and affinity purified fluorescein-conjugated secondary antibody
(2pg/ml goat anti-rabbit IgG) (Kirkegaard and Perry Laboratories) was added. The
secondary antibody incubation was 90 minutes at 25°C which was stopped by washing
coverslips in PBS and mounting to microscope slides for fluorescent microscopic
analysis and photography. Untreated FRL cells were included in every protocol. As
positive controls they received both primary and secondary antibody treatment and as
negative controls they received non-immune rabbit sera and secondary antibody or
secondary antibody only to determine non-specific fluorescence.

Protein extraction and Western blotting of Cx43 in FRL cells
FRL cells were grown on 100mm dishes and at 80% confluence treated with
lOpM OAG. At various times after treatment cells were harvested by scraping in lysis
buffer (lOmM NaH2P04, 150mM NaCl, 2mM EDTA, 150mM BME, 19mM DTT,
lOpM leupeptin, 3fjiM aprotinin, 28pM E-64, 50nM pefabloc, IpM pepstatin) (100).
Protease inhibitors were obtained from Boehringer Mannheim, Germany. The
suspended cells were further disrupted by liquid nitrogen freeze/thawing and shearing
with a 22-gauge needle. The cell lysates were ultracentrifuged at 35,000xg for
60 minutes at 4°C., the supernatant (cytosolic fraction) removed, placed on ice and
Triton-X-100 and SDS added to a final concentration of 1% and 3%, respectively.
The pellet (membrane and microsomal fraction) was resuspended in lysis buffer
containing 1% Triton-X-100 and 3% SDS and incubated on ice for 45 minutes. The
cytosolic and membrane fractions were sonicated using a Kontes sonicator set at 8.5
for 3 seconds, the samples were then stored at -20°C.
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Protein (50-100jig) was loaded, without prior heating, onto a 8x10cm, 1mm
thick, 12% polyacrylamide Tris-HCl gel (Bio-Rad Laboratories, Richmond, CA) and
electrophoresed (177). Markers consisted of phosphorylase B (106kDa), bovine serum
albumin (80kDa), ovalbumin (49.5kDa), carbonic anhydrase (32.5kDa), soybean
trypsin inhibitor (27.5kDa) and lysozyme (18.5kDa) (Bio-Rad Laboratories).
Electrophoretic blotting to nitrocellulose was done at 100 volts for 75 minutes. Blots
were washed twice in Tris-buffered saline (TBS: 20mM Tris-HCl, 500mM NaCl, pH
7.5) and blocked with 3% gelatin in TBS at 42°C for 1 hour. After blocking blots
were washed in TBS containing 0.05% Tween (TIBS) for 10 minutes.
Cx43 antisera was diluted 1:2000 in TTBS with 1% gelatin added (antibody
buffer), blots were incubated overnight at room temperature with constant agitation,
washed twice in TTBS, followed by the addition of a 1:1000 dilution of peroxidase
labelled goat-anti-rabbit IgG. Secondary antibody incubation was for 3 hours at room
temperature followed by washing twice in TTBS and twice in TBS before developing.
Color development was achieved with the Bio-Rad peroxidase color development
system (Bio-Rad Laboratories).

Immunoprecipitation of Cx43 in the cytosol of FRL cells
FRL cells were treated with 100pM OAG, harvested with 200jxl of
immunoprecipitation buffer (lOmM Na^PC^, 150mM NaCl, 2mM EDTA, lOmM
leupeptin, 3pM aprotinin, 28pM E-64, 50nM pefabloc, IpM pepstatin, pH 7.0) and
disrupted as described above. Cell lysates were ultracentrifuged at 30,000 x g for
60 minutes at 4°C. The supernatant (cytosolic fraction) was removed and a 1:1000
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dilution of Cx43 antisera added. After an overnight incubation, 25pi of protein Asepharose (Gibco-BRL Grand Island, NY) was added and the samples further
incubated for 1 hour at 4°C. The immune-complexed samples were washed three
times with 1ml of wash buffer (50mM TRIS-HC1, 150mM NaCl, O.lmM EDTA,
0.5% Tween-20, pH 7.5). A final distilled water wash was decanted and the antigen
and antibody released from the staph-A sepharose by a 20 minute, 25°C incubation
with 60pl of lysis buffer. The samples were pulsed at high speed in a microfiige for
40 seconds and the supernatant transferred to clean microfuge tubes. Samples were
electrophoresed and electroblotted as described above.

Treatment of FRL cells with transcription and translation inhibitors
The effect of pKC activation on the turnover rate of Cx43 mRNA levels in
FRL cells was determined by pre-treating with 50pg/ml of the transcription inhibitor
5,6-Dichloro-l-B-D-Ribo-Furanosyl-Benzimidazole (DRB) (50mg/ml stock in
dimethylsulfoxide) plus and minus TPA, OAG or 8Bromo-cAMP with time points
harvested at 0, 1, 2, 4 and 6 hours thereafter. Cycloheximide (CHX) was used to
determine if the TPA/OAG-induced pKC effect on cell-cell communication required
protein synthesis. CHX (lOpg/ml) was given one half-hour prior to the addition of
TPA or OAG with time points harvested at 0 (absolute zero, no treatment), CHX 0
(30 minute pretreatment with CHX), 2, 4, 6, and 8 hours.
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C. Reduced Cell-Cell Communication in a Spontaneous Murine Model of
Autoimmune Thyroid Disease (MRL-lpr/lpr Mice)

Immunocytochemistry on murine thyrocytes and thyroid tissue
Thyroid cryosections or cultured cells were fixed in -20°C absolute ethanol for
15 minutes, rehydrated in PBS for 5 minutes and the primary antisera were added for
16-20 hours at 4°C. This fixative procedure solubilized the plasma membrane
sufficiently to allow access of the antisera to the cytoplasmically contained epitopes.
The primary antisera used were all rabbit polyclonal antisera, and included: anti-Cx43
antisera, CT-360, generated against amino acids 360-381 of Cx43 (178); anti-Cx32
and anti-Cx26 generated against synthetic peptides from the cytoplasmic sequences of
the respective proteins (179), and anti-human-thyroglobulin (Tg) (Biomeda). The
tissue or cells on coverslips or slides were incubated with primary antibody, after
which they were washed in PBS containing 0.5% Tween-20 (PBST) and incubated
with fluorescein-conjugated, affinity purified goat anti-rabbit IgG secondary antibody
(lOpg/ml) (Accurate Scientific) for 90 minutes at 25°C. The samples were washed in
PBST and photographed by fluorescent microscopy. Non-specific fluorescence was
determined by incubating cells with and without non-immune rabbit sera and
secondary antibody.

Molecular Biology
RNA extraction from murine thyroids: RNA was extracted from tissue using
standard procedures as described by Davis et.al. (164). Briefly, thyroid glands were
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trimmed free of extraneous tissues, cut into smaller pieces, rinsed in serum free media
and the pellet frozen in liquid nitrogen. The tissue was then ground with a mortar and
pestle, transferred to a 50 ml conical tube and sonicated in the presence of GIT
(10ml/0.5gm tissue). The RNA was extracted from the GIT-cell lysate with phenol
followed by alcohol precipitation and quantitation of RNA by
spectrophotometry (A260/A280).
Northern blot analysis: 1% agarose gels containing approximately 20pg of
total RNA were electrophoresed at room temperature (22-24°C) in circulating running
buffer. RNA was transferred to Hybond-N membranes, and UV cross-linked by a
4 minutes exposure to 300nm irradiation. The membranes were stained with
methylene blue and the ribosomal bands marked and photographed. The blots were
hybridized with alpha-32P-cDNA probes at 42°C for 36 hours, washed, placed on film
and developed after a 1-3 day exposure. Grain densities were quantitated
densitometrically and corrected for differences in the total RNA loaded per lane. The
original slicing of the thyroid tissue, prior to freezing and extraction removed many,
but not all of the loosely associated lymphocytes.

Primary culture of thyroid epithelial cells
Thyroids were excised aseptically and immediately washed in Hanks buffered
saline (Gibco) containing 2x penicillin, streptomycin and fungizone (Gibco). The
thyroid tissue was finely minced and incubated in 2mg/ml collagenase (Boehringer
Mannheim) for 60 minutes at 37°C with continuous stirring. The resulting cell
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suspension was removed from undigested thyroid tissue by gravity sedimentation and
the pellet placed in fresh collagenase for an additional 60 minutes.
The cell suspension was >80% single cells with the remaining cells in the form
of 5 to 10 cell clusters. The two collagenase supernatants were pooled, centrifuged at
500 rpm for 5 minutes and resuspended at approximately 1X105 cells/ml in
DMEM:Hams F-12 medium (Gibco) (50:50 v/v) supplemented with glutamine,
lOng/ml somatostatin, lOug/ml insulin, lOnM cortisol, 5ug/ml transferrin, lOng/ml
Gly-Lys-His (180), lx penicillin and streptomycin](Sigma Chemical Co. and
CalBiochem), and 5% bovine calf serum (BCS) (GEMINI, Calabasas, CA). The cells
were then seeded in 12 well tissue culture plates containing 12mm square coverslips
(immunocytochemistry), or in 35mm dishes containing 25mm glass coverslips
(microinjection studies). Coverslips were coated with 30ug/cm2 rat tail and rat skin
type-I collagen (Upstate Biotechnologies Inc., Lake Plascid, NY) in PBS for 1 hour at
room temperature, prior to plating. The dishes or plates were incubated undisturbed at
37C in 5%C02 for 2 days, followed by a media change to reduce the BCS to 0.5%.

Microinjection of murine thyrocytes
Microinjections were done as described under electrophysiology on FRL cells.
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D. Elevated PKC Activity Can Explain the Decrease in Cx43-Mediated Cell-Cell
Communication in Thyrocytes from Mice with Autoimmune Thyroiditis

Reagents
12-0-tetradecanoylphorbol-13-acetate (TPA) (Sigma Chemical Co.) was used as
a lOOpM stock in dimethylsulfoxide (DMSO). Octyl,2-acetyl glycerol (OAG) (Sigma
Chemical Co.) was used as a lOmM stock in DMSO. Calphostin C (Calbiochem) was
used as a lOOpM stock in DMSO. Heptanol (Sigma Chemical Co.) was used as a
300mM stock in PBS.

Primary culture of thyroid epithelial cells for inducement offollicle formation
Thyroids were excised aseptically and immediately washed in Hanks' buffered
saline (HBSS) (GIBCO) containing 2-fold concentrated penicillin, streptomycin and
fungizone (GIBCO). The thyroid tissue was finely minced and incubated in 5 mg/ml
collagenase (Boehringer Mannheim) for 60 min at 37°C with continuous stirring. The
resulting cell suspension was gravity sedimentated for 20 min to remove lymphocytes.
The pellet was placed in fresh collagenase for an additional 60 min and then gravity
sedimentated for another 20 min.
The cell suspension was more than 80% single cells, with the remaining cells in
the form of 5 to 10-cell clusters. The cells were washed with HBSS and resuspended
at approximately 1X105 cell/ml in Thyroid Medium [DMEM-Ham's F-12 medium
(Fischer Scientific, Fair Lawn, NJ) (50:50, vol/vol) supplemented with glutamine,
lOng/ml somatostatin, 20[xg/ml insulin, lOnM cortisol, 5pg/ml transferrin, lOng/ml
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Gly-Lys-His (180), 1-fold concentrated penicillin and streptomycin (Sigma Chemical
Co. and Calbiochem)] supplemented with 5% BCS (GEMINI). The cells were then
seeded in 12-well tissue culture plates or in 35mm dishes coated with 30pg/cm2 rat
tail type I collagen (Upstate Biotechnologies Inc.) in PBS for 1 hr at room temperature
before plating. The dishes or plates were incubated undisturbed at 37°C in 5% C02
for 2 days followed by a medium change to reduce the BCS to 1.5%.

Treatment to alter pKC activity in primary thyrocyte cultures
Primary thyrocyte cultures from non-diseased and diseased thyrocytes were
established in 35mm dishes. Non-diseased thyrocyte cultures were treated with either
lOOnM TPA, lOpM OAG or 3mM heptanol and incubated at 37°C for 4 hrs. Diseased
thyrocyte cultures were treated with lOOnM Calphostin C for 3 hrs. Representative
cultures of non-diseased and diseased thyrocytes were left untreated to serve as
controls. After incubation, cells were used for immunocytochemistry
and microinjections.

Microinjections of treated and untreated cultured thyrocytes
The methods for electrophysiological measurements were performed as described
in Electrophysiology’ of FRL cells except 35mm plates of cultured thyrocytes were
used instead of coverslips.
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Immunocytochemistry on treated and untreated cultured thyrocytes
Cultured thyrocytes were fixed in -20°C absolute ethanol for 15 min and the
primary antisera were added for 16-20 hrs at 4°C. This fixative procedure solubilized
the plasma membrane sufficiently to allow access of the antisera to the cytoplasmically
contained epitopes. The primary antisera used were all rabbit polyclonal antisera and
included the anti-Cx43 antiserum, CT-360, and anti-human thyroglobulin (Tg)
(Biomeda). The cells in 35mm dishes were incubated with primary antibody, after
which they were washed in PBS containing 0.5% Tween-20 and incubated with
fluorescein-conjugated affinity-purified goat-anti-rabbit immunoglobulin G (IgG)
secondary antibody (10 |xg/ml) (Accurate Scientific) for 90 min at 25°C. The samples
were washed in PBS containing 0.5% Tween-20 and photographed by fluorescent
microscopy. Nonspecific fluorescence was determined by incubating cells with and
without nonimmune rabbit serum and secondary antibody.

Protein kinase C activity assay on isolated thyroid cells
Non-diseased and diseased thyroids were collagenase digested as described for
cell culture. After digestion, cells were suspended in DMSO:BCS (1:10, vohvol) and
frozen in liquid N2 prior to use.
Cells were thawed and washed in BBSS. For determination of basal pKC activity,
non-diseased and diseased thyrocytes were resuspended directly in 150pl pKC
extraction buffer (20mM TRIS, pH 7.5, 0.5mM EDTA, 0.5mM EGTA, lOmM BME,
0.5% Triton-X 100, 6.25fig Leupeptin, 6.25fig Aprotinin). For determination of pKC
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activation in non-diseased thyrocytes by heptanol, cells were resuspended in Thyroid
Medium supplemented with 1.5% BCS and divided into 500|j.l samples of 5X105 cells
each. 3mM heptanol was then added to the samples. Samples were incubated at 37°C
with constant rocking. At the times indicated, cells were collected by centrifugation at
lOOOXg for 5 min, washed with HBSS and resuspended with 150pl of pKC
extraction buffer.
Cells in pKC extraction buffer were lysed by freeze/thawing in liquid N2 and
shearing with a 22-gauge needle. Lysates were incubated on ice for 30 minutes to
allow dissociation of pKC from the lipid. An aliquot was removed for protein
quantitation (Bradford analysis) (167) prior to centrifugation at maximum speed in a
microfuge for 5 minutes. Supernatants were removed to clean eppendorf tubes. The
pKC assay was performed as previously described (169). The assay tubes contained
10-20pl lysate, 20mM TRIS, 50pM acetylated-myeiin basic protein-(4-14) (acMBP) (GIBCO-BRL, Gaithersburg, MD), 20pM ATP, 2-2.5pCi gamma-32P-ATP,
ImM CaCl2, 20mM MgCl2, 0.5pg phosphatidylserine, 0.5pg phosphatidylinositol and
O.lpg diolein. Samples were incubated at 30°C for 5 min and the reaction terminated
by spotting 25pi of each sample onto phosphocellulose disks. Prior to scintillation
counting, disks were washed twice in 1% (vol/vol) phosphoric acid and twice in water
(5min/wash). The activity in picomoles per min per mg of protein was calculated.

Protein kinase A activity assay on isolated thyroid cells
Thyroids from non-diseased mice were collagenase digested and frozen in liquid
N2. Cells were thawed, washed in HBSS, resuspended in Thyroid Medium
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supplemented with 1.5% BCS and divided into 500pl samples of 5X105 cells each.
3mM heptanol was then added to the samples and the samples incubated at 37°C with
constant rocking. Cells were harvested at the times indicated, washed with HBSS and
resuspended in ISOpl pKA extraction buffer (5mM EDTA, 50mM Tris, pH 7.5). Cell
were lysed by freeze/thawing in liquid N2 and shearing with a 22-gauge needle. The
lysate was then centrifuged at maximum speed in a microfuge for 10 min and
supernatant transferred to fresh tubes. Prior to centrifugation an aliquot was taken for
protein quantitation by Bradford analysis (167). The pKA assay was performed
similarly to that previously described by Whitehouse and Walsh (168). Briefly, each
lysate was divided into 4 tubes, 2 received lOmM cAMP and 2 received nothing.
These samples were assayed in the presence of substrate solution (50|liM Kemptide,
IOOjxM ATP, lOmM MgCl2, 0.25mg/ml BSA, 50mM TRIS, pH 7.5) containing
approximately 5|xCi gamma-32?-AT?. Incubations were done at 30°C for 5 min and
the reaction terminated by spotting 20pl of each sample onto phosphocellulose disks.
Prior to scintillation counting, disks were washed twice in 1% (vol/vol) phosphoric
acid and twice in water (5 min each). The activity in picomoles per min per mg of
protein was calculated.

Determination of cultured thyrocyte density by MTS
Cell density was determined by a colorimetric method using 3(4,5demethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt (MTS) (Promega, Madison, WI) and the electron coupling
reagent phenazine methosulfate (PMS) (Promega). To begin, a standard curve was
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obtained. A solution of MTS/PMS was added to 10-fold serial dilutions (1X106 to
1X102 cells) of collagenase-digested non-diseased thyrocytes. The final
concentrations of MTS and PMS were 333^ig/ml and 25respectively. Cell
suspensions were incubated at 37°C for 30 min with constant rocking, after which,
cells were centrifuged and supernatant harvested. The absorbance of the supernatant
(lOOpl per triplicate sample) was then read at 490nm on a microplate
spectrophotometer. Results were analyzed by linear regression and used as standards.
A solution of MTS/PMS was added to cultured non-diseased thyrocytes at a final
concentration of 333pg/ml MTS and 25pM PMS. Cell were incubated at 37°C for
30 minutes. Supernatants were then harvested and absorbance read at 490nm. Cell
number in the cultures was then determined by comparison to the standards.

Free thyroxine (TJ assessment in culture supernatants from non-diseased
thyrocytes treated with either TPA, OAG and heptanol
Primary cultures from non-diseased mice were established. 16 hrs before use,
0.5nM Nal was added. Cell density was then determined by MTS. Media was then
changed to Thyroid Medium supplemented with 0.5% BCS and 0.5nM Nal. Cells
were incubated (37°C) for 20 hrs to allow for acclimation to the media change. Cells
were then treated with either lOOnM TPA, lOpM OAG or 3mM heptanol and
incubated (37°C) for 6 hrs. Supernatants were then harvested for free
T4 determination.
Free T4 was measured using a Stratus (161) fluorometric enzyme assay (Baxter
Diagnostics, Deerfield, IL). All data analysis was performed by microprocessor linked
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fluorescence analyzer. Sensitivity is 0.2ng/dl with a pooled standard deviation of
0.04ng/dl.

E. Thyrocytes from Mice with Spontaneous Autoimmune Thyroiditis Produce the
Soluble Form of the 55Kd TNF-a Receptor

Protein kinase C activators and inhibitor
12-0-tetradecanoylphorbol-13-acetate (TPA) (Sigma Chemical Co.) was used as
a 100pM stock in dimethylsulfoxide (DMSO). Octyl-2-acetyl glycerol (OAG)
(Sigma Chemical Co.) was used as a lOmM stock in DMSO. Calphostin C
(Calbiochem) was used as a lOOpM stock in DMSO.
Tumor Necrosis Factor-alpha
Human-TNF-a was obtained from Becton Dickinson, Bedford, MA.
Recombinant murine-TNF-a (rmTNF-a) was obtained from R&D Systems,
Minneapolis, MN.

Antibodies
Polyclonal rabbit-anti-human TNF-a antisera and monoclonal murine-anti
human TNF-a antisera was supplied by Dr. Carl Ware. Goat-anti-murine TNF-a
was obtained from R&D Systems. Rabbit-anti-murine TNF-a receptor p55 (anti-Rl)
was obtained from Genentech, South San Francisco, CA. Peroxidase-conjugated
rabbit-anti-goat IgG was obtained from Sigma Chemical Co. Peroxidase-conjugated
goat-anti-rabbit IgG, fluorescein-conjugated anti-murine CDS and fluoresceinconjugated anti-murine CD45R were obtained from GIBCO-BRL. Fluorescein-
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conjugated goat-anti-human IgG was obtained from Accurate Scientific. Fluoresceinconjugated goat-anti-rabbit IgG was obtained from Kirkegaard and Perry Laboratories
Inc. Anti-TSH receptor antisera (TBI) was obtained from Dr. Gerald Nelson.

Collagenase digestion of thyroids
Thyroids were excised aseptically and immediately washed in Hanks' buffered
saline (HBSS) (GIBCO) containing 2-fold concentrated penicillin, streptomycin and
fungizone (GIBCO). The thyroid tissue was finely minced and incubated in 5mg/ml
collagenase (Boehringer Mannheim) for 60 min at 37°C with continuous stirring. The
resulting cell suspension was gravity sedimented for 20 min to remove lymphocytes.
The pellet was placed in fresh collagenase for an additional 60 min and gravity
sedimented for another 20 min. The pellet was then washed with HBSS.
For Western blotting and pKC activity assays, the cells were frozen in liquid N2
until use. For fluorescent flow cytometry and culture, freshly digested cells were
passed through a 200-gauge screen (Sigma Chemical Co.), in order to remove large
cell aggregates, before use.

Enzyme-linked immunosorbent assay for detection of Tumor Necrosis Factor-a in
sera
The detection of TNF-a in sera from diseased and non-diseased mice was
measured using ELISA. Briefly, a 96-well plate was coated overnight at 4°C with
lOOpl/well of a 1:1000 dilution of polyclonal rabbit anti-human TNF-a antisera in
coating buffer (0.1M TRIS, pH 9.6). Before use, the plates were washed 4 times with
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PBS containing 0.05% NaN3 and 0.1% Tween-20 (washing buffer). Sera and
recombinant human TNF-a were serially diluted in PBS in a separate 96-well plate
and transferred to the antibody coated plate. Plates were incubated at room
temperature for 90 minutes, washed and lOOpl/well of 2.3pg/ml of monoclonal anti
human TNF-a antisera added. The plates were incubated at room temperature for an
additional 90 minutes, washed and lOOpl/well of peroxidase-conjugated anti-murine
IgG (2pg/ml) was added. The plate was incubated again at room temperature for
90 minutes, washed and lOOpl/well of TMB Microwell peroxidase substrate
(Kirkegaard and Perry Laboratories Inc.) added. Absorbance was then read at 650nm.

Membrane-bound TNF-a receptor sample preparation for Western blotting
For determination of TNF-a receptors on non-diseased and diseased thyrocytes,
cells were resuspended in 200pl of HBSS with 0.2% BCS (GEMINI). Murine TNFa was added at a final concentration of lOOnM and cells were then incubated at 4°C
for 1 hr. After incubation, mTNF-a was crosslinked to the receptor by the addition of
EGS [ethylene glycolyl, bis (succinimidyl succinate)] (Sigma Chemical Co.) to a final
concentration of ImM. Cells were incubated at 4°C for 30 min more. The reaction
was stopped by the addition of 1ml of lOmM glycine in HBSS. Cells were then
washed twice with HBSS and resuspended in 500pl immunoprecipitation buffer
(lOmM NaH2P04, 150mM NaCl, 2mM EDTA, lOmM Leupeptin, 3pM Aprotinin,
28pM E-64, 50nM Pefabloc, IpM Pepstatin, pH 7.0) (inhibitors were purchased from
Boehringer Mannheim). Cells were lysed by freeze/thawing in liquid N2 and shearing
with a 22-gauge needle.
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Cellular membranes were isolated by ultracentrifugation at 100,000Xg for 1 hr at
4°C. Membrane pellets were resuspended in 220pi immunoprecipitation buffer with
2% NP-40 (Calbiochem) and incubated on ice for 30 min. A 20pi aliquot was
removed for protein quantitation (Bradford analysis) (167). Equivalent amounts of
protein from each sample in a given experiment were removed and the final volume
brought to 200pl. Samples were then immunoprecipitated by the addition of 4pl of
Ipg/ml stock anti-murine TNF-a. Samples were incubated for 16-20 hrs at 4°C with
constant rocking. The immune-complexed samples were isolated by the addition of
lOOpl protein A-sepharose (GIBCO-BRL) and incubated for 1 hr at 4°C. After
incubation, the samples were washed 3 times with 1 ml wash buffer (50mM TRIS,
150mM NaCl, O.lmM EDTA, 0.5% Tween-20, pH 7.5). A final distilled water wash
was decanted and the antigen and antibody released from the protein A-sepharose by
a 20 min, RT incubation in 35pl lysing buffer (lOmM Na^PC^, 150mM NaCl, 2mM
EDTA, lOmM Leupeptin, 3pM Aprotinin, 28pM E-64, 50nM Pefabloc, IpM
Pepstatin, 150mM BME, 1% Triton-X-100 and 3% SDS). The samples were pulsed
at high speed in a microfuge for 40 sec and the supernatant transferred to clean
microfuge tubes. Samples were then electrophoresed and Western blotted.

Soluble TNF-a receptor sample preparation for Western blotting
Liquid N2 frozen collagenase-digested non-diseased and diseased thyrocytes were
thawed, washed with HBSS and resuspended in 500pl serum free Thyroid Medium
[DMEM-Ham's F-12 Medium (Fischer Scientific) (50:50, vol/vol) supplemented with
glutamine, lOng/ml somatostatin, 20pg/ml insulin, lOnM cortisol, 5pg/ml transferrin,
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lOng/ml Gly-Lys-His (180), 1-fold concentrated penicillin and streptomycin (Sigma
Chemical Co. and Calbiochem)]. Cells were incubated at 37°C for 4 hrs with constant
rocking. After incubation, cell viability was checked by tryphan blue exclusion and
supernatants were harvested. 100pi of supernatant was immunoprecipitated with antiR1 (final concentration of 30pg) as described for membrane samples.
Polyacrylamide gel electrophoresis and Western blotting
Markers and samples (total volume of 35pi) were heated at 90°C for 5 min and
then loaded onto a 8X10cm, 1mm thick, 12% polyacrylamide TRIS-HCL gel (BioRad Laboratories) and electrophoresed (177). Markers consisted of Posphorylase B
(106kDa), bovine serum albumin (80kDa), ovalbumin (49.5kDa), carbonic anhydrase
(32.5kDa), soybean trypsin inhibitor (27.5kda) and lysozyme (18.5kDa) (Bio-Rad
Laboratories). Electrophoretic blotting to nitrocellulose was done at 100 volts for
75 minutes. Blots were washed twice with TBS and blocked with 3% gelatin in TBS
at RT for 1 hr. After blocking, blots were washed in TBS containing 0.05% Tween20 (TTBS) for 10 minutes at room temperature.
Primary antibodies were diluted in TTBS with 1% gelatin (antibody buffer).
Anti-murine TNF-a (Ipg/ml stock) was diluted 1:500 and rabbit-anti-Rl (7.4mg/ml
stock) was diluted 1:1000. Blots were incubated overnight at room temperature with
constant agitation, washed twice in TTBS, followed by the addition of peroxidaseconjugated secondary antibodies. Peroxidase-conjugated rabbit-anti-goat IgG was
diluted 1:500 in antibody buffer. Peroxidase-conjugated goat-anti-rabbit IgG was
diluted 1:1000 in antibody buffer. Secondary antibody incubation was for 3 hrs at
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room temperature followed by washing twice in TTBS and twice in TBS before
developing. Color development was achieved with the Bio-Rad peroxidase color
development system (Bio-Rad Laboratories).

Sample preparation for the determination of the presence of the soluble form of
TNF-R55 within the intracellular membranes of diseased cells
Frozen collagenase-digested diseased cells were thawed, washed 2 times in HBSS,
suspended in Thyroid Medium with 0.2% BCS. Cells were incubated at 37°C for
4 hrs. After incubation, viability was checked by tryphan blue exclusion. Cell were
then harvested, resuspended in 500pl HBSS with 0.2% BCS and mTNF-a (lOOnM
final concentration) added. Binding of mTNF-a and crosslinking with EGS was done
as described for membrane-bound TNF-a receptor sample preparation.
Receptor:TNF-a complexes were removed by incubation at 4°C for 1 hr with protein
A-sepharose (GIBCO-BRL). After incubation, samples were centrifuged at 3000 rpm
in a microfuge and supernatant was collected. Receptors were immunoprecipitated by
the addition of anti-Rl (30pg final concentration). Samples were incubated overnight
at 4°C with constant rocking. Protein A-sepharose was then added and the
antigenrantibody complexes were isolated as described for soluble TNF-a receptor
isolation. Samples were then electrophoresed and Western blotted.

Incubation of isolated thyroid cells with modulators of pKC activity
Isolated non-diseased thyrocytes were resuspended in Thyroid Medium with 0.2%
BCS (for membrane-bound TNF-a receptor determination) or serum free Thyroid
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Medium (for soluble TNF-a receptor determination) and divided into 2 aliquots. One
aliquot was left untreated while the other was treated with lOOnM TPA (final
concentration) or lOpM OAG (final concentration). Isolated diseased thyrocytes were
also resuspended in Thyroid Medium with 0.2% BCS (for membrane-bound TNF-a
receptor determination) or serum free Thyroid Medium (for soluble TNF-a receptor
determination) and divided into 2 aliquots. One aliquot was left untreated and the
other was treated with lOOnM Calphostin C (final concentration). Cells were
incubated at 37°C for 4 hrs with constant rocking. After incubation, cell viability was
determined by trypan blue exclusion and the cells or supernatants were then collected.
Cells were resuspended in HBSS with 0.2% BCS. For membrane-bound TNF-a
receptor analysis by Western blotting, mTNF-a was added and crosslinked, the
membranes isolated and receptor:TNF-a complexes immunoprecipitated. For
fluorescent flow cytometry, anti-Rl was added to the cells. Supernatants were
immunoprecipitated with anti-Rl, electrophoresed and Western blotted.

Fluorescent flow cytometry
Freshly digested non-diseased and diseased thyroid cells were resuspended in
200|xl HBSS with 0.2% BCS and primary antibody added. For determination of the
lymphocyte population in the diseased cell preparation, lOpl of rat sera was added and
cells were incubated at 4°C for 10 minutes before the addition of 1.5pg fluoresceinconjugated anti-murine CDS and 1.5pg fluorescein-conjugated anti-murine CD45R.
For determination of the thyrocyte population in the diseased cell preparation, 13.6p,g
of TBI was added. For determination of TNF-R55 on both the non-diseased and
diseased thyroid cells, 15pg anti-Rl was added. After addition of primary antibody,
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cells were incubated at 4°C for 30 minutes with constant rocking. Cells were then
washed twice with 1 ml HBSS with 0.2% BCS. Cells were resuspended in 200pl
HBSS with 0.2% BCS and secondary antibody added. For determination of the
thyrocyte population, l.Spg fluorescein-conjugated goat-anti-human IgG was added.
For determination of TNF-R55, 5pg fluorescein-conjugated goat-anti-rabbit IgG.
(No secondary antibody was needed for the determination of the lymphocyte
population.) Cells were then incubated at 4°C for another 30 minutes with constant
rocking. After incubation, cells were washed once with HBSS with 0.2% BCS and
once with serum free HBSS. Cells were resuspended in 300pl of 2%
paraformaldehyde (Ted Pella, Redding, CA).
Cells were evaluated with a FACSort flow cytometer (Becton Dickenson,
Mountain View, CA). Forward scatter was set at E00, side scatter was set at 315,
FL-1 was set at 370. Results were analyzed by Kolmogorov-Smimov statistics.

Kolmogorov-Smirnov statistics
Kolmogorov-Smimov (K/S) two-sample test uses the summation of the curves
and the number of positive events in each histogram to calculate an index of
similarity. This gives the probability that two histograms are different.
Calculations were done using LYSYS II software (Becton Dickenson).

Protein kinase C activity assay
PKC activity assays on isolated non-diseased thyrocytes was done as described
under Protein kinase C activity assay on isolated thyroid cells except cells were
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treated with lOOnM TPA or lOfxM OAG (final concentrations). Samples were
incubated at 37°C with constant rocking. At the times indicated, cells were harvested,
washed with HBSS and resuspended with 150pl of pKC extraction buffer (20mM
TRIS, pH 7.5, 0.5mM EDTA, 0.5mM EGTA, lOmM BME, 0.5% Triton-X-100,
6.25pg Leupeptin, 6.25(jig Aprotinin).
Determination of relative cell density by MTS
Fresh collagenase-digested thyrocytes from non-diseased and diseased mice were
cultured in 96-well plates as previously described in Primary culture of thyroid
epithelial cells for inducement of follicle formation. Once a confluent monolayer was
obtained, cell density was determined by a colorimetric method using 3(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt) (MTS) (Promega) and the electron coupling reagent phenazine
methosulfate (PMS) (Promega). A solution of MTS/PMS was added to cultured
thyrocytes at a final concentration of 333pg/ml MTS and 25pM PMS. Cells were
incubated at 37°C for 30 min. Supernatants were then harvested and absorbance read
at 490nm on a microplate spectrophotometer. New Thyroid Medium with 1.5% BCS
was then added before the addition of TNF-a.
Determination of TNF-a cytotoxicity
After relative cell density was determined by MTS, 70nM (final concentration) of
mTNF-a was added to the cells. Matched wells were left untreated to serve as
controls. The cells were incubated at 37°C for 48 hrs. After incubation, cytotoxicity
was determined using 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide
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(MTT) (Sigma Chemical Co.) as previously described (181). Briefly, 20pi of MTT
stock solution (5mg/ml) was added to the cells. The cells were incubated at 37°C for
4 hrs, after which, supernatant was removed. Cells were then lysed and the MTT
formazan solubilized by the addition of 100pi of acidified isopropyl alcohol (0.04N
HCL in isopropanol). The optical density at 570nm was then measured with a
microplate spectrophotometer and percent cytotoxicity determined after adjustments for
variations in cell density.

CHAPTER 3
RESULTS

A. Characterization of Autoimmune-Thyroiditis in MRL-Ipr/lpr Mice

This investigation was initiated to determine if MRL-lpr/lpr mice
spontaneously develop thyroiditis as part of their systemic disease. Evidence is
presented here that includes: reduced serum levels of thyroxine, increased levels of
TSH, the presence of high concentrations of circulating anti-thyroid auto-Ab,
expression of H2 IaK and morphologic changes that were not detectable in agematched, non-diseased, allelic counterpart MRL-7+ mice. The data supports that the
MRL-lpr/lpr mouse is a suitable model for the study of spontaneous AT.

Comparative histology of thyroid tissue from MRL mice
The thyroid glands obtained from the MRL mice were not paraffin embedded
because it would interfere with a number of subsequent tests to be performed on the
tissue (manuscript in preparation). Paraffin adds to the rigidity of the tissue and when
sectioned, the thyroid follicles are sliced through, giving the morphological structure of
exposed lumenal surfaces. As a result of sectioning fresh tissue, the H+E staining of
the MRL mouse thyroid tissue in Figure 4 does not show typical open follicles. The
slices of thyroid tissue obtained from the periphery of the lobe tended to be composed
of small, nearly uniform follicles which increased in size as sectioning proceeded
toward the center of the thyroid lobe. The larger central follicles were sectioned
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Figure 4. Comparative Histology of Thyroid Tissue from MRL Mice. Fresh frozen thyroid sections
were paraformaldehyde fixed and stained with hematoxylin-eosin. Thyroid tissue from MRL-V+ mice have
a normal, sparse scattering of non-aggregated lymphocytes (panel a (40X magnification)) and relatively
small thyroid follicles (panel b (SOX magnification)) which are characteristic of sections taken from the
peripheral edge of the lobe. In contrast, similarly obtained sections from MRL-lpr/lpr mouse thyroids
revealed massive infiltration organized into lymphoid follicle centers (panel c (40X)) and extensive
interstitially distributed mononuclear cells (panel d (SOX)).
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through exposing thyroid follicular lumenal surfaces. The increasing follicular size
distribution was similar for both MRL-7+ and MRL-lpr/lpr mouse thyroid tissue.
The thyroid tissue required fixing prior to subjecting it to the H+E staining
procedure which involves multiple washing steps that would potentially remove
unanchored infiltrating cells. Paraformaldehyde was selected for its crosslinking
properties. The fixed sections from MRL-7+ mouse thyroid show sparsely distributed
mononuclear cells throughout the epithelium [Figure 4, panel a (40X magnification)
and panel b (BOX magnification)] with an occasional small cluster of leukocytes
observed (not shown). The MRL-7+ thyroid was essentially negative with regard to
lymphocytic infiltration in comparison to the MRL-lpr/lpr mouse thyroid tissue.
When screening serial sections from diseased mice, following H+E staining, it became
evident that the heaviest concentration of infiltrating lymphocytes were located in
sections obtained from the peripheral portion of the thyroid lobe. Numerous lymphoid
follicle centers (Figure 4, panel c (40X magnification)) and extensive interstitially
distributed lymphocytes (Figure 4, panel d (BOX magnification)) are evident. Centrally
obtained sections were also heavily infiltrated but clearly less than the outer edges of
the thyroid lobes (data not shown). All of the MRL-lpr/lpr mouse thyroids examined
(n=33) had >50% of a given field occupied by infiltrating cells. This has been
previously designated severe or +4 thyroiditis (50).
To better characterize the autoimmune reaction taking place in the MRL-lpr/lpr
mouse thyroid tissue, IaK expression and the distribution of infiltrating lymphocytes
was determined by immunocytochemistry (Figure 5). To test for thyroid follicular cell
expression of H2 IaK surface protein, thyroid tissue cryosections were fixed in -20°C
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Figure 5. Immunocytochemical Determination of IaK Expression and B- and
T-lymphocyte Distribution in MRL Thyroid Cryosections. Fixed tissue sections
from MRL-+/+ Mice (non-diseased)(a,c,e) and MRL-lpr/lpr Mice (diseased)(b,d,Q
were incubated with anti-IaK (a and b), anti-mwrme IgG (c and d), and anti-CD3epsilon antisera (e and f). The non-diseased tissue is negative for all three, it does
not express IaK and is not infiltrated by lymphocytes. Whereas, the diseased tissue
expresses high levels of IaK on the thyroid follicular cells (panel b), has
B-lymphocytes organized as lymphoid follicular centers (panel d) and T-lymphocytes
interstitially distributed (panel f). Magnification 120X.
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absolute ethanol which maintains the integral membrane protein structure but does
notretain the infiltrating (loosely associated) cells. MRL-+/+ thyroid tissue does not
express detectable levels of IaK as is evident by the negative immunofluorescence,
represented in Figure 5, panel a. In contrast, the diseased thyroid cryosections were
intensely positive for immunofluorescent labelling, indicating that high levels of IaK
was being expressed on the surface of these cells (Figure 5, panel b). The intensity
was so bright that an additional blocking filter was inserted to protect the camera. All
the other images in the composite labelled Figure 5 (panels a,c,d,e,f) were taken with
identical optical parameters for comparative purposes.
The identification and localization of B-lymphocytes within the thyroid tissue
was performed on cryosection that had been fixed in 2% paraformaldehyde (as in the
H+E staining described above) prior to the addition of FITC-conjugated rabbit anti
mouse IgG specific antisera. MRL-+/+ thyroid tissue is not infiltrated with
lymphocytes and does not specifically bind the anti-IgG antisera (Figure 5, panel c).
The MRL-lpr/lpr thyroid shown in Figure 5, panel d, reveals an illuminated aggregate
(lymphoid follicle center) of Ig+ B-cells within the diseased tissue. The T-cells
localization study employed an antisera that recognized CDS component epsilon. This
required that the cryosections be fixed first in 2% paraformaldehyde, to retain the
lymphocytes, and then in absolute ethanol to permeablize the lipid, allowing access to
the cytoplasmic epitope. The non-diseased thyroid tissue did not specifically bind the
anti-CD3 antisera (Figure 5, panel e). The additional fixing step resulted in a loss of
many lymphocytes, however immunofluorescence was detected in the diseased tissue
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in inter-follicular spaces. Shown in Figure 5, panel f, is a group of T-cells adjacent
to a follicle similar to that depicted in the H+E staining Figure 4, panel d.
Further histologic examination of the MRL-lpr/lpr thyroid sections revealed
that approximately one out of every five (20%) fields examined microscopically
contained lymphocytic foci, and 10-15% of these B-cell clusters were associated with
atrophic thyroid follicles. The MRL-lpr/lpr thyroid tissue was relatively more fluid
with more interstitial space between follicles (Figure 4, panels c and d; Figure 5,
panels b,d,f) than the MRL-7+ thyroid tissue (Figures 4, panels a and b; Figure 5,
panels a,c,e). Fibrosis in the diseased thyroid tissue was minimal, evident in less than
one field per one-hundred examined (<1%). When detected it was located in areas of
small atrophic thyroid follicles adjacent to lymphocytic aggregates (data not shown).
The tissue sections shown in Figure 6 were obtained from the center of the
thyroid lobe and reveal large follicles that have been sliced through. The fixative
solution used on these slices was absolute ethanol which permeablizes the plasma
membrane allowing access of the rabbit anti-human-Tg Ab and the fluorescent
secondary goat-anti-rabbit Ab to the cytoplasmically contained Tg epitopes. This
procedure provides no crosslinking and therefore does not retain the infiltrating cells.
The MRL-7+ (panel a) and the MRL-lpr/lpr (panel b) tissue sections show positive
immunofluorescent staining for cytoplasmic Tg. The diseased thyroid tissue
(Figure 6, panel b) consistently labelled with greater fluorescent intensity than did the
non-diseased mouse thyroid tissue (Figure 6, panel a). This suggests that the diseased
thyrocytes may be producing relatively more Tg than the non-diseased thyrocytes.
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Figure 6. Immunocytochemical Localization of Thyroglobulin in Thyroid Cryosections from MRL
Mice. Absolute ethanol fixed fresh frozen thyroid sections were labelled with rabbit polyclonal anti-human
Tg and fluorescein-conjugated goat anti-rabbit IgG secondary Ab. Thyroid tissue sections obtained from
the center of the lobe have a generally larger follicle size and, as shown here, MRL-+/+ (panel a) and
MRL-lpr/lpr (panel b) thyroid tissue label positive for Tg. The Tg was localized to the cytoplasm of the
epithelial cells that line the exposed lumenal surfaces of the thyroid follicles. This binding of anti-Tg was
not evident in the control MRL-+/+ sections that were incubated with non-immune rabbit sera and
fluorescent secondary Ab (panel c). The magnification of the tissue is 120X.
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MRL-7+ thyroid tissue was incubated with non-immune rabbit sera to test for species
cross-reactivity and non-specific binding (panel c), and as shown here was negative
for immunofluorescence.

Serological findings from MRL mice used in this study
Sera from MRL-lpr/lpr and MRL- +/+ mice were fluorometrically tested for
Free-T4 concentration and for the presence of TSH, anti-dsDNA and anti-thyroid Abs
by ELISA, the results are compiled in Table 1. The data was obtained in two sets, the
first included 5 non-diseased and 5 diseased and the second included 8 non-diseased
and 10 diseased subjects. Statistical calculations were performed by set and compared,
the results revealed that the second set yielded equivalent or better "p" values then the
first set. However, the difference between diseased and non-diseased were significant
for all parameters measured. The values listed in Table 1 lists the average values
obtained when sets one and two were combined.
The non-diseased mice had an average level of 2.23ng/dl of Free-T4 whereas,
the diseased mice had an average level of 1.34ng/dl in their serum (Table I,
column 1). This is a 40% decrease in Free-T4 which was determined to be highly
significant (p=< 0.001) using the manova statistical analysis program. The values
obtained and reported in Table I (column 2) for serum TSH levels are relative
measurements, in that they were not quantitated against murine TSH. They are listed
as the average optical density values of duplicate samples times 10. The average
serum TSH level for the MRL-+/+mice was 1.88 and for the MRL-lpr/lpr mice was
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Table 1.
Serological findings of MRL mice examined in this study
Free T/
Subjects
TSH” Anti-ds-DNAc
Anti-Tgd
Anti-TPO'
MRL-V+
1 N1
2.04
NT
56
0
0
1.84*
1 N2
NT
48
0
2
1 N3
2.28
NT
206
0
NT
1 N4
2.22
NT
78
0
NT
2.05’
1 N5
NT
149
0
NT
2N6
2.41
1.99
80
0
2
2N7
2.44
1.50
42
0
3
2N8
2.41
2.46
75
10
2
3.07
2N9
2.56
120
0
1
2 N10
2.14*
1.50
79
10
1
2 Nil
2.14*
1.67
45
6
0
2 N12
2.14’
1.58
50
4
1
2 N13
NT
1.79
200
2
1
Meanf
2.23±0.23
1.88±0.42
96.89±60
2.5±2
1.4±0.84
MRL-lpr/lpr
1 D1
1.69*
3.00
559
200
700
1 D2
1.20
NT
404
2050
NT
1 D3
1.23*
3.60
970
>3500
>1000
1.64*
1 D4
NT
389
600
NT
1.44
1 D5
NT
317
290
NT
2D6
1.28*
3.32
380
700
925
2 D7
1.38*
3.80
400
925
720
2 D8
0.99’
2.30
200
1240
600
2 D9
1.43*
2.75
300
400
550
2 D10
1.24*
3.00
290
690
670
2 Dll
1.25*
2.68
210
910
600
2 D12
1.49*
3.45
200
620
665
1.18*
2 D13
2.20
800
830
620
2 D14
0.99*
2.30
982
900
678
2 D15
1.21*
2.00
905
810
652
Meanf
1.34±0.20
2.85±0.57
497.25±284 1065±811
694.62±128
a) Units in ng/dl, sensitivity 0.2ngfdl with a pooled standard deviation of 0.04ng/dl.
b) Optical Density (times 10).
c) Relative units.
d) Values normalized to standard, units equivalent to dilution giving half-maximum
(0.5) optical density.
e) International Units (IU).
f) Mean value plus and minus standard error.
NT= Not Tested, insufficient serum.
*= The sample was undiluted.
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2.85. This reflects an approximate 30% higher level of TSH in the serum of the
diseased mice (p< 0.001).
The ELISA to measure ds-DNA employed a high titer SLE-diseased human sera
as a standard. The resulting curve was used to calculate values obtained from the
mouse samples. The 1:100 dilution of the human sera gave an optical density
measurement of 1.00 OD units and was assigned an arbitrary unit value of 1000. The
values obtained from the mouse sera were extrapolated from the curve and assigned a
corresponding, relative unit value. The non-diseased mice had an average
anti-ds-DNA Ab of 97 units, with a five-fold difference between the lowest (42) and
the highest (206). The diseased mice had an average anti-dsDNA level of 497 units
with an approximate four and one half-fold difference in the highest and lowest values
measured (Table 1, column 3). The differences between diseased and non-diseased
subjects were significant (p=< 0.01).
The measurement of anti-Tg in the murine sera was performed using our
ELISA. The positive control was rabbit polyclonal anti-human-Tg which was diluted
1:50 and further titrated to provide a standard curve. The mouse serum samples were
titrated, normalized to the standard and reported as units equivalent to the dilution of
sera giving a half maximal optical density (0.5 OD). The non-diseased mouse sera
were negative for the presence of anti-Tg Ab. The diseased mouse sera were always
positive, but the difference between the lowest (200) and highest (>3500) unit value
was 17-fold (Table 1, column 4). Statistically the results were within acceptable
limits (p< 0.01) and the percent error between duplicate samples 6 to 11% and
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Figure 7. Enzyme-Linked Immunosorbent Assay for the Detection of
Microsomal Anti-Thyroperoxidase Antibodies in Serum from MRL Mice. Serum
samples were initially diluted 1:100 in PBS followed by two-fold serial dilutions.
Shown here are samples from: ( £ ) Positive control human anti-human TPO,
( Q ) mixed normal human sera (negative control), ( □ ) MRL-7+ N1 (nondiseased mouse #1), ( A ) MRL-7+ N2 (non-diseased mouse #2), ( | ) MRLIpr/lpr D1 (diseased mouse #1) and ( A ) MRL-lpr/lpr D3 (diseased mouse #3).
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between duplicate trials 8 to 14%. The second set of mice (D6-D15) showed
considerably less variation and a "p" value of less than 0.001.
Measurements for the detection of anti-TPO Ab in the MRL mouse sera used a
commercially available ELISA. The control standard provided was a 1:100 dilution of
human sera with a high titer of anti-TPO Ab. Used at this dilution it gave an OD of
1.00 and an assigned international unit value of 850 IU. Standard curves for the
positive control sera and a pooled normal human sera, that we added as a negative
control, are shown along with serum titration from two non-diseased and two diseased
mice in Figure 7 (standard error bars indicated). Units for the mouse sera were
derived from the known units assigned to the control. The MRL-V+ mice were
essentially negative for anti-TPO Ab (1.4, n=10) while the 13 MRL-lpr/lpr mice
tested had an average unit value of 695, which was nearly equivalent to the high titer
human control sera of 850 IU (Table 1, column 5) (p< 0.001).
In summary, Table 1, shows that there is considerable variation between the
diseased mice, but thyroid reactivity appears to be 100% based on our findings
(n=33, MRL-lpr/lpr; n=26, MRL-V+ ). The best characterized 13 non-diseased and
15 diseased mice are represented here and show significant to highly significant
differences between the serologic indicators we investigated. The most extreme is
diseased mouse #3, which was lower in free T4, and higher in TSH, anti-ds-DNA,
anti-Tg and anti-TPO.
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B. Mechanisms Regulating Cx43-Mediated Cell-Cell Communication in a Fetal
Rat Lung Cell Line

These studies were undertaken to resolve some of the discrepancies in the
literature concerning the role of pKC in modulating Cx43-mediated communication.
The effects of pKC activation on Cx43 intercellular communication were examined at
the level of terminal channel function, protein processing and mRNA expression.

Northern analysis of connexin mRNA
ERL cells were assessed for connexin transcript expression by Northern blot
analysis. Blots containing total RNA from adult rat lung, adult rat heart, ERL cells
and adult mouse liver were hybridized with connexin-specific cDNAs (Figure 8).
The hybridization signals revealed that Cx43 was expressed in lung, heart and ERL
cells. Cx40 was expressed in both lung and heart tissue. Cx32 was expressed in adult
mouse liver, whereas, Cx26 was found in liver and the ERL cells. Although the
transcript for Cx26 was present, protein was not detected by immunocytochemistry or
immunoblotting (data not shown). A similar finding has been reported in fetal
heart tissue wherein Cx40 transcript was expressed but the protein was
undetectable (95,182).

Intercellular transfer of Lucifer Yellow dye in TPA treated FRL cells
ERL cells express Cx43-type gap junctions and are extremely well coupled
with LY dye transfer proceeding to fourth order contacting cells (at least three cells
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Figure 8. Northern Analysis of Connexin mRNA Expression in Fetal Rat Lung
Cells. Shown are five northern blots containing RNA from; adult rat lung (lane 1),
adult rat heart (lane 2), FRL cells (lane 3) and adult mouse liver (lane 4). The blots
were hybridized with 32P-labelled cDNA specific for the connexins indicated. Cx43 is
expressed in heart and FRL cells, Cx40 is expressed in lung and heart, Cx32 is
expressed in liver, Cx26 is expressed in FRL cells and liver. The migratory location
of the 28S and 18S ribosomal RNA bands are indicated by arrows.
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between the injected cell and the recipient cells) and beyond within 2 minutes of
injection. However, treatment with lOOnM TPA greatly alters this pattern, as shown in
Figure 9. Panel b shows basal dye transfer with essentially 100% incidence of
coupling (n >100). FRL cells treated for 2 hours with TPA failed to transfer LY dye
to any contacting neighboring cells (n >50) (panel d). TPA containing media was
removed at 2 hours and partial recovery (50%) was seen by 10 hours (panel f) with a
near 100% recovery of dye transfer occurring 24 hours after removal of TPA
(panel h). This procedure was repeated using lOpM OAG, a more selective stimulator
of pKC, with results very similar to that of TPA with the only notable difference being
that OAG required 4-6 hours less time to recover (data not shown).

Protein kinase A and protein kinase C activity induced in FRL cells in response to
TPA and OAG
TPA is known to activate pKC through the binding of its lipophilic tail to a
specific site on this enzyme (11). The majority of pKC isozymes isolated to date have
a phorbol ester binding site and can be activated by TPA or related compounds
(11,183,184). However, it is also clear that in addition to its activation of pKC, TPA
has pleiotropic effects, including the activation of pKA (207,208). PKA activity
assays were performed to determine if TPA was concomitantly activating pKA and
pKC in FRL ceils. Figure 10 shows the pKA activity of cell lysates harvested from
cultures that had received either lOOnM TPA or lOpM OAG over an 8 hour time
period. The results revealed that TPA increased cellular pKA activity, with a peak
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Figure 9. Intercellular Transfer of Lucifer Yellow Dye in TPA Treated Fetal Rat
Lung Cells. FRL cells were microinjected with LY dye as a measure of cell-cell
communication competence in untreated and TPA treated samples. The composite is
arranged with the phase images (a,c,e,g) adjacent to their corresponding fluorescent
images to reveal the number of cell contacts not evident from the extent of dye
transfer. The arrowhead in the phase image indicates the randomly selected cell in the
monolayer that was microinjected. Untreated FRL cells shown 2 minutes after
injection of LY dye (panel b). Dye transfer proceeds to fourth-order neighboring cells
with 100% incidence of coupling. Whereas, after 2 hours of exposure to 100/iA/ TPA
no dye transfer is observed (panel d). Recovery from the TPA-induced
down-regulation of cell-cell communication is approximately 50% by 10 hours
(panel f) and 100% by 24 hours (panel h).
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Figure 10. Protein Kinase A Activity Induced in Fetal Rat Lung Cells in
Response to TPA or OAG. Serum free monolayers of FRL cells were treated with
either lOOnAf TPA ( JL ) or 10|liM OAG ( H ). Treated cell lysate were harvested
at times indicated and tested in a standard pKA assay that measured P-incorporation
into the substrate kemptide as pM/minute/mg of protein. Untreated FRL cells were run
in four sets of quadruplicates to determine basal levels. The resulting changes in pKA
activity as a consequence of TPA or OAG treatment are graphed as relative increase in
pKA activity over the treatment period. The inset represents a similar experiment
wherein pKC activity is assessed following TPA (
) or OAG ( H ) treatment by
the incorporation of 32P- into the substrate acetylated myelin basic protein. Standard
error bars are indicated and represent the average of three trials. Note: several of the
standard error bars in the inset are contained within the symbol.
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induction of 3.7 times basal levels occurring at 150 minutes post TPA stimulation.
The pKA levels returned to basal values by 6 hours. The more selective activation of
pKC by OAG did not appreciably enhance pKA activity in FRL cells (Figure 10).
The values of pKA activity obtained in the assays on FRL cells following OAG
stimulation ranged from zero to 30% with an average fluctuation between 10-15%.
The data in Figure 10 are graphed as the relative level of pKA activity verses time
in minutes.
The insert in Figure 10 shows the induction of pKC activity, measured by
gammaincorporation into acetylated myelin basic protein, following treatment
with TPA (lOOnM) or OAG (lOpM). TPA treatment resulted in a 3.3 fold increase in
pKC activity at 60 minutes. Whereas, OAG induced a similar increase (3.2 times
above unstimulated) at 90 minutes. These experiments were repeated three time and
in each case varied by less than 8%. The deviation at 60 minutes with OAG
treatment was obtained consistently.
The resulting co-induction of pKA by TPA necessitated further investigation as
to whether increased pKA activity was affecting cell-cell communication at the level
of fluorescent dye transfer in FRL cells. To test this, cultures either received
exogenously added 8Br-cAMP (0.5mM) or were induced to increase their endogenous
levels through stimulation of adenylate cyclase by forskolin (lOpM). Both of these
treatments facilitate the catalytic activation of the cAMP-dependent protein kinase A
(pKA) (185). However, neither of these treatments had any negative effect on dye
transfer in FRL cells (data not shown). This suggests that the decrease in dye transfer
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induced by TPA and equally by OAG is most likely a result of their ability to
activate pKC.

Effects of pKC on alkaline phosphatase treated FRL cells
On average, injection of fluorescent dye into a single FRL cell results in dye
being transferred to third or fourth order contacting cells within 2 minutes
(n>100) (Figure 11, panels a,b,f). When FRL cells were first injected with alkaline
phosphatase (Figure 11, panel d) and 5 minutes later with LY dye (Figure 11, panel e),
cell-cell dye transfer was greatly reduced (n >50), indicating that a minimum level of
phosphorylation was required to maintain communication competence. When the same
cell was injected with pKC, dye transfer resumed in 2-3 minutes (n >50) (Figure 11,
panel c), although it did not reach the level of untreated controls (Figure 11,
panels a,b,f). Injection of free catalytic subunit of pKA similarly restored
communication between a phosphatase treated FRL cell and its contacting neighbors.
Regardless of the concentration or time following the introduction of free C subunit of
pKA, the effects on dye transfer were always positive (data not shown), which is
consistent with prior results (166).
When FRL cells were first injected with pKC and then 5 minutes later with LY
(Figure 11, panel g), dye movement was markedly restricted over the next 5 minutes
(Figure 11, panel h) to 10 minutes (Figure 11, panel i). When cellular pKC was
maximally activated with TPA, the injection of free C subunit of pKA or inhibiting
pKC with CKI was able to prevent the shut down of dye transfer provided they were
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Figure 11. Alkaline Phosphatase-Mediated Down-Regulation of Intercellular Dye
Transfer and Reversal by Microinjection of pKC. FRL cells were injected with LY
dye (arrow in panel a) which moves to all primary contacting cells within 1 minute
(panel b) and beyond them to 4-5 cells by 2 minutes (panel f). A randomly selected
cell within a monolayer was injected with alkaline phosphatase and then 2-3 minutes
later with LY dye (arrow in panel d). Dye transfer over the next 5 minutes was
appreciably reduced relative to controls, but was seldom eliminated (panel e). When
phosphatase treated cells were injected with pKC, dye transfer returned within
3 minutes (panel c) in greater than 40% of cells (n= >50). To test the ability of pKC
to influence dye transfer (without alkaline phosphatase pre-treatment), FRL cells were
injected with pKC, then 3 minutes later with LY dye (arrow in panel g). Dye
movement over the next 5 minutes (panel h) to 10 minutes (panel i) was significantly
retarded relative to basal controls (panels a-c). Alkaline phosphatase and pKC that
had been inactivated had no effect.
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introduced within 60 minutes of TPA treatment (data not shown). The differences in
LY dye movement induced by pKC activity in FRL cells under basal and activated
conditions suggests that the response was dependent on the phosphorylation status of
Cx43 prior to treatment. Inactivated pKC, pKA, CKI and 500nM 4-0-methylphorbol ester (non-active analog of TP A) had no effect on dye transfer.

Cx43 protein localization and changes induced by activation of pKC
FRL cells have under basal conditions a large portion of their plasma
membrane specialized as gap junctional plaques at regions of cell-cell contact.
TPA and OAG treated cells showed a progressive loss of these plaques which declined
to approximately one-half that of untreated levels by 60 minutes. This loss of
immunoreactive Cx43 in the membrane corresponded to an increase in cytoplasmic
fluorescent intensity, suggesting a removal, and not a dispersal, of Cx43 aggregates
from the plasma membrane (data not shown). Immunocytochemistry revealed that the
normally well coupled FRL cells (Figure 12, panel a) completely lost
membrane-associated gap junctional proteins 2 hours after the addition of lOOnM TPA
(panel b). Recovery was 50% by 10 hours (panel c) with a nearly 100% recovery
observed at 24 hours (panels d).
These results were repeated using lOpM OAG which, as in the dye transfer
experiments (Figure 9), gave inhibitory effects similar to those seen with TPA.
The only notable difference with OAG treatment was the 4-6 hours less time required
to reestablish gap junctions. FRL cells equivalently express two of the
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Figure 12. Immunocytochemical Localization of Connexin 43 Protein in Fetal Rat
Lung Cells Following TPA Treatment. Cx43 protein localization was detected by
immunocytochemistry using anti-Cx43 antisera and FITC-conjugated goat anti-rabbit
IgG secondary antibodies. Untreated FRL cultures show extensive areas of discrete
plasma membrane associated punctate fluorescence corresponding to aggregates of gap
junctional plaques at points of adjacent cell contact (panel a). However, 2 hours
following TPA treatment (panel b) there is a striking absence of immunoreactive gap
junctional structures. Recovery from the TPA-induced loss of gap junctions is
approximately 50% by 10 hours (panel c) and returns to near basal levels by
24 hours (panel d).
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Ca++-dependent isoforms of pKC (alpha and beta) (LaBue and Green, unpublished
observation) and treatment with bradykinin which increased intracellular levels of
Ca++, and presumably activated the Ca++-dependent forms of pKC (186) yielded results
indistinguishable from those of TPA or OAG. Additionally, CHX pretreatment did not
prevent the pKC-induced loss of Cx43 protein from the plasma membrane indicating
that protein synthesis was not required for this affect of pKC (data not shown).

Post-translational processing induced by pKC activation
It has been previously demonstrated that post-translational processing of Cx43
occurs with the most dramatic evidence being the electrophoretic mobility shifts due to
phosphorylation (100,112,187,188,189,190). Three predominant species have been
reported, an np form (nonphosphorylated) with an apparent molecular weight of
41-42kDa, a PI form migrating at 43-44kDa, and a P2 form of 46-47kDa. Cx43-Pl
is intermediate in molecular weight relative to Cx43-P2. The differences in
electrophoretic mobility are most likely a function of conformational changes caused
by phosphorylation of particular residues and are not necessarily due to the weight or
charge of the added phosphate(s). The slight differences in reported molecular weights
may reflect technical differences. However, all of the lower mobility species can be
reduced to the parent (np) form by alkaline phosphatase
treatment (100,187-189,191,192).
To determine the phosphorylation and post-translational processing in OAG
treated FRL cells, cultures were harvested over a 3 hour period and extracted cell
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Figure 13. Western Blots of Connexin 43 from Microsomal/Membrane and
Cytosolic Fractions from Fetal Rat Lung Cells Following OAG Treatment. FRL
cells were treated with 10
OAG and samples taken at times indicated. The
cytosolic fractions were immunoprecipitated with anti-Cx43 antisera prior to Western
blotting (Panels a & b). Protein was overloaded in Panel a in order to visualize the
42kDa band (np-form), which decreases sharply at 60 minutes. Diluted cytosolic
samples were loaded in Panel b to better demonstrate the 47kDa band (P2-form). An
increase in the P2-form is evident at 120 minutes. The membrane fractions (Panel c)
were not immunoprecipitated and contained only the 47kDa band (P2-form), which
steadily increased over time. The maximum increase in concentration was 27-fold
greater than the basal level and ocurred 45 minutes after pKC stimulation.
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lysates separated into a cytosolic and membrane-microsomal fraction. The cytosolic
fractions contained 2 forms of Cx43 that had electrophoretic mobilities of 42kDa and
47kDa. The very low concentration of these forms necessitated immunoprecipitating
and overloading the gel in order to quantitate the lower molecular weight band
(Figure 13, panel a). This 42kDa species (Cx43-np) increased at 5 minutes but then
steadily decreased over the next 60 minutes. There was an additional increase at
90 minutes with the levels thereafter remaining equal to or greater than basal levels
through 180 minutes. To better resolve the changes in the higher molecular weight
species of soluble Cx43 P2, gels were run with diluted samples as shown in Figure 13,
panel b. This form of Cx43 increased at 5 minutes, then remained relatively constant
with the most significant increase observed at 120 minutes.
Western blots of the membrane fractions revealed only the 47kDa species of
Cx43 (P2) present at sufficient concentration as to not require immunoprecipitation.
This species of Cx43 increased steadily, reaching a peak 27 times greater than
unstimulated levels 45 minutes following OAG treatment (Figure 13, panel c).
The 2 and 3 hour membrane samples decreased slightly but remained above
untreated levels.

Relative levels of Cx43 mRNA in FRL cells following treatment with TPA and OAG
Northern analysis was performed to determine what effect, if any, increased
pKC activity had on Cx43 transcript levels in FRL cells. Cultures were switched to
serum free medium and treated with lOOnM TPA or lOpM OAG after which RNA
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Figure 14. Relative Levels of Connexin 43 mRNA in Fetal Rat Lung Cells Following Treatment with
TPA or OAG. Shown are Cx43-cDNA hybridized northern blots of total RNA extracted from FRL cells
harvested at selected times following treatment with lOOnM TPA (panel a) or lOpM OAG (panel b). The
ribosomal band location is indicated by arrows. The hybridization signals were scanned dcnsitometrically
and adjusted for differences in total RNA loaded per lane. The corrected signals are represented in the
histogram as relative level of Cx43 mRNA versus time. Both TPA ( |<|| ) and OAG (
) resulted in a
reduction of Cx43 mRNA levels with a maximum decrease of 75% occurring at 6 hours. Repeat
experiments were within +/- 5% of the values shown.
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was extracted. The film image of RNA samples from the treated cultures are shown
in Figure 14. The histogram (lower portion of the figure) is a graph of data after
adjustments for differences in total RNA loaded per lane. The amount of Cx43 mRNA
decreased more rapidly in the OAG treated samples with a near 50% reduction by
2 hours. However, by 6 hours both TPA and OAG treatments coincided with Cx43
mRNA levels reduced by 75% that of control levels.

Cx43 mRNA half-life
To investigate whether the TPA and OAG associated decrease in Cx43 RNA
was a direct effect of pKC at the level of transcript, the above experiments were
repeated in the presence of the transcription inhibitor DRB. Figure 15 shows the film
images of northern blots containing total RNA from FRL cells pre-treated with
50|xg/ml DRB, and then treated with; nothing (panel a), TPA (panel b), OAG (panel c)
or 8Br-cAMP (panel d). RNA was extracted from treated cultures over 6 hours.
The lower portion of Figure 15 is the data graphed linearly. Regression analysis of
the DRB only samples corresponds to a message half life of 3 hours and 30 minutes;
the DRB plus TPA samples had a message half-life of 3 hours and 54 minutes; DRB
plus OAG had a mRNA half-life of 4 hours 24 minutes and DRB plus 8Br-cAMP
samples revealed a half-life equal to 3 hours and 12 minutes.
Repeated testing of RNA levels gave values within 10 minutes of those just
described with the exception of DRB only and DRB plus OAG, which had measured
half-lives of 4 hours, and 3 hours and 20 minutes, respectively. Collectively these
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Figure 15. Connexin 43 Message Half-Life in Response to TPA, OAG and 8BrcAMP Treatment. To determine if the decrease in Cx43 mRNA, induced by
activation of pKC, was due to changes in the stability or turnover rate of Cx43
message, protein kinase modulation was repeated in the presence of the transcription
inhibitor DRB. Total RNA was extracted from DRB treated FRL cell cultures
incubated with; nothing (panel a), lOOnM TPA (panel b), 10fxM OAG (panel c) or
0.5mM 8Br-cAMP (panel d). The blots were hybridized with 32P-labelled cDNA
specific for Cx43, ribosomal 28S and 18S bands are indicated. The resulting
autoradiographic signals were quantitated densitometrically and adjusted for
differences in total RNA loaded per time point. The values are graphed as relative
levels of Cx43 mRNA versus time. Regression analysis of the DRB only samples
( © ) gave a slope of -0.156 and a correlation coefficient (r) of 0.98. This slope
corresponds to a message half life of 3 hours and 30 minutes. The DRB plus TPA
( A. ) samples gave a slope of -0.145 with an r value of 0.99, corresponding to a
message half-life of 3 hours and 54 minutes. DRB plus OAG ( £ ) gave a slope
of -0.117, r=0.99 and a half-life of 4 hours 24 minutes. DRB plus 8Br-cAMP ( Q )
gave a slope of -0.131, r=0.98 and a half-life equal to 3 hours and 12 minutes.
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differences between repeated sets were determined not to be significant by statistical
analysis. The regression analysis revealed that the activation of pKC by either TPA or
OAG did not accelerate Cx43 mRNA turnover rate indicating that the decrease in
mRNA for Cx43 (Figure 14) was not occurring at the level of transcription.
Additionally, increasing cellular levels of cAMP and therefore pKA activity also did
not alter Cx43 mRNA turnover.

Relative levels of Cx43 mRNA in FRL cells treated with TPA or OAG in the
presence of cycloheximide
To determine if the negative effect of pKC on Cx43 transcript levels required
translation, experiments were repeated in the presence of the protein synthesis inhibitor
CHX. Figure 16 is the northern blot of RNA extracted from treated cultures at the
times indicated. The composite is arranged with CHX only (panel a), CHX plus TPA
(panel b) and CHX plus OAG (panel c). The lower portion of the figure is a graph of
the data after corrections for differences in the total RNA loaded per lane.
The results indicated that inhibiting protein synthesis prevented the TPA or OAG
induced decrease in Cx43 mRNA. This suggested that, in this system, the increased
activity of pKC was inducing a protein which either inhibited the production or
blocked the action of a message-stabilizing protein, or alternatively induced a message
destabilizing factor. The level of Cx43 mRNA in CHX treated cultures reveal a
steady increase in the accumulation of transcript. Superinduction of mRNA and
protein are a common finding when protein synthesis and transcription inhibitors are
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Figure 16. Relative Levels of Connexin 43 mRNA in Fetal Rat Lung Cells Treated with TPA or OAG
in the Presence of Cycloheximide. Cultures of FRL cells were incubated with the protein synthesis
inhibitor CHX to determine if new translation was required for the observed pKC-mediated decrease in
Cx43 mRNA. Shown are northern blots containing RNA from FRL cells treated with; CHX only (panel a),
CHX plus lOOrtA/ TPA (panel b) and CHX plus lOpM OAG (panel c). The ribosomal band locations are
indicate by arrows. The resulting hybridization signals were corrected for differences in total RNA loaded
per lane. The relative levels of Cx43 mRNA for the times indicated are depicted in the graph as CHX only
([]]), CHX plus OAG ( ^ ) and CHX plus TPA ( ^ ). There is evidence of some superinduction
which is most pronounced for the TPA treated samples. However, the pKC-mediated decrease in Cx43
mRNA was prevented when protein synthesis was inhibited.
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used (193,194). The rise is most dramatic in the TPA treated samples, which may in
part be due to the global nature of phorbol ester stimulation.

C. Reduced Cell-Cell Communication in a Spontaneous Murine Model of
Autoimmune Thyroid Disease (MRL-Ipr/lpr Mice)

During autoimmune thyroiditis in humans, there is often extensive lymphocytic
infiltration with interstitially distributed T-cells and lymphoid follicle centers that are
composed of polyclonal B-cells. Chronic inflammation eventually causes connective
tissue and fibrotic changes with near complete replacement of the thyroid follicular
epithelium (Reviewed in: 195). Thus inflammation can result in disruption of cell to
cell contact which could lead to the elimination of intercellular communication.
Maintenance of critical cellular processes is linked to the integrity of the
extracellular environment and influenced by changes in physical contact between cells
(196-198). Therefore, this study was undertaken to ascertain whether autoimmune
diseased thyroid tissue had altered gap junctional communication. Cx protein,
Cx mRNA, and gap junction location were examined in thyroid tissue from
MRL-lpr/lpr mice manifesting autoimmune thyroiditis and from their non-diseased
allelic counterpart (MRL-lpr +/+) mice. Functional differences in cell-cell
communication as well as Cx expression were then assessed in primary thyrocytes
established from normal and diseased animals.
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Comparative histology of thyroid tissue from diseased and control MRL mice
Since physical disruption of the thyroid tissue by inflammation may be important
to the interpretation of the results of this study we examined the extent of lymphocytic
infiltration. In cryosections of MRL-+/+ mouse thyroid mononuclear cells were
sparsely distributed throughout the epithelium (Figure 17, panel a). Tissue from the
diseased mice had extensive interstitially distributed lymphocytes and organized
lymphoid follicle centers (Figure 17, panel b). The presence of lymphocytic foci in
the MRL-lpr/lpr mouse thyroid was observed in one out of every five fields examined
microscopically, and there was a marked decrease in follicle size proceeding from the
center of the lobe toward the periphery. Fibrosis was minimal, with less than one
percent of examined tissue showing fibroblast growth. When detected it was usually
adjacent to atrophic follicles.

Immunocytochemical detection of connexin protein expression in fresh thyroid tissue
cryosections from MRL mice
Immunocytochemistry was done to determine if the diseased mouse thyroid
tissue had altered Cx expression. The non-diseased (MRL-+/+) (top panels) and
diseased (MRL-lpr/lpr) thyroid tissue (bottom panels) were positive for all three
Cx-proteins (Figure 18). In the MRL-+/+ tissue the primary antisera binding was
visualized as punctate fluorescence, corresponding to aggregates of Cx channels in the
form of gap junctional plaques. In screening dozens of slides a discrete distribution
corresponding to the specific Cxs became apparent. Cx43 was primarily localized on
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Figure 17. Comparative Histology of Thyroid Tissue from MRL Mice. Fresh
frozen thyroid sections were paraformaldehyde fixed and stained with hematoxylineosin. Thyroid tissue from MRL-7+ mice have a sparse scattering of non-aggregated
lymphocytes (panel a) In contrast, similar sections from MRL-lpr/lpr mouse thyroids
revealed massive infiltration organized into lymphoid follicle centers and extensive
interstitially distributed mononuclear cells (panel b)(66 X magnification).
Also see Figure 4.
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Figure 18. Immunocytochemical Detection of Connexin Protein Expression in MRL Thyroid
Cryosections. Fresh thyroid cryosections from MRL-+/+ (non-diseased) (top panels) and MRL-lpr/lpr
(diseased) (bottom panels) were fixed and incubated with rabbit polyclonal antisera specific for; Cx43
(panel a,d), Cx32 (panel b,e) and Cx26 (panel c,f). Cx43, 32 and 26 are well expressed in the non-diseased
thyroid tissue and are assembled as gap junctional plaques at points of membrane contact (a,b,c). In the
diseased thyroid Cx43 and 26 (panels d,f) are dramatically reduced in immunofluorescent intensity and none
of the CX are localized to the plasma membrane at points of neighboring cell contact (d,e,f). Magnification
is approximately 240X.
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the extra-luminal (basal) side of thyroid follicular cells (panel a). Cx32 in the tissue
was more prominent than Cx43 and the majority of Cx32-junctional plaques occurred
between the cells within individual follicles (lateral to the follicular lumen) (panel b).
Most Cx26 gap junctional plaques were distributed at or near the lumenal surface
(panel c). In the MRL-lpr/lpr thyroid tissue both the intensity of fluorescence and the
discrete punctate distribution of Cx43 (panel d) and Cx26 (panel f) proteins were
reduced. The intensity of Cx32 (panel e) was greater than that seen for either Cx43 or
Cx26, but was also not localized as discrete punctate fluorescence.
Connexin mRNA expression in MRL-+/+ and MRL-lpr/lpr thyroid tissue
To determine if the reduced protein for Cx43 and Cx26 in the diseased tissue
was associated with concomitant reductions in mRNA expression, total RNA was
extracted and hybridized with Cx-specific cDNAs. The amount of total RNA loaded
for the diseased and non-diseased thyroid tissue was approximately the same.
The level of Cx43 mRNA was unchanged between the diseased and non-diseased
mouse thyroid tissue. In contrast the MRL-lpr/lpr thyroid tissue expressed 60% less
Cx32 and 40% less Cx26 mRNA than did non-diseased thyroid tissue (Figure 19).

Basal state intercellular transfer of Lucifer Yellow dye in primary thyrocyte cultures
from MRL mice
Primary thyroid cell cultures were established using identical conditions to
investigate functional communication in thyrocytes obtained from the diseased and
non-diseased mice. Greater than 98% of the cells from 5 day cultures of both
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Figure 19. Northern Analysis for Connexin Expression in MRL-lpr Thyroid
Tissue. Shown are the results of hybridization of 4 northern blots containing total
RNA from; rat lung (lane 1), rat heart (lane 2), fetal rat lung cells (lane 3), mouse
liver (lane 4), MRL-lpr/lpr thyroid (lane 5) and MRL-+/+ thyroid (lane 6). The blots
were hybridized with the Cx-specific cDNAs indicated. Ribosomal bands are marked
with arrows.
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non-diseased (Figure 20, panel a) and diseased mouse cultures (Figure 20, panel b)
labelled positive with anti-Tg antisera. Thus the cultured cells from the experimental
and control animals were thyroid epithelial cells.
As a measure of functional cell-cell communication cultured thyrocytes were
microinjected with LY dye. Gap junctional coupling can be determined by the degree
and amplitude of dye transfer. Phase images (Figure 21, A and B) demonstrate the
extent of membrane contacts not evident from the fluorescent images alone
(panels b,d). The non-diseased thyrocytes (Figure 21A) were communication
competent and transferred LY dye from the injected cell to adjacent cells (primary
transfer) in nearly all trials (Table 2). In contrast transfer of dye was dramatically
reduced in diseased thyroid cells (Figure 21B).

Immunocytochemical detection of connexin protein expression in thyroid cultures
from diseased and non-diseased mice
The lack of functional communication implied that the diseased cells, like the
tissue, would have aberrant gap junctions. The cultured normal thyroid cells contained
predominantly Cx43, with less Cx26, and Cx32 protein. The diseased cells displayed
the same order of specific Cx expression, but all three Cxs were reduced relative to
control cells. The most obvious difference between the diseased and non-diseased
thyroid cells was the location of the immunofluorescence. This is best depicted using
cultures immunolabelled with Cx43 antisera shown in Figure 22. In the non-diseased
thyroid cells (panel a) Cx43 is present in the plasma membrane at points of cell-cell

Os

Figure 20. Immunocytochemical Labelling of Thyroglobulin in Cultured Thyroid Cells. Thyroid
cultures were fixed in absolute ethanol and labelled with rabbit polyclonal anti-human Tg and fluoresceinconjugated goat anti-rabbit IgG secondary antibody. MRL-+/+ (panel a) and MRL-lpr/lpr (panel b) thyroid
cells label positive for Tg. The Tg was localized to the cytoplasm of the epithelial cells. However this
binding of anti-Tg was not evident in control MRL-+/+ sections that were incubated with non-immune
rabbit sera and fluorescent secondary antibody (panel c). The magnification is approximately 630X.
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Figure 21. Basal State Intercellular Transfer of Lucifer Yellow Dye In Primary
Thyrocyte Monolayers From MRL Mice. Figure 21A shows non-diseased cultures
and Figure 21B, diseased thyroid cultures. The composites are arranged with the
phase images (panels a,c) to the left of the corresponding fluorescent images (b,d).
The phase images are shown to indicate the extent of membrane contacts not evident
from the fluorescent image alone. Microinjection studies were done on culture days
3 (panel a,b) and 7 (panel c,d)- Arrowheads indicate the randomly chosen cell within
the monolayer that was microinjected with lucifer yellow dye. Images were captured
within two minutes of injection. The non-diseased thyrocytes (MRL-+/+)(21A) show
second order or greater dye transfer to contiguous cells within the monolayer, whereas
the diseased thyrocytes (MRL-lpr/lpr)(21B) are severely reduced in their ability to
transfer dye with the exception of an occasional primary transfer to one adjacent
neighboring cell (see 21B, panel d). The magnification is approximately 400X.
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Table 2.

Intercellular Dye Transfer In Primary Thyrocytes From Autoimmune
Diseased and Non-Diseased Mice.

Degree of Dye
Transfer*

0°
1°
2° & 3°

(% of Trials * )
Non-Diseasedb
(MRL-+/+)

5
20

75

Diseased0
(MRL-lpr/lpr)

80
20
0

a 0° = No dye transfer, 1° = Dye transfer from the injected cell to cells in direct contact,
and 2° & 3° = Dye transfer from the injected cell to peripheral cells not in direct contact,
but separated by one or two intervening cells, respectively.
b Percentage based on 100 Injections.
c Percentage based on 75 Injections.
*Dye transfer images were captured at one and two minutes after injection, percentage
calculations were made from the extent of dye transfer at two minutes.

121

Figure 22. Immunocytochemical Detection of Connexin-43 Protein Expression in
Thyroid Cultures from MRL Mice. Cultured thyroid cells were labelled with rabbit
polyclonal anti-Cx43 antisera and fluorescein-conjugated goat anti-rabbit IgG
secondary antibody. Arrows indicate plasma membrane contact between adjacent
cells. MRL-7+ cells have immuno-fluorescence corresponding to aggregates of Cx43
protein assembled into gap junctional plaques in the plasma membrane at points of cell
to cell contact (panel a). The MRL-lpr/lpr thyroid cells show similar punctate
fluorescence but it is not located in the plasma membrane. The diseased cells show
cytoplasmic and perinuclear Cx43 protein aggregates (panel b). Non-immune rabbit
sera and fluorescent secondary antibody controls are identical to that shown in
Figure 20. The magnification is approximately 630X.
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contact while the Cx43 in the diseased cells was in the form of punctate fluorescence
but was distributed intracellularly and localized to perinuclear regions of the cells.

D. Elevated PKC Activity Can Explain the Decrease in Cx43-Mediated Cell-Cell
Communication in Thyrocytes from MRL-lpr/lpr Mice

We have just seen that cultured thyrocytes from diseased mice are comparatively
communication incompetent, as indicated by their inability to transfer Lucifer Yellow
(LY) dye, and by the significant reduction of immunocytochemically identifiable gap
junctional plaques (Cx43) in their plasma membranes. Cx43 is the predominant
connexin found in monolayers of thyrocytes. Despite efforts to maximize physical
contact and remove inflammatory mediators and infiltrating lymphocytes, disruption of
cell-cell communication and the loss of membrane-associated Cx43 persisted in these
cultures. This sustained uncoupling suggests that additional mechanisms are operating
in the autoimmune diseased thyroid that prevents the re-establishment of Cx43 gap
junctions even when the cells are intimately opposed.
PKC has been shown by us and others (113,166,191,199, this dissertation) to
decrease Cx43-mediated cell-cell communication in a variety of clonal cell lines and
primary cells by closing existing channels and preventing insertion of new gap
junctions into the plasma membrane. A dramatic decrease in dye transfer is also seen
when porcine and rat thyroid cells are treated with the pKC activator, TPA (116,117).
Therefore, in this portion of the study we investigated whether thyrocytes from mice
with autoimmune thyroiditis have aberrant basal pKC activity and whether this activity
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concomitantly alters Cx43-mediated cell-cell communication. Further, we assessed
the contribution of intercellular communication to murine thyroid function.

Basal pKC activity levels in thyroid cells from diseased and non-diseased mice
Thyroids from diseased and non-diseased mice were collagenase digested and
basal pKC activity levels determined by standard 32P-incorporation assays (methods).
The thyrocytes from diseased mice had an average pKC activity level of
119 pmol/min/mg protein whereas the thyrocytes from non-diseased mice had an
average activity level of 82 pmol/min/mg protein. The tabulated results are shown in
Table 3. The average differences between thyrocytes from diseased and non-diseased
mice corresponded to a 45% greater pKC activity in the diseased thyroid cells.
This was determined to be significant (PcO.Ol) using a standard Student
T test (n=5 and n=3).

Immunocytochemical labeling of Tg in cultured cells from murine thyroids
Primary thyrocyte cultures from diseased and non-diseased thyroids were used
extensively in this study. Therefore it was necessary to confirm that the cultured cells
were thyrocytes. Representative cultures were immunocytochemically labeled for
thyroglobulin (Tg) (Figure 23). Greater than 98% of the cells in the culture labeled
positive for Tg, thus identifying the cells as thyrocytes and additionally indicating that
the cells retained a measure of their differentiated thyroid status.
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Table 3.

PKC

activity

levels

in

thyrocytes

from

diseased and autoimmune diseased mice

Subjects

PKC Activitya'b

MRL +/+

Subjects

PKC Activity*'*

MRL-lpr/lpr

N1

81 ± 0.10

D1

122 ± 8.90

N2

81 ± 0.40

D2

134 ±6.80

N3

85 ± 1.30

D3

100 ±5.80

N4

83 ± 2.00

N5

81 ± 11.0

Meanc

82 ± 0.70

Meanc

119 ± 9.96

aUnits in pmole/min/mg protein
bValue ± standard error between replicates in an assay
cMean value ± standard error

non-
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Figure 23. Immunocytochemical labeling of Tg in cultured thyroid cells. Thyroid
cultures were fixed in absolute ethanol and labeled with rabbit polyclonal antihuman
Tg and fluorescein-conjugated goat anti-rabbit IgG secondary antibody. Nondiseased (a) and diseased (b) thyroid cells label positive for Tg. The Tg was localized
to the cytoplasm of the epithelial cells. In panel c, non-diseased thyroid cells were
incubated with nonimmune rabbit serum and fluorescent secondary antibody
(negative control). Magnification, approximately 630X.
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Intercellular dye transfer in primary thyrocyte monolayers from non-diseased mice
after increasing pKC activity with TPA or OAG
Enhanced pKC activity has previously been shown to result in decreased
Cx43-mediated cell-cell communication with reduced plasma membrane-associated
Cx43 gap junctions (113,166,191,199). We set out to determine if increasing pKC
activity in cultured thyrocytes from non-diseased mice could change their
communication status. To achieve this, cell-cell communication in 5 to 7 day old
cultured non-diseased thyrocytes was measured by LY dye transfer. The degree of
dye transfer from the microinjected cell to adjacent cells was used to assess our ability
to effect gap junctional coupling by increasing pKC activity.
PKC activity was increased in cultures of non-diseased thyrocytes by treatment
with either lOOnM TPA or lOpM OAG for 4 hours. Identical cultures were left
untreated. Untreated non-diseased thyrocytes transferred LY dye to secondary and
tertiary contacting neighboring cells in greater than 90% of injections (Figure 24,
panels a and b). Treatment of non-diseased thyrocytes with TPA (Figure 24,
panels c and d) or OAG (Figure 24, panels e and f) resulted in the loss of dye transfer
in 95% and 75% of trials respectively. Therefore, increasing pKC activity by
treatment with TPA and OAG abolishes Cx43-mediated communication in
non-diseased thyroid cells. The compiled results of LY dye transfer are shown
in Table 4.
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Figure 24. Intercellular dye transfer in primary thyrocyte monolayers from nondiseased mice after treatments with TPA, OAG or heptanol. The composite is
arranged with phase images (a,c,e and g) to the left of the corresponding fluorescent
images (b,d,f and h). The phase images are shown to indicate the extent of membrane
contact not evident from the fluorescent image alone. Arrowheads indicate the cell
within the monolayer microinjected with lucifer yellow dye. Images were captured
within 2 min of injection. Monolayers of thyrocytes from non-diseased mice were
either untreated (a and b) or treated with lOOnM TPA (c and d), lOpM OAG (e and f)
or 3mM heptanol (g and h) for 4 hrs. Untreated thyrocytes (b) show tertiary order dye
transfer to contiguous cells within the monolayer. Thyrocytes treated with TPA (d),
OAG (f) and heptanol (h) were severely reduced in their ability to transfer dye. Note
the beginning of follicular development in panel e. Magnification,
approximately 400X.
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Table 4.

Intercellular
thyrocytes

LY

dye

transfer

in

primary

from non-diseased and autoimmune

diseased mice after modulations of pKC activity

Degree of LY Dye Transfera'b
Orgins of Culture

Treatment

0

1

MRL +/+

Untreated0

5%

15%

80%

lOOnM TPAd

95%

5%

0%

lOpM 0AGd

75%

25%

0%

3mM Heptanol6

100%

0%

0%

Untreated0

90%

10%

0%

lOOnM
Calphostin Cf

10%

10%

80%

MRL-lpr/lpr

2 & 3

a0. No dye transfer; 1, dye transfer from the injected cell to
cells in direct contact; 2 & 3, dye transfer from injected
cell to peripheral cells not in direct contact but separated
by one or two intervening cells
bDye transfer images were captured 2 min after injection
Percentage based on 100 injections
Percentage based on 20 injections
Percentage based on 15 injections
Percentage based on 40 injections

132
Immunocytochemical detection of Cx43 protein expression in cultured non-diseased
thyrocytes after activation of pKC with TPA or OAG
Functional communication is associated with immunocytochemically identifiable
gap junctional plaques in the plasma membrane (200). We have previously established
that monolayer cultures of thyrocytes from non-diseased mice predominantly express
Cx43 with localization in the plasma membrane at points of cell contact. Therefore
we looked at the distribution of Cx43 immunocytochemically identifiable plaques in
cultured non-diseased thyroid cells prior to and following increasing pKC activity.
As expected, untreated cultured thyrocytes from non-diseased mice have punctate
fluorescence corresponding to gap junctional plaques in the plasma membrane
(Figure 25, panel a). However, treatment with lOOnM TPA (Figure 25, panel b) or
lOpM OAG (Figure 25, panel c) for 4 hours resulted in a complete loss of plasma
membrane associated gap junctions, evident by the loss of discrete punctate
fluorescence at contacting cell interfaces.

Intercellular dye transfer in primary thyrocyte monolayers from diseased mice after
decreasing pKC activity
We have previously established that cultured thyroid cells from MRL-lpr/lpr mice
were communication deficient. Since increasing the pKC activity in non-diseased
thyrocytes decreased cell-cell communication, it was reasonable that the elevated pKC
activity in the diseased thyrocytes was responsible for their deficient intercellular
communication. Therefore, inhibition of pKC activity in these cells could conceivably
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Figure 25. Immunocytochemical detection of Cx43 protein expression in cultured
non-diseased thyrocytes after treatments with TPA, OAG or heptanol. Cultured
thyroid cells from non-diseased mice were either untreated (a) or treated with lOOnM
TPA (b), lOpM OAG (c) or 3mM heptanol (d) for 4 hrs, fixed with absolute ethanol
and labeled with rabbit polyclonal anti-Cx43 antisemm and fluorescein-conjugated
goat anti-rabbit IgG secondary antibody. The arrows indicate plasma membrane
contact between adjacent cells. Untreated thyrocytes (a) have punctate
immunofluorescence corresponding to aggregates of Cx43 plaques in the plasma
membrane at points of cell to cell contact. Thyrocytes treated with TPA (b), OAG (c)
and heptanol (d) show no punctate fluorescence in the plasma membrane at contacting
cell interfaces. Nonimmune rabbit serum and fluorescent secondary antibody controls
are negative and similar to those shown in Fig. 23. Magnification,
approximately 630X.
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restore their cell-cell communication. To reduce the elevated pKC activity in diseased
cells, Calphostin C, an inhibitor of pKC activity, was employed. Cultured diseased
thyrocytes (5 to 7 days old) were treated with lOOnM Calphostin C, incubated for
3 hours and then microinjected with LY dye. As a control, untreated cells were also
microinjected. Untreated diseased thyroid cells did not transfer LY dye to neighboring
cells (Figure 26, panels a and b). These results changed dramatically when cultured
thyrocytes from diseased mice were treated with Calphostin C. The Calphostin Ctreated diseased thyrocytes transferred dye from the injected cell to cells in direct
contact (primary transfer) and to peripheral cells separated by one (secondary transfer)
or by two (tertiary transfer) intervening cells in approximately 90% of trials
(Figure 26, panels c and d). These results indicate that inhibiting pKC with
Calphostin C restored, communication in the diseased thyrocytes (see Table 4).

Immunocytochemical detection of Cx43 protein expression in cultured diseased
thyrocytes after decreasing pKC activity
We have previously shown that thyroid tissue from diseased mice have a
significant reduction of gap junctional plaques at contacting cell interfaces.
Additionally, cultured diseased thyrocytes did not have Cx43 gap junctional plaques in
the plasma membrane, regardless of the extent of cell contact. Inhibiting pKC by
Calphostin C restored dye transfer in diseased thyrocytes. Therefore, we examined the
distribution of Cx43 immunocytochemically identifiable plaques prior to and following
inhibition of pKC activity.
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Figure 26. Intercellular dye transfer in primary thyrocyte monolayers from
diseased mice after decreasing pKC activity with Calphostin C. Monolayers of
thyrocytes from diseased mice were either untreated (a and b) or treated with lOOnM
calphostin C (c and d) for 3hrs. The composite is arranged with phase images
(a and c) to the left of the corresponding fluorescent images (b and d). The phase
images are shown to indicate the extent of membrane contact not evident from the
fluorescent image alone. Arrowheads indicate the cell within the monolayer
microinjected with Lucifer Yellow dye. Images were captured within 2 min of
injection. Untreated thyrocytes (b) exhibit no dye transfer to contiguous cells within
the monolayer. Thyrocytes treated with Calphostin C (d) show a dramatic
reinstatement of dye transfer extending to tertiary contacting cells. Magnification,
approximately 400X.
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As expected, untreated cultures from diseased mice showed no punctate
fluorescence in the cell membranes (Figure 27, panel a). However, when pKC activity
was reduced in these cells by treatment with lOOnM Calphostin C, they established
Cx43 channels in their plasma membrane at points of cell to cell
contact (Figure 27, panel b).

Effect of pKC activity on T4 release by non-diseased thyrocytes
Iodide organification and thyroid hormone secretion have been shown to be
influenced by pKC {Reviewed in: 201). However, the effect of pKC on thyroid
function varies according to the species being investigated. We have previously
reported that diseased mice have low serum T4 levels. Since pKC is elevated in the
thyroids from diseased mice, we questioned whether pKC was involved in this
decrease. The inability of cultured thyrocytes from diseased mice to readily
follicularize necessitated the use of thyroid cell cultures from non-diseased mice,
which do form follicles in culture. In fact, cultures of thyroid cells from non-diseased
mice exhibited follicular formation without the addition of exogenous bovine TSH,
which we found to be toxic to these cells (unpublished observation M. LaBue
and L.M. Green).
TPA and OAG were used to elevate pKC activity in non-diseased thyrocytes.
Because cultured thyrocytes can become depleted in stored iodide, we replenished
intracellular iodide levels by adding 0.5nM Nal to the cultures 24 hours prior to the
start of our experiments. Thyrocyte cultures with follicular development
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Figure 27. Immunocytochemical detection of Cx43 protein expression in cultured
diseased thyrocytes after decreasing pKC activity with Calphostin C. Cultured
thyroid cells from diseased mice were either untreated (a) or treated with
lOOnM calphostin C (b) for 3 hrs, fixed with absolute ethanol and labeled with rabbit
polyclonal anti-Cx43 antiserum and fluorescein-conjugated goat anti-rabbit IgG
secondary antibody. The arrows indicate plasma membrane contact between adjacent
cells. Untreated thyrocytes lack punctate immunofluorescence in the plasma
membrane at areas of cell contact but show cytoplasmic and perinuclear Cx43 protein
aggregates (a). Thyrocytes treated with calphostin C (b) show a recovery of punctate
immunofluorescence in the plasma membrane corresponding to Cx43 gap junctional
plaques. Magnification, approximately 630X.
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(5 and 7 days old) were either left untreated (controls) or treated with lOOnM TPA or
10nM OAG for 6 hours. Culture supernatants were collected and T4 measured by
fluorometric enzyme analysis (160). Seven day old cultured thyrocytes consistently
secreted more T4 than 5 day old cultures. This could reflect their degree of
follicularization. However, regardless of the age of the culture, pKC activation by
TPA or OAG resulted in a decrease in T4 secretion by 78% (p<0.01) and 34%
(p<0.001), respectively (Figure 28). Significance was determined by standard Students
T-test by compiling a minimum of 3 separate trials using each chemical agent.
Furthermore, the reduction of T4 release was significantly greater (p<0.02) with TPA.
These results indicate that an increase in pKC activity caused a significant
reduction in T4 release by murine thyroid cells.

Effect of Heptanol-mediated reduction of intercellular communication on T4 release
by thyrocytes from non-diseased mice
We have established that pKC down-regulates intercellular communication and
causes a significant reduction in T4 release from non-diseased cultured thyrocytes.
Therefore, to investigate whether pKC was influencing T4 release directly or through
its effect on intercellular communication we employed the long chain alkanol,
heptanol. By closing gap junction channels with heptanol, we could determine the
contribution of cell-cell communication to T4 release. Heptanol abolishes gap
junctional communication without altering protein kinase activity, Ca2+ levels or
intracellular pH (202). To ensure that heptanol could reduce communication in our
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Figure 28. Effects of pKC activation and heptanol-mediated reduction of
intercellular communication on T4 release by non-diseased thyrocytes. Cultured
thyrocytes from non-diseased mice were either untreated or treated with lOOnM TPA,
lOpM OAG or 3mM heptanol for 6 hrs. Culture supernatants were collected and T4
levels determined. Values are expressed as ng/dl/106 cells. Results are graphed as
percent of relative values ± SEM. Activation of pKC by TPA and OAG coincided
with significant decreases in T4 release. The most dramatic decrease in release is seen
after treatment with TPA. Disruption of cell-cell communication by heptanol also
resulted in a significant decrease in T4 release which was equivalent to that seen
with OAG.
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system, cultured thyrocytes from non-diseased mice (5 to 7 days old) were treated
with 3mM heptanol for 4 hours and then injected with LY dye. Dye transfer was
completely abolished (Figure 24, panels g and h) in all trials (Table 4). Corresponding
to the loss of dye transfer was an absence of immunocytochemically identifiable Cx43
gap junctional plaques in the plasma membrane (Figure 25, panel d).
The effect of heptanol on T4 secretion was determined in 5 and 7 day old cultures
of thyrocytes from non-diseased mice. Prior to use, the cells were incubated with
0.5nM Nal for 24 hours. Cultures were then treated with 3mM heptanol for 6 hours,
after which supernatants were harvested and T4 levels measured. Heptanol
significantly reduced (p>0.001) T4 levels by an average of 36% (standard students
T-test) (Figure 28).
Heptanol did not decrease T4 secretion to the levels seen with TPA and these
differences in response were found to be significant (p<0.01). Therefore the effects of
TPA on T4 release is not solely due to the ability of TPA to decrease cell-cell
communication, but may also involve additional intracellular effects of this global
activator. In contrast, heptanol did decrease T4 release to levels equal to those
obtained by treatment with OAG. This may indicate that OAG reduces T4 release
through its effect on intercellular communication. Overall, these results indicate that
communication status is an important parameter in the regulation of T4 release by
murine thyrocytes.
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Effect of heptanol on protein kinase activity in isolated non-diseased thyrocytes
To confirm that heptanol was not effecting the activity of pKC and pKA in our
thyrocytes, we measured the activities of these kinases after treatment with
3mM heptanol. Figure 29 shows that heptanol did not significantly alter the basal
activities of either pKC or pKA in thyrocytes from non-diseased mice over the
60 minute time course.

E. Thyrocytes from Mice with Spontaneous Autoimmune Thyroiditis Produce the
Soluble Form of the 55Kd TNF-a Receptor

We have just seen that the hypothyroidism in mice with autoimmune thyroiditis
correlates with decreased gap-junctional mediated cell-cell communication caused, in
part, by increased PKC activity (140,146-148). Since PKC appears to be a regulator
of TNF-a receptor shedding, we hypothesized that TNF-a receptor shedding may be
occurring in the thyrocytes obtained from the diseased mice. We examined TNF-a
cell-surface receptor levels in the thyroid tissue from both normal and diseased mice
as well as soluble receptor production by normal and diseased thyrocytes.
Additionally, we investigated the cytotoxic effect of TNF-a on cultured thyroid
epithelial cells.

TNF-a in non-diseased and diseased mouse sera
Since TNF-a has been shown to effect thyroid function (153,154), TNF-a serum
levels were measured by ELISA in diseased and non-diseased mice. We found serum
levels of TNF-a were 41% (p<0.05) higher in the diseased mouse relative to the
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Figure 29. Effect of heptanol on protein kinase activity in isolated non-diseased
thyrocytes. Collagenase digested thyrocytes from non-diseased mice were treated
with 3mM heptanol. Activities of pKC and pKA were measured by the incorporation
of 32P from gamma-labeled ATP into ac-MBP and Kemptide, respectively. Data is
graphed as relative activity ± SEM. (A) shows pKC activity in thyrocytes after
treatment with heptanol. There were no significant changes in pKC activity with
heptanol treatment at any time point nor was there any significant changes in
pKA activity (B).
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non-diseased mouse (Figure 30). Significance was determined by standard
Student's T-test.

TNF-a receptor identification and cell-surface levels in non-diseased and diseased
thyrocytes
It has been shown that thyrocytes express TNF-a receptors (152). However, the
type(s) of TNF-a receptors present on thyrocytes has not been identified.
We examined plasma membrane TNF-a receptor expression in thyrocytes from
non-diseased and diseased mice. Thyrocytes were collagenase digested. Infiltrating
lymphocytes were removed by two successive gravity sedimentations. Thyrocytes
were then stored in liquid nitrogen until use. Storage in liquid nitrogen resulted in the
death of the remaining contaminating lymphocytes. At the beginning of the
experiment, thyrocytes were resuspended and cell number adjusted to 1X106 cells per
sample. Thyrocytes were incubated with murine TNF-a to allow binding to the
plasma membrane receptor. Once bound, TNF-a was crosslinked to the receptor, the
cells were lysed and the membranes isolated. Receptor:TNF-a complexes were
isolated by immunoprecipitation with anti-murine TNF-a. Immunoprecipitated
receptor:TNF-a complexes were subjected to polyacrylamide gel electrophoresis
(PAGE) and Western blotted. Anti-murine TNF-a and peroxidase-conjugated
secondary antibody were used to detect the complexes.
Murine thyrocytes, like most epithelial cells, express only the TNF-R55 in their
plasma membranes (Figure 31). TNF-R75 was not present. Furthermore, levels of
the TNF-R55 :TNF-a complexes were 60% lower in the plasma membranes of
diseased thyrocytes (Figure 31), as determined by densitometric scanning.
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Figure 30. TNF-a levels in non-diseased and diseased mouse sera. Serum levels
of TNF-a was measured by ELISA. Serum samples from non-diseased and diseased
mice were initially diluted 1:100 in PBS followed by 2-fold serial dilutions.
Recombinant human TNF-a (rhuTNF-a) at an initial concentration of O.lpg/ml was
also serially diluted 2-fold. Sera from the diseased mouse had significantly higher
levels of TNF-a than sera from the non-diseased mouse.
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Figure 31. TNF-a receptor identification and cell-surface levels in non-diseased
and diseased thyrocytes. Suspensions of 1X106 non-diseased and diseased thyrocytes
were incubated with murine TNF-ot for 30 min. TNF-a was then crosslinked to the
cell-surface receptors. Membranes were isolated and receptor:TNF-a complexes were
immunoprecipitated with anti-murine TNF-a, subjected to PAGE and Western
blotted. The blots were labeled with anti-murine TNF-a and peroxidase-conjugated
anti-goat IgG. The lanes are marked as: (M) markers, (N) non-diseased thyrocytes
and (D) diseased thyrocytes. TNF-R55 was the only receptor present on murine
thyrocytes. Levels of TNF-R55:TNF-a complexes isolated from diseased thyrocytes
were significantly lower (by 60%) than levels in non-diseased thyrocytes, as
determined by densitometric scanning.
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This experiment was repeated with three separate non-diseased and diseased thyroids
with similar results.

Lymphocyte and thyrocyte populations in diseased thyroids as detected by fluorescent
flow cytometry
For fluorescent flow cytometry, thyroids were collagenase digested and freshly
digested thyroid cells were used. The majority of the contaminating lymphocytes in
the digests of the diseased thyroids were removed by gravity sedimentations.
However, some lymphocytes remained. Since lymphocytes normally possess
TNF-R55, it was therefore necessary to determine the flow cytometry parameters
which would include the majority of thyrocytes while excluding lymphocytes.
Fortunately, the differences in size and granularity between thyrocytes and
lymphocytes enabled this to be done. Two discrete populations of cells (Gate R1 and
Gate R2) were visible by scatter plotting (Figure 32A). To distinguish the lymphocyte
population from the thyrocyte population, cells from diseased thyroids were labeled
with a mixture of fluorescein-conjugated antibodies to CDS (pan T-cell marker) and
CD45R (pan B-cell marker). In Gate Rl, 41% of the cells labeled positive
(Figure 32B, panel a). A much lower labeling was observed in Gate R2, wherein 5%
of the cells labeled positive (Figure 32B, panel b). Therefore, the majority of the
lymphocytes were found in the ceil population that comprised Gate Rl.
The thyrocyte population was identified using antibodies to the Thyroid
Stimulating Hormone receptor (TBI) obtained from Grave's patient sera. Digests of
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Figure 32. Lymphocyte and thyrocyte populations in diseased thyroids as
detected by fluorescent flow cytometry. (A) shows the scatter plot of cells isolated
by collagenase digestion of diseased thyroids. Two distinct populations of cells are
visible and comprise Gate R1 and Gate R2. The lymphocyte population is shown in
(B). Digested cells were labeled with fluorescein-conjugated antibodies to CDS
(pan T-cell marker) and CD45R (pan B-cell marker) and the resulting histograms are
shown. In Gate R1 (panel a), 41% of the cells labeled positive. In Gate R2
(panel b), 5% of the cells labeled positive. Therefore the majority of lymphocytes are
in Gate Rl. The thyrocyte population is shown in (C). Digested cells were labeled
with TBI and fluorescein-conjugated anti-human IgG. The resulting histograms are
shown. In Gate Rl (panel a), 63% of the cells labeled positive. In Gate R2
(panel b), 87% of the cells labeled positive. Therefore the majority of the thyrocytes
are in Gate R2. Gate R2 will be used for subsequent fluorescent flow
cytometry studies.
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diseased thyroids were labeled with TBI and a fluorescein-conjugated secondary
antibody. In Gate Rl, 63% of the cells labeled positive (Figure 32C, panel a). In
Gate R2, 87% of the cells labeled positive (Figure 32C, panel b), thereby indicating
that the majority of thyrocytes were located in this population.
Since the majority of thyrocytes and a minimum of lymphocytes were found in
Gate R2, this gate was used for all additional flow cytometry studies.

TNF-R55 levels in the plasma membrane of non-diseased and diseased thyrocytes
as detected by fluorescent flow cytometry
The observed reduction in TNF-R55:TNF-a complexes in the plasma membrane
of diseased thyrocytes could be the result of decreased TNF-R55 density or a decrease
in receptor affinity. To determine which was occurring, the density of TNF-R55 on
the plasma membranes of non-diseased and diseased thyrocytes was ascertained by
fluorescent flow cytometry.
Thyroids were collagenase digested and labeled with anti-murine TNF-R55
(anti-Rl) and fluorescein-conjugated secondary antibody. Controls were cells labeled
with either anti-Rl or secondary antibody. Fluorescence intensity was reduced on
diseased thyroid cells indicating fewer receptors per cell (Figure 33). These results
were determined to be significant by Kolmogorov-Smirnov statistics.
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Figure 33. TNF-R55 levels in the plasma membrane of non-diseased and
diseased thyrocytes as detected by fluorescent flow cytometry. Collagenase
digested thyroid cells from non-diseased and diseased mice were labeled with anti-Rl
and fluorescein-conjugated anti-rabbit IgG. Fluorescence intensity on cells in Gate
R2 was measured. Fluorescence was significantly reduced on diseased thyrocytes.
Insert shows determination of significance by Kolmogorov-Smirnov statistics.
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Soluble TNF-R55 production by non -diseased and diseased thyrocytes
Soluble TNF-a receptors have been shown to be produced by proteolytic cleavage
of the extracellular domain (shedding) of the plasma membrane receptors
(146,147,149). Therefore, as soluble receptor levels increase, the plasma membrane
receptor level decreases (147-148). Our finding of decreased plasma
membrane-associated TNF-R55 in diseased thyrocytes suggested the possibility of
soluble TNF-R55 production by these cells.
Thyrocytes from non-diseased and diseased mice were isolated by collagenase
digestion. Digested thyrocytes were stored in liquid nitrogen prior to use.
Suspensions of diseased and non-diseased thyrocytes (1X106 cells per sample) were
incubated at 37°C for 4 hours. Viability was assessed after incubation by trypan blue
exclusion. 90% of the cells were viable. The culture supernatants were then collected
and soluble TNF-R55 immunoprecipitated with anti-Rl. Fresh media was
immunoprecipitated as a negative control. Samples were subjected to PAGE and
Western blot analysis. Detection of soluble TNF-R55 was performed using anti-Rl
and peroxidase-conjugated secondary antibody. Soluble TNF-R55 has an
approximate molecular weight of 28kDa. Anti-Rl binding was observed at 55kDa in
all samples, including the fresh media negative control (Figure 34, lane 3).
However, the negative control showed no binding at 28kDa. Therefore, any binding
seen in culture supernatants at this molecular weight was due to the presence of
soluble TNF-R55.
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Figure 34. Soluble TNF-R55 production by non-diseased and diseased
thyrocytes. Supernatants from suspensions of 1X106 non-diseased and diseased
thyrocytes were collected and soluble TNF-R55 immunoprecipitated with anti-Rl.
Immunoprecipitated samples were subjected to PAGE and Western blotted. The blot
was labeled with anti-Rl and peroxidase-conjugated anti-rabbit IgG. Fresh media
was also immunoprecipitated and Western blotted for use as a negative control.
The lanes are marked as: (M) markers, (1) supernatant from non-diseased thyrocytes,
(2) supernatant from diseased thyrocytes and (3) fresh media negative control.
Anti-Rl binding is seen in all samples, including the negative control, at 55kDa and
therefore can be attributed to small amounts of contaminating TNF-R55 in the media.
The molecular weight of soluble TNF-R55 is 28kDa. Soluble receptor is barely
detected in supernatant from non-diseased thyrocytes. Diseased thyrocytes produce
80% more soluble receptor than non-diseased thyrocytes, as determined by
densitometric scanning. No anti-Rl binding is seen at 28kDa in the negative control.
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Non-diseased thyrocytes produced low levels of soluble TNF-R55 (Figure 34,
lane 1). Diseased thyrocytes produced 80 percent more soluble TNF-R55 than
non-diseased thyrocytes (Figure 34, lane 2), as determined by densitometric scan.

Effect of increasing pKC activity on soluble TNF-R55 production by non-diseased
thyrocytes
PKC has been reported to stimulate TNF-a receptor shedding (146). Therefore
we investigated the effect of elevating pKC activity on soluble TNF-R55 production
by non-diseased thyrocytes. To accomplish this, suspensions of isolated non-diseased
thyrocytes were split into two portions consisting of 6X105 cells/sample. One portion
was treated with agents that activate pKC (lOOnM TPA or lOpM OAG). The other
portion was left untreated. Thyrocytes were incubated for 4 hours, after which
viability was determined by trypan blue exclusion. Approximately 90% of the cells
were viable. Supernatants were then harvested and soluble TNF-R55
immunoprecipitated with anti-Rl. Immunoprecipitated samples were subjected to
PAGE, Western blotted and soluble TNF-R55 detected with anti-Rl and
peroxidase-conjugated secondary antibody.
Soluble TNF-R55 was not detected in untreated non-diseased thyrocytes
(Figure 35, lane 1). This changed after activation of pKC by treatment with lOOnM
TPA, wherein TPA stimulated the production of detectable levels of soluble TNF-R55
(Figure 35, lane 2). However, activation of pKC by treatment with lOpM OAG did
not result in production of soluble TNF-R55 (data not shown). These differences in
the results between TPA and OAG could be a consequence of differences in
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Figure 35. Effects of increasing pKC activity on soluble TNF-R55 production by
non-diseased thyrocytes. PKC activity in non-diseased thyrocytes
(6X105 cells/sample) was increased by treatment with lOOnM TPA. Untreated
non-diseased thyrocytes were used as a control. Supernatants were collected after a
4 hr incubation and soluble TNF-R55 immunoprecipitated with anti-Rl.
Immunoprecipitated samples were subjected to PAGE and Western blot analysis. The
blot was labeled with anti-Rl and peroxidase-conjugated anti-rabbit IgG. The lanes
are marked as: (M) markers, (1) supernatants from untreated non-diseased thyrocytes
and (2) supernatants from TPA-treated non-diseased thyrocytes. Soluble TNF-R55 is
28kDa. No soluble TNF-R55 is detected in supernatants from untreated non-diseased
thyrocytes. However, soluble receptor was detected from TPA-treated
non-diseased thyrocytes.
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permeability, stability within the membrane or differential activation of specific
pKC isoforms.

Effect of decreasing pKC activity on soluble TNF-R55 production by diseased
thyrocytes
We have previously reported elevated pKC activity in the thyroids from diseased
mice. We questioned if this enhanced pKC activity was related to production of
soluble TNF-R55 in these cells (see Figure 34). To determine this, pKC activity was
decreased in suspensions of diseased thyrocytes (1.5X105 cells/sample) by treatment
with lOOnM Calphostin C for 4 hours. Untreated cells were also incubated for
4 hours. After incubation, viability was checked by trypan blue exclusion.
Ninety percent of the cells were viable. Supernatants were harvested.
immunoprecipitated with anti-Rl, gel electrophoresed and Western blotted. Soluble
TNF-R55 was detected with anti-Rl and peroxidase-conjugated secondary antibody.
Detectable levels of soluble TNF-R55 were produced by untreated diseased
thyrocytes (Figure 36, lane 1). In contrast, decreasing pKC activity with Calphostin C
resulted in a reduction of soluble TNF-R55 production below detectable levels
(Figure 36, lane 2). Therefore, soluble TNF-R55 production by diseased thyrocytes is
related to their enhanced pKC activity.
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Figure 36. Effect of decreasing pKC activity on soluble TNF-R55 production by
diseased thyrocytes. PKC in diseased thyrocytes (1.5X105 cells/sample) was
decreased by treatment with lOOnM Calphostin C. Untreated diseased thyrocytes were
used as a control. Supernatants were collected after a 4 hr incubation and soluble
TNF-R55 immunoprecipitated with anti-Rl. Immunoprecipitated samples were
subjected to PAGE and Western blot analysis. The blot was labeled with anti-Rl and
peroxidase-conjugated anti-rabbit IgG. The lanes are marked as: (M) markers,
(1) supernatant from untreated diseased thyrocytes and (2) supernatant from
Calphostin C-treated diseased thyrocytes. Soluble TNF-R55 is 28kDa.
Soluble TNF-R55 was detected in supernatant from diseased thyrocytes.
No detectable levels of soluble receptor were seen in supernatant from diseased
thyrocytes treated with Calphostin C.

167

168
TNF-R55 plasma membrane levels after modulating pKC activity in non-diseased
and diseased thyrocytes
During proteolytic cleavage, release of the extracellular domain from the
membrane results in a decrease in functional plasma membrane receptors (147,148).
Therefore, to determine if the production of soluble TNF-R55 receptors by murine
thyrocytes was the result of proteolytic cleavage, we examined plasma membrane
TNF-R55 density after modulating pKC activity.
Suspensions of isolated non-diseased (3.5X105 cells/sample) and diseased
(6.0X105 cells/sample) thyrocytes were treated with agents that modulate pKC activity
(TPA and Calphostin C, respectively) for 4 hours. Untreated thyrocytes were used as
controls. Trypan blue exclusion was used to check viability after incubation and each
suspension was found to contain approximately 90% viable cells. Murine TNF-a was
added to the cell suspensions and allowed to bind to cell-surface TNF-R55.
After binding, TNF-a was crosslinked to the receptor, cells were lysed and the
membranes isolated. The membrane fractions were immunoprecipitated with
anti-murine TNF-a in order to isolate the receptor:TNF-a complexes.
Immunoprecipitated samples were then gel electrophoresed and Western blotted.
Receptor:TNF-a complexes were detected using anti-murine TNF-a and peroxidaseconjugated secondary antibody.
The results obtained were unexpected. Levels of TNF-R55 in the plasma
membrane of non-diseased thyrocytes were not altered by activation of pKC with
lOOnM TPA (Figure 37, lanes 1 and 2). Similar results were seen when the elevated

169

Figure 37. TNF-R55 plasma membrane levels after modulating pKC activity in
non-diseased and diseased thyrocytes. Suspensions of non-diseased thyrocytes
(3.5X105 cells/sample) were either untreated or treated with lOOnM TPA. Suspensions
of diseased thyrocytes (6.0X105 cells/sample) were either untreated or treated with
lOOnM Calphostin C. After 4 hrs of incubation, murine TNF-a was allowed to bind
to cell-surface TNF-R55 and then crosslinked. Membranes were isolated and
receptor:TNF-a complexes immunoprecipitated with anti-murine TNF-a, subjected to
PAGE and Western blot analysis. The blot was labeled with anti-murine TNF-a and
peroxidase-conjugated anti-goat IgG. The lanes are marked as: (M) markers,
(1) untreated non-diseased thyrocytes, (2) TPA-treated non-diseased thyrocytes,
(3) untreated diseased thyrocytes and (4) Calphostin C-treated diseased thyrocytes.
Modulating pKC activity had no effect on plasma membrane TNF-R55 levels in either
non-diseased or diseased thyrocytes.
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pKC activity of diseased thyrocytes was reduced by treatment with lOOnM
Calphostin C. Plasma membrane TNF-R55 levels in Calphostin C-treated diseased
thyrocytes were unchanged from untreated cell levels (Figure 37, lanes 3 and 4).
These experiments were repeated at least twice and yielded similar results.
These results show that production of soluble TNF-R55 was not concomitant with
a reduction in plasma membrane receptor concentrations.

Determination by fluorescent flow cytometry of TNF-R55 levels in the plasma
membrane of diseased thyrocytes after reduction of pKC activity
Cell-surface TNF-R55 levels after reduction of pKC activity in diseased
thyrocytes were detected by fluorescent flow cytometry. Collagenase digested
diseased thyrocytes were incubated with lOOnM Calphostin C for 3 hours. Separate
samples of diseased thyrocytes were left untreated and also incubated for 3 hours.
After incubation, thyrocytes were labeled with anti-Rl and fluorescein-conjugated
secondary antibody. Cell-surface TNF-R55 levels in Calphostin C-treated diseased
thyrocytes (Figure 38B) were not significantly different from levels in untreated
thyrocytes (Figure 38A). This confirms that reducing pKC activity in diseased cells
has no effect upon cell-surface TNF-R55 density.

Secretion of soluble TNF-R55 by diseased thyrocytes
The finding of soluble TNF-R55 production without concomitant reduction of
plasma membrane receptor levels suggested that production of soluble TNF-R55 by
murine thyrocytes may not be due to proteolytic cleavage. This led us to speculate
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Figure 38. Determination by fluorescent flow cytometry of TNF-R55 levels in the
plasma membrane of diseased thyrocytes after reduction of pKC activity.
Diseased thyrocytes were either untreated (A) or treated with lOOnM Calphostin C (B)
for 3 hrs and then labeled with anti-Rl and fluorescein-conjugated anti-rabbit IgG.
No significant difference in fluorescence intensity was observed between untreated and
treated diseased thyrocytes.
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whether soluble TNF-R55 was being secreted by these cells. To test this, diseased
thyrocytes were used since they readily produce soluble TNF-R55.
Murine TNF-a was crosslinked to the cell-surface TNF-R55 on diseased
thyrocytes. The cells were lysed and the total cellular membranes isolated.
The TNF-R55 :TNF-a complexes (plasma membrane-associated receptor) were
removed by immunoprecipitation with anti-murine TNF-a. Once the plasma
membrane-associated receptors were removed, the remaining membrane isolate was
immunoprecipitated with anti-Rl. The immunoprecipitated TNF-R55 was subjected
to PAGE, Western blotted and detected by anti-Rl and peroxidase-conjugated
secondary antibody. The results yielded several molecular weight forms of TNF-R55
(Figure 39). The highest molecular weight form corresponded to the full length
plasma membrane receptor (55kDa). These were most likely receptors destined for
insertion into the plasma membrane. Additionally, four lower molecular weight bands
were seen. One band, a 28kDa form, corresponded to the soluble receptor we
observed in culture supernatants. Another band, at 31kDa, could possibly be the
28kDa form with a leader peptide attached. Two other bands were also seen at 41kDa
and 45kDa. Since the molecular weights of these two forms differ by approximately
4kDa, it is possible that the 45kDa form is the 41kDa form with a leader peptide. We
have not been able to detect the 41kDa form in supernatants from diseased thyrocytes,
therefore, its significance is unknown.
These results suggest the possibility of the synthesis of truncated versions of
TNF-R55 by diseased murine thyrocytes.
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Figure 39. Secretion of soluble TNF-R55 by diseased thyrocytes. Murine TNF-a
was bound and crosslinked to cell-surface TNF-R55 on diseased thyrocytes.
Membranes were isolated and TNF-R55 :TNF-a complexes were removed by
immunoprecipitation with anti-murine TNF-a in order to deplete the sample of
plasma membrane-associated receptor. TNF-R55 in the remaining membranes was
immunoprecipitated with anti-Rl, subjected to PAGE and Western blot analysis.
The blot was labeled with anti-Rl and peroxidase-conjugated anti-rabbit IgG.
The Western blot shows a 55kDa form of TNF-R55, corresponding to the full length
receptor, and 4 smaller forms; a 28kDa form, a 31kDa form, a 41kDa form and a
45kDa form. The 28kDa form corresponds to the soluble receptor. The 31kDa form
could be the soluble receptor (28kDa form) with a leader peptide attached.
Additionally, the 45kDa form is most likely the 41kDa form with a leader peptide.
The 41kDa form is not secreted from the cells and its significance is unknown.
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Activation of pKC in non-diseased thyrocytes after treatment with TPA and OAG
OAG, unlike TP A, was ineffective in stimulating TNF-R55 production by
non-diseased thyrocytes. It was possible that OAG was not effectively activating
pKC. Therefore, the efficiency of OAG and TPA in elevating pKC activity in
non-diseased thyrocytes was assessed. Suspensions of non-diseased thyrocytes were
treated with lOOnM TPA or 10(iM OAG. Untreated thyrocytes were used as controls.
PKC activity was assessed by 32P-incorporation into acetylated myelin basic protein
(ac-MBP) over a 60 minute time course. TPA significantly increased pKC activity by
43% after 30 minutes (p<0.05) of exposure and activity remained elevated at
60 minutes (p<0.001) (Figure 40). Treatment with OAG resulted in a 51% increase in
pKC activity (p<0.05) by 30 minutes. However, by 60 minutes pKC activity returned
to untreated levels (Figure 40).
These results indicate that both TPA and OAG can activate pKC in non-diseased
thyrocytes. However, TPA was able to maintain the elevation in pKC activity longer
than OAG.

Effect of TNF-a on non-diseased and diseased thyrocytes survival
We assessed the ability of TNF-a to induce cytotoxicity in diseased thyrocytes.
Non-diseased thyrocytes were also tested for comparison purposes. Monolayers of
diseased and non-diseased thyrocytes were established in 96-well plates. At the start
of the experiments, cell density was determined by a colorimetric assay using the
bioreduction of MTS. Mitomycin C was not added to the cultures to prevent cell

178

Figure 40. Activation of pKC in non-diseased thyrocytes after treatment with
TPA and OAG. Suspensions of non-diseased thyrocytes were either untreated or
treated with lOOnM TPA or lOpM OAG over a 60 min time course. PKC activity
was measured by 32P-incorporation into ac-MBP. Data was graphed as percent
activity relative to untreated levels. TPA increased pKC activity significantly at
30 and 60 min. PKC activity after treatment with OAG increased significantly at 30
min but was equivalent to untreated levels at 60 min.
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division since we found this agent to be toxic to murine thyrocytes (unpublished
observation M. LaBue and L.M. Green). Also, media was changed before the addition
of TNF-a in order to minimize interference from soluble TNF-R55. Cultures were
then exposed to 70nM murine TNF-a for 48 hours. Cytotoxicity was assessed by a
colorimetric assay measuring mitochondrial dehydrogenase activity with MTT.
We found TNF-a was not cytotoxic to either diseased or non-diseased thyrocytes
(Figure 41). To ensure that our murine TNF-a was active, we assessed cytotoxicity
on L929 cells (181). The LDS0 was found to be 25nM, thereby confirming the activity
of our murine TNF-a (data not shown).

181

Figure 41. Effect of TNF-a on non-diseased and diseased thyrocyte survival.
Cell density was determined in monolayers of non-diseased and diseased thyrocytes
by bioreduction of MTS. Culture media was changed prior to the addition of TNF-a
in order to minimize interference from soluble TNF-R55. Thyrocytes were either
untreated or treated with 70nM murine TNF-a for 48 hrs. Cytotoxicity was
determined by bioreduction of MTT. Murine TNF-a is not cytotoxic to non-diseased
and diseased thyrocytes.
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CHAPTER 4
DISCUSSION

A. Characterization of Autoimmune Thyroiditis in MRL-lpr/Ipr Mice

Collectively the findings of decreased levels of Free T4, increased levels of TSH,
extensive lymphocytic infiltration of the thyroid tissue, and relatively high
concentrations of circulating auto-Ab to Tg and TPO support that these mice have
autoimmune thyroiditis and are functionally hypothyroid.
The diseased thyroid tissue obtained from the MRL-lpr/lpr mice was strikingly
similar to human AT (34) as indicated by extensive infiltration of inter-follicular
spaces by T-lymphocytes. Furthermore, the majority of focal aggregates of
lymphocytes were organized as lymphoid follicle centers composed of Ig positive
B-cells (Figures 4 and 5). For these mice the heaviest localization of infiltrate was in
the peripheral regions of the lobe, coincident with generally smaller thyroid follicles
(Figure 4, panels c and d). An asymmetry similar to this has been previously noted in
humans, with only a partial lobe extensively infiltrated while other areas are relatively
unaffected. This has been referred to as nodular Hashimotos' Thyroiditis and the
explanation for it is currently unknown (34). This asymmetry was seen in all the
MRL-lpr/lpr mice thyroid glands examined.
In centrally obtained cryosections the follicles were larger and the distribution
of interstitial lymphocytes more diffuse. The non-diseased mouse thyroid tissue
contained only a few lymphocytes that were generally well dispersed with an
occasional small cluster of 10-20 lymphocytes observed. Both diseased and
183
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non-diseased mouse thyroid tissue had a similar distribution of increasing follicle size,
as sectioning proceeded toward the isthmus. The Tg stained cryosections in Figure 6
show the increased follicle size of thyroid sections obtained from the center of the
lobe and for comparison, the H & E stained sections in Figure 4 were obtained from
the outer portion of the lobe.
Autoimmune thyroiditis is usually associated with hypothyroidism, although,
numerous variations have been noted making a serologic determination critical to the
diagnosis (34). Free T4 and TSH levels were tested to determine if thyroid function
was altered in the MRL-lpr/lpr mice. Total T4 is present in serum in two forms, free
(>0.1%) and protein bound (99.9%) (161). A number of non-thyroidal diseases,
physiologic and pathologic factors can affect the levels of thyroxine binding proteins
and subsequently the level of Bound-T4 (203). Free T4 measurements better reflect
thyroid function than either Total-T4 or Bound-T4 serum levels because they are
subject to fluctuations in thyroid hormone binding protein levels (161,203). Free T4
concentration was on average approximately 40% lower in serum obtained from
diseased mice then from non-diseased mice (Table 1).
A reduction in Free T4 levels suggest that the diseased mice were hypothyroid,
and with that, TSH levels would be expectedly elevated (34). Our results, however
relative, support that the MRL-lpr/lpr mice have approximately 30% higher levels of
TSH in their serum then do the non-diseased mice (Table 1). Additional signs of
hypothyroidism were also observed in the diseased mice which included a loss of fur,
predominantly around the head area, and a general lethargy that was not evident in the
non-diseased mice.
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The auto-reactive Abs detected by ELISA and reported in this study are all of
the IgG class, as the peroxidase secondary Ab used was goat anti-mouse IgG specific.
The presence of anti-DNA Ab in the lupus mice has been previously reported and
correlates well with the lupus nephritis which indicates the severity of their disease
state (54,60). The values of anti-ds-DNA auto-Ab titer that we measured are
reported in Table 1. They are included here to show the variation between individual
mice both diseased and non-diseased. The level of anti-Tg Abs ranged from 200 to
>3500 units in the diseased mouse sera but was undetectable in the non-diseased
mouse sera (Table I). The selective presence of IgG-type anti-Tg Ab detected only
in the diseased mice suggests that they are probably cytotoxic and contributing to the
thyroid dysfunction demonstrable in the MRL-lpr/lpr mice.
A more significant measure of thyroid infiltration and dysfunction is the
detection of serum auto-Abs to TPO. The MRL-lpr/lpr mouse sera tested had an
695 IU average anti-TPO Ab concentration based the standard anti-human TPO
antisera. Rat sera has been previously found to crossreact with human TPO (37) and
as we demonstrate here mouse anti-TPO Abs also bind to recombinant human TPO
(Figure 7). If the species difference reduces the specificity, it is conceivable that the
murine sera levels of anti-TPO Ab are even greater then the levels reported here.
SLE in the MRL-lpr/lpr mice, like in the human SLE that they model, can
present with any tissue or organ system involved in inflammation-mediated
autoimmune tissue destructive processes (52,53,55,56). The presence of numerous
circulating auto-Ab in human SLE and the MRL-lpr/lpr mice is expected.
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In patients with SLE, with no evidence of thyroid involvement, can have anti-Tg and
anti-TPO Abs detectable in their serum (204). However, determining the fine
specificity of these Abs revealed that they differed in both the epitopes they recognize
and their Ig functional properties when compared to anti-TPO Abs isolated from
patients with clinically diagnosed thyroid disease (205). The association between SLE
and AT is approximately 51% (206). These patients are found to have circulating
anti-thyroid Abs and to be slightly hypothyroid (206). It is likely that these numbers
would increase with age and severity of this progressive disease, if not for the
chemotherapeutic efforts to suppress T-cell (immune) function in these patients.
These measures are not taken in the MRL-lpr/lpr mice and the incidence of AT, based
on this study, is 100% of mice >5.5 months old.
A drawback to the existing models of EAT is that the induction procedure
appears to significantly skew the balance of resident T-cell populations, thereby
complicating the study of selection mechanisms that actually function in the initiation
of thyroid disease. A spontaneous model of AT would eliminate this problem.
The only existing spontaneous model of mammalian AT that we are aware of is the
non-obese diabetic mouse which has an increased incidence of AT (50). This model
provides a better source of information than the induced models, but is limited.
The development of AT in these mice is highly variable even in litter-mates housed
together (50,51). Another factor that detracts from this model is that only 35% of the
mice have anti-thyroid auto-Abs even when mouse thyroid extract was used as the
source of epitotic recognition (50). This extract should contain the majority of thyroid
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auto-antigens and would be expected to have an increased frequency of detecting
circulating anti-thyroid Abs.
MRL-lpr/lpr mice spontaneously develop an SLE-like disease, and as we
document in this study, they also consistently present with AT. This study describes a
spontaneous model for autoimmune thyroiditis that does not require any manipulative
procedures that would alter naturally occurring T-cell sub-sets. Therefore, employing
this MRL-lpr/lpr mouse model will allow assessment of the development and
phenotypic distribution of thyroid reactive clones to be determined in a genetically
defined context.

B. Mechanisms Regulating Cx43-Mediated Cell-Cell Communication in a Fetal
Rat Lung Cell Line

Effect of pKC on Cx43 -mediated dye transfer
This investigation was undertaken to better define the ability of pKC-mediated
phosphorylation to modulate cell-cell communication through Cx43 gap junctions.
FRL cells were chosen because they are extremely well coupled by Cx43 gap
junctions, express equivalent levels of two isoforms of pKC (alpha and beta) and
respond to activation of their pKC with a loss of intercellular dye transfer. Treatment
with TPA reduces cell-cell communication in FRL cells from their basal well-coupled
state to undetectable dye transfer in 2 hours or less. Dye transfer remained
undetectable for 6 hours, after which time it gradually returned, reaching 100% by
24 hours after treatment with TPA.
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It became apparent early in these studies that the effects of TPA would be difficult
to interpret because this tumor promoter activated both pKA and pKC, as indicated in
the present study and in previous studies (207,208). Thus, in each protocol where
TPA was used, we repeated those experiments using OAG which did not co-activate
pKA. By this means our results could be compared to those of the many reports that
have used TPA, and in addition, greatly reduce the chance that pKA activation was
contributing to the observed responses.
The fact that alkaline phosphatase injection eliminated cell-cell communication
demonstrates that under basal conditions Cx43 is polymerized as phosphorylated
hemichannels. This is consistent with previous in vitro studies (189). However, after
phosphatase treatment communication was restored fully by injection of pKA but only
transiently by the injection of pKC. These results extend our earlier observations
(166) and indicate that there are at least two separate sites that can be phosphorylated
by pKC. One of these sites may be shared with pKA since both enzymes can reinstate
Cx43-communication (166) that had been eliminated by phosphatase injection.
The other site, however, may be a better substrate for pKC and when phosphorylated
causes a decrease in cell-cell communication. This may normally be the signal for
channel closure and turnover. The existence of this putative second phosphorylation
site is further supported by our observation that the inhibitory effects of pKC on dye
transfer could be prevented within a limited time period (<60 minutes) following pKC
activation. This was achieved by injection of the CKI inhibitor protein and,
alternatively, by an increase in pKA activity. A similar observation was reported by
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Kanno et.al. (209) where cAMP prevented the decrease in cell-cell communication
provided the intracellular levels of cAMP were sufficiently elevated prior to complete
pKC-induced uncoupling. More recently, it was observed that clonal L-929 cells
transfected with a mutant Cx43 consisting of a replacement of Ser364 by a proline had
altered responses to injected pKA and pKC (210). Introduction of pKA into cells
expressing the mutant Cx43 had no effect on dye transfer whereas cells transfected
with the wild type Cx43 exhibited an increase in the amplitude of dye transfer.
However, injection of pKC into cells expressing mutant Cx43 resulted in a significant
increase in dye transfer while the cells expressing the wild-type Cx43 were either
unaffected or exhibited a slight decrease. These observations in the context of the
results presented here can most easily be explained by the existence of a site on the
Cx43 protein that is normally phosphorylated by pKC but not by pKA. In this regard,
an in vitro study by Saez, et.al (70) showed that a synthetic peptide corresponding to
the carboxy tail of Cx43 was phosphorylated on serine residues 368 and 372.
Although the exact serine residues responsible for the opened or closed status of Cx43
are not absolutely assigned, the reports we have just described suggest that the three
tandem, paired serines in the carboxy terminus of the Cx43 molecule (71) may be the
targets of this phosphorylation based regulatory mechanism.
The majority of reports on pKC and pKA-induced modulation of dye transfer
in Cx43-expressing cells are in agreement with the results discussed above. However,
a recent report by Lampe (199) states that when undissociated pairs of Novikoff
hepatoma cells were treated for 60 minutes with 50nM TPA they retained their ability
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to transfer dye. Interpreting these results is difficult because OAG was not used as a
surrogate and no assays measuring cellular pKA or pKC activities as a result of TPA
treatment were reported. This leaves open the possibilities that the hepatoma cells
may have been refractive to TPA, or the tumor promoter may be increasing pKA as
has been found in other hepatoma cells (207) and as described here (Figure 10).

Immunocytochemical localization and post-translational processing induced by pKC
activation
Integral membrane proteins, in general, are co-translationally processed
through the endoplasmic reticulum and Golgi in order to maintain their conformation
(211). Co-translational assembly is dependent on the presence of a leader peptide
which orients the newly translated protein. Studies on synthesis and trafficking
document that this is also true for connexin proteins (200,212). Given this, we can
combine the results of our immunocytochemical localization and post-translational
studies to determine the fate of Cx43-protein following pKC activation. The gradual
loss of immuno-reactive Cx43 from the plasma membrane of FRL cells following
pKC activation coincided with an increased cytoplasmic localization of this protein.
This increase in cytoplasmic Cx43 has been seen by others following exposure of cells
to agonists of pKC or low levels of extracellular Ca++ (190,213). Of the total Cx43
extracted from FRL cells only about 2% or less was represented by the cytosolic
forms, Cx43-np (42kDa) and Cx43-P2 (47kDa). FRL cells do not appear to contain
the intermediate molecular weight form of Cx43-Pl, which is also absent in adult
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heart tissue (100,214). This suggests that the Cx43-Pl species may represent a form
of Cx43 that is not an isolated intermediate in extremely well coupled cells or tissue.
Immunoprecipitation of these cytosolic forms of Cx43 revealed an initially
decreasing but otherwise un-remarkable level of Cx43-np. The Cx43-P2 form was
9 fold greater in concentration than the Cx43-np form and steadily increased during
the 2 hours following pKC activation. Currently, cytosolic Cx43-np is thought to be a
precursor to the Cx43-P2 form (187,213). In our study, the large difference between
these species prevented our confirming a similar relationship. However, purified Cx43
(alphaJ is not phosphorylatable in vitro by pKA unless it is denatured at 90°C
(unpublished observation, Maithili Shah and William Fletcher). This implies that
removal of Cx43 from phospholipid causes a conformational change that masks critical
serine residues. It is highly unlikely that a soluble form of Cx43 could be inserted or
re-inserted into phospholipid. Based on this, cytosolic Cx43-np is more likely a
reduction product of cytosolic Cx43-P2 rather than a precursor to Cx43-P2.
This information supports a conclusion that increased Cx43 in the cytoplasm is
generated predominantly from Cx43 that has been removed from phospholipid and the
plasma membrane. The peak increase in cytosolic Cx43-P2 at 120 minutes coincides
with the complete loss of plasma membrane identifiable gap junctions at 2 hours.
The dephosphorylation of this cytosolic Cx43-P2 would be expected to produce a
Cx43-np species. Alternatively, a small percentage of Cx43 transcripts may lack a
signal peptide and therefore would not be co-translationally inserted into the
endoplasmic reticulum (200). In this scenario, upon completion of protein synthesis,
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the protein would be released to the cytosol and could potentially contribute to
Cx43-np isolated from the cytosol. These forms of Cx43 generated without a signal
peptide could not participate in functional gap junctions or cell-cell communication.
Given that the half-life of Cx43 protein appears to be 1.5-2 hours (112), the
ability of TPA or OAG to completely eliminate detectable Cx43-protein from the
plasma membrane by 2 hours clearly constitutes an acceleration of the normal Cx43
half-life. There is preliminary evidence that Cx43 protein is removed from the
membrane and degraded by the ubiquinone-proteosome pathway (215). It is a
common finding that prior to ubiquination, target proteins are first phosphorylated and,
in our system, this may be mediated by pKC.
Following TPA or OAG activation of pKC, 16-24 hours were required for
plasma membrane assembled Cx43 gap junctions to be restored to untreated levels.
Evidence presented by Laird et.al. (112) suggests that constitutive production of Cx43
protein creates a reservoir of newly synthesized protein that should be readily available
for replacement of turned over connexons. Therefore, the delay in recovery suggests
that the down-regulatory effect of pKC was not limited to acting on existing Cx43
channels. For example, increased pKC activity must also be phosphorylating the pool
of Cx43 and thereby render it unable to be inserted into the plasma membrane.
Further support for this conclusion comes from the microsomal/plasma membrane
phospholipid pellet isolated in our post-translational experiments. This fraction
contained only the Cx43-P2 form and constituted approximately 98% of the total
cellular Cx43 protein which steadily and significantly increased (27 times basal levels)
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following pKC activation. The elevated level of lipid-associated Cx43-P2 persisted
throughout the 3 hours measured. This sustained increase could not be coming from
the plasma membrane because by 2 hours after increasing pKC there were no
identifiable Cx43 gap junction in the plasma membrane. These results strongly
suggest that the increased level of Cx43-P2 must represent newly produced
phosphorylated Cx43 as it was being shuttled to the plasma membrane. Therefore, the
protracted recovery could be due to this premature phosphorylation of Cx43 that
renders the pool unusable.
These findings, combined with those reported by Lampe (199), demonstrate
that the experimentally elevated and sustained activity of pKC phosphorylates Cx43 to
a P2 form which prevents its subsequent assembly into gap junctional plaques in the
plasma membrane. Additionally, these results can be extrapolated to explain the
ability of enhanced pKA activity to rescue cells from pKC-mediated inhibition.
PKA may be able to salvage Cx43 in transit by facilitating its incorporation into the
plasma membrane prior to its being rendered uninsertable by pKC-mediated
phosphorylation. If so, it would have to occur before the stores of Cx43 were
prematurely converted to an unusable P2 form by pKC. Once Cx43 phosphorylated
by pKA was incorporated into the plasma membrane, it would then be subjected to the
same pKC-mediated inhibitory events as other existing plasma membrane associated
Cx43 channels.
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Effect of pKC on transcription of Cx43
The ability of enhanced pKC activity to reduce Cx43 (alpha x) mRNA was
previously reported in keratinocytes (191). In FRL cells there was a 75% reduction in
Cx43 mRNA by 6 hours post TPA or OAG treatment. Although the mechanism of
this decrease in Cx43 mRNA has not been previously explored, there are several
alternative explanations that can be addressed. 1.) Enhanced pKC activity could act
directly at the level of Cx43 transcription resulting in a decreased production of
mRNA. 2.) Increased pKC activity could act at the level of transcription and induce
the synthesis of transcripts that give rise to either a message destabilizing protein, or
alternatively, to a protein that blocks the action of normal message stabilizing proteins.
3.) The activation of pKC could phosphorylate existing proteins that function in
message degradation, and 4.) The activity of pKC could phosphorylate existing
proteins that act to prevent message stabilization. To distinguish between these
possibilities several experiments were performed.
When new transcription was inhibited with DRB, prior to activating pKC, the
decrease in Cx43 mRNA was prevented. The fact that blocking transcription allowed
Cx43 mRNA to be degraded at a normal rate indicated that transcription was required
for the accelerated decrease in Cx43 mRNA following pKC activation. It does not,
however, reveal whether pKC was acting directly on Cx43 mRNA (possibility 1), or
whether it was acting on some other transcript(s) (possibility 2). Inhibiting
transcription with DRB does not affect existing proteins, and as such argues against
possibilities 3 and 4 as tenable explanations for the decrease in Cx43 mRNA. Further,
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inhibiting protein synthesis with CHX also prevented the decrease in Cx43 mRNA
following activation of pKC. This demonstrates that translation of a pKC-induced
transcript was required for the observed effect on Cx43 mRNA and thereby supports
possibility 2 as the most likely mechanism for the decline in Cx43 mRNA.
The decrease in Cx43 transcript caused by increased pKC activity was independent of
its action on gating, intra-cellular distribution and post-translational processing.
However, this reduction in message would be expected to contribute to a protracted
recovery by delaying replacement of stores of available Cx43 protein.
Conclusions
The findings presented here are consistent with the following model of
regulation of Cx43 by pKC. The amino acid sequence of Cx43 contains a number of
potentially phosphorylatable sites, including three tandem sets of duplicate serine
residues located in the carboxyterminus (71). Under dephosphorylated, possibly also
under basal conditions, pKA and pKC are capable of maintaining Cx43 channels in an
open configuration. However, an experimentally sustained increase in pKC activity
results in a closure of Cx43 channels, possibly by a phosphorylation-driven conversion
of Cx43-P2 to a closed form of the protein. This elevated activity of pKC may also
render Cx43 that is in transit to a form that can not be incorporated into the plasma
membrane. The conversion of Cx43 to an uninsertable form, in conjunction with the
reduced Cx43 mRNA, can account for the extended recovery time. This can also
explain reports wherein activated pKC was associated with an increase in Cx43-P2
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isolated from membrane/microsomal phospholipid in the absence of cell-cell contact,
extracellular calcium and functional communication (191,192,213). Resolution of
these three putatively different species of Cx43-P2 on denaturing polyacrylamide gels
removes them from the constraints of boundary lipid and could result in conformations
that are unresolvable under denaturing conditions. Support for this idea comes from a
recent report by Lang et.al. (182) wherein, the 5 different phosphorylated forms of
Cx45 have identical electrophoretic mobilities on SDS page. Collectively, these
findings suggest that intracellular location and conformation of Cx43 at the time of
phosphorylation is critical to its functional status.

C. Reduced Cell-Cell Communication in a Spontaneous Murine Model of
Autoimmune Thyroid Disease (MRL-lpr/lpr Mice)

Our original premise was that chronic inflammation would decrease gap
junctional mediated cell-cell communication in this murine model of spontaneous
autoimmune thyroiditis. The initial studies focussed on the amount and location of
connexin proteins in normal and diseased thyroid tissue. The quantities of two
connexin proteins, Cx43 and Cx26, were substantially decreased. More importantly, in
the diseased tissue these two Cxs, as well as Cx32, were not located in gap junctional
plaques in the plasma membrane. Thus thyroiditis was associated with both reduced
levels of Cx and fewer gap junctions. This suggested that cell-cell communication
might also be impaired. This decrease in gap junctions could be due to lack of
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physical contact among thyrocytes secondary to the presence of infiltrating
lymphocytes (mechanical-physical disruption).
To create a system to directly examine gap junction function and to reduce the
effects of the confounding physical factors described above we established monolayer
cultures of cells isolated from normal and diseased thyroids. Several technical factors
are important to consider in order to interpret the dye transfer studies. 1) A number of
different matrix preparations were compared in the initial experiments to establish the
thyroid cells in culture. The components tested included vitronectin, enactin, laminin,
fibronectin, collagen and various combinations of these matrix factors. There was
virtually no difference in the plating efficiency, growth, viability, state of
differentiation, or cell-cell communication with the use of any of these mixtures
(data not shown). Therefore type I collagen from rat tail and rat skin was used for all
cultures. 2) Theoretically, the cell populations isolated from the normal and diseased
thyroids could be different due to the presence of lymphocytes and other inflammatory
cells in the diseased thyroids. Virtually all cells (>98%) labelled with antibody to Tg
demonstrating that there was minimal contamination by inflammatory cells and
excludes overgrowth by fibroblasts. Furthermore, it demonstrates that the cultured
cells maintain some aspect of the differentiated thyroid epithelial cell phenotype.
3) Although the diseased cells contain Tg they did not form follicles to the same
degree as cells isolated from normal animals. To maintain uniformity in the
experimental and control cultures we used conditions that supported monolayers but
did not promote follicle formation in the normal cells. 4) As with many differentiated
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epithelial cells, the thyrocytes from both normal and diseased animals "age” in primary
culture. With long term cultures the cells retract from each other and ultimately
become communication deficient (108). All Cx and communication studies were done
on culture days 3-7, a time point prior to this "aging" process.
Cells isolated from the normal mice rapidly establish gap junctions and
intercellular communication as demonstrated by dye transfer to primary, secondary and
tertiary cells. These results are similar to the rapid establishment of communication in
primary cultures of normal porcine thyroid epithelial cells, although there are some
methodologic (10% BCS) and Cx specific differences (Cx26 is not expressed) (216).
In contrast, the cells isolated from the MRL-lpr/lpr thyroids transferred dye to primary
contacts in only 20% of experiments, and to secondary cells in none of the trials.
The reduced Cx protein and lack of discrete plasma membrane assembled gap
junctions in the cultured diseased thyroid cells strongly suggests that decreased dye
transfer was due to abnormal assembly of Cx into functional connexon channels and/or
possibly decreased Cx production. Furthermore, the relative reduction and abnormal
localization of Cx was nearly the same in the cultured thyrocytes as was found in the
diseased thyroid tissue. Thus short term culture appears to be a reasonable model for
the in vivo abnormalities of Cx and gap junctions, especially with regard to Cx43.
Reduced cell-cell communication was not due to physical disruption by
infiltrating lymphocytes since these cells were not present in the cultures and the
routine histology clearly demonstrated that the cells isolated from diseased thyroids
were not physically separated from one another to any greater degree than the
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thyrocytes isolated from normal mice. We cannot exclude the possibility that
cytokines released by the inflammatory cells in situ caused the abnormal Cx
production and gap junctional assembly. However, if those factors are responsible
they must have prolonged (>5 days) effect on the thyroid cells ability to produce Cx
or assemble the Cx into gap junctions.
The quantity of Cx43 and Cx26 proteins was reduced in the diseased thyroids.
In the same tissue Cx32 and Cx26 mRNA were reduced while Cx43 mRNA was equal
to Cx43 mRNA in the control thyroids. The presence of residual lymphocytes, which
contain Cx43 mRNA but no Cx32 or Cx26 mRNA, in the diseased tissue may
contribute significantly to the measured Cx43 mRNA. In addition the relative
abundance of Cx mRNAs did not reflect the relative abundance of Cx proteins in
either control or experimental thyroids. Thus the significance of inflammationinduced reduction of Cx mRNA is unclear. The minimum quantity of Cx transcript
needed to maintain junctional competency has not been determined. As such, there
are tightly coupled cells that have very low concentrations of Cx mRNA (95).
Those results indicate that quantity of Cx mRNA may be less important to the
maintenance of communication than other factors such as posttranslational processing
(phosphorylation and protein half-life), the assembly of Cx monomers into multimeric
hemi-channels, or the trafficking to and insertion of those channels into the
plasma membrane.
Like other endocrine tissues (217-220) the thyroid may have a
non-homogeneous distribution of TSH receptors. Thus when TSH binds to
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TSH-receptor bearing cells the signal would normally be sent through Cx channels to
contacting and even to distant follicular cells which lack TSH receptors. This would
result in a coordinated response to TSH and increase the production and release of
'

thyroid hormones. As we have seen, the MRL-lpr/lpr mice are relatively hypothyroid.
The physical infiltration of inflammatory cells in this autoimmune thyroid disease may
lead to separation and destruction of follicular epithelial cells. However, our results
demonstrate that the thyroid tissue and cells isolated from these thyroids have reduced
Cx and aberrantly located Cx aggregates and that the cultured cells exhibited less
cell-cell communication. This may provide an additional mechanism for deficient
thyroid hormone secretion even when the physical disruption in vivo is limited.
The normal murine thyroid tissue produced three Cx proteins. Our results
suggest that each of the three Cx assembles into gap junctions in the thyroid epithelial
cell at unique locations in the plasma membrane: Cx32 connects cells within
individual follicles; Cx43 connects cells in adjacent follicles; and Cx26 is found
predominantly at the follicle lumenal surface. This distribution suggests that each Cx
could have a specific or unique role in signalling, in Tg or thyroid hormone transport,
or in tissue organization. While the above hypotheses are clearly speculative, at this
stage these possibilities are indirectly supported by several other findings: 1) The
same specific pattern of Cx localization is seen in normal rat thyroid (114). Thus the
pattern is not species specific. 2) The cultured normal murine thyroid cells contain
small quantities of Cx32 under conditions where they do not form significant numbers
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of follicles in vitro. 3) Cells isolated from normal porcine thyroid glands produce
large amounts of Cx32 (and Cx43) just prior to forming follicles in vitro (216).
Collectively our findings document that the spontaneous autoimmune thyroid
disease which occurs in MRL-lpr/lpr mice is associated with variably reduced Cx
proteins and mRNA, with abnormal localization of Cx-assembled gap junctions, and
with decreased thyroid epithelial cell-cell communication. The loss of tissue integrity
due to infiltration of inflammatory cells or fibrosis cannot account for these anomalies.
We have preliminarily noted similar results in a thyroglobulin-induced model of
thyroiditis in rats (10). Thus these abnormalities are not limited to either the mouse or
to the unique spontaneous disease in these mice. Furthermore the specific localization
of the Cx in normal thyroid tissue and thyroid cells in tissue culture suggest that
individual Cx gap junctions may participate in different thyroid functions and/or
tissue organization.

D. Elevated PKC Activity Can Explain the Decrease in Cx43-Mediated Cell-Cell
Communication in Thyrocytes from Mice with Autoimmune Thyroiditis

In this study we document that pKC activity is increased in thyrocytes obtained
from MRL-lpr/lpr mice with spontaneous autoimmune thyroiditis. There are several
possible mechanisms which could account for this increase in pKC activity. 1). The
m-form of pKC could be present in thyrocytes from diseased mice. The m-form is a
truncated from of pKC which lacks the regulatory domain and therefore is
constitutively active (221). 2). There could be a defective G-protein.
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Mutationally activated Gal2 facilitates arachidonic acid mobilization (222) and point
mutations in Gaq resulted in constitutive phosphoinoside hydrolysis by phospholipase C
(223,224). 3). PKC protein levels could be increased, resulting in increased overall
activity. Of these three possible mechanisms, the last mechanism is the most plausible
since several pKC isoforms are increased, with a corresponding increase in activity, in
thyrocytes from Lewis rats with adjuvant/Tg-induced experimental autoimmune
thyroiditis (manuscript in preparation).
We have reported in this dissertation that gap junctional mediated communication
was decreased in the thyroids from the autoimmune-diseased mice. Thyroid tissue
from these mice had decreased expression in the plasma membrane of the three gap
junctional proteins found in the thyroid, Cx43, Cx32 and Cx26. The decrease in
cell-cell communication persisted in culture despite maximizing physical contact and
removal of inflammatory mediators. This indicated that physical disruption was not
the cause of the altered communication. The increase in pKC activity in thyrocytes
from the diseased mice suggested that this was the most likely cause of their altered
Cx43-mediated communication. PKC has previously been shown by our laboratory
and others (113,166,191,199) to decrease Cx43-mediated cell-cell communication in a
variety of clonal cell lines and primary cells by closing existing channels and
preventing insertion of new gap junctions into the plasma membrane. Cx43 is the
primary gap junctional protein found in monolayers of thyrocytes. In this present
study, we have found that modulating pKC activity in the diseased and non-diseased
thyrocytes results in dramatic changes in Cx43-mediated intercellular communication.
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When cultured diseased thyrocytes were treated with the pKC inhibitor Calphostin C,
Cx43-mediated communication was fully restored to levels comparable to those found
in thyrocytes from non-diseased mice. This was indicated by restoration of LY dye
transfer and appearance of Cx43 gap junctional plaques in the plasma membrane.
Conversely, when cultured non-diseased thyrocytes were treated with the pKC
activators TPA and OAG, Cx43-mediated communication was abolished, as indicated
by a lack of LY dye transfer and Cx43 plaques in the plasma membrane. This is in
agreement with Muneri-Silem, et. al, who found TPA blocked the dye coupling of
porcine thyroid cells in reconstituted follicles (116). Therefore, by merely modulating
pKC activity we can alter the communication competence of both the non-diseased
cells and, more importantly, the diseased thyrocytes. These results clearly indicate
that the pKC is a potent regulator of Cx43-mediated cell-cell communication in
murine thyrocytes. Furthermore, the observed decreased in Cx43-mediated cell-cell
communication in the diseased thyrocytes is directly related to their enhanced
pKC activity.
There was some difference between the effectiveness of TPA and OAG in
decreasing communication. OAG decreased communication less efficiently than TPA.
This may simply be due to differences in permeability or to the transient presence of
OAG in the plasma membrane verses the persistence of phorbol esters (225).
Alternatively, some isoforms of pKC are more readily activated by diacylglycerol
(DAG) analogs, like OAG, than other isoforms. The alpha and gamma isoforms of
pKC are much less responsive to activation by DAG than the Beta^^ and Betau
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isoforms. The Beta isoforms are more readily activated by DAG, even in the absence
of Ca2+ (11). TPA activates these isoforms equally well. We do not know if the
individual isoforms have different specificities for Cx43. It is possible that isoforms
which are more readily activated by OAG are less specific for Cx43, which could
explain the less efficient down-regulation of communication by OAG in our system.
In addition to its effects on Cx43-mediated communication, pKC has been
implicated in the control of differentiated thyroid function. The effect of pKC on
thyroid metabolism, specifically iodide organification, has been shown to be variably
affected by pKC in several species. Treatment of ovine (29), canine (30) and porcine
(31,32) cultured thyrocytes with TPA or DAG analogs resulted in decreased iodide
uptake and incorporation. The opposite was found in murine thyroids. In murine
follicles TPA stimulated iodide incorporation (33). These interspecies variations may
be the result of differences in pKC isoform expression and/or their state of activation.
TPA also affects secretion of iodinated proteins. In ovine thyrocytes, secretion of
iodinated Tg and thyroid hormones was increased upon treatment with TPA (226).
Additionally, TPA was reported to stimulate the release of T3 by mouse thyroid tissue
(227). We, however, found that TPA and OAG significantly reduced T4 secretion in
cultured thyrocytes from our non-diseased mice, with OAG being a less potent
inhibitor of T4 release. We do not know at this time if this decrease in T4 release is
the result of decreased synthesis or an increase in conversion of T4 to T3 within the
thyroid. At this time, we favor the possibility of increased conversion to T3. This is
based on previous studies using murine thyroid tissue which show an increase in
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iodide organification (33) and an increase in T3 release (227) in response to pKC
activation. An increase in conversion would reconcile our results with these other
studies since increased conversion could conceivably result in decreased T4 release
with a simultaneous increase in release of T3* We are currently investigating the effect
of elevated pKC activity on T3 release by cultured thyrocytes from our
non-diseased mice.
The mechanism by which pKC influences thyroid metabolism remains to be
elucidated. We investigated whether pKC was exerting its effect on murine thyroid
function (decreased T4 release) through its down-regulatory effect on cell-cell
communication. Cell-cell communication has previously been shown to influence
insulin and amylase secretion by pancreatic cells (96,97). In order to investigate the
effect of altered cell-cell communication on T4 release by murine thyroid cells, it was
necessary to decrease communication without affecting protein kinase activity. In our
study, heptanol was used to achieve this. Heptanol reduces communication by
changing membrane fluidity thereby preventing connexon aggregation (202). It does
not effect protein kinase activity, as demonstrated in Figure 29. Therefore any effect
observed on T4 release as a result of treatment with heptanol can be attributed to
closure of gap junctional channels and not due to activation of protein kinases.
Heptanol completely abolished cell-cell communication in cultured thyrocytes from
non-diseased mice. Elimination of communication with heptanol significantly reduced
T4 release. This decrease was equivalent to that seen with OAG but not as great as
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that seen with TPA. This indicates that gap junctional communication can regulate the
release of T4.
The inability of the heptanol-induced elimination of cell-cell communication to
fully mimic the effect of TPA on T4 release indicates the existence of other
mechanism(s) by which pKC (or TPA) is influencing thyroid metabolism. These
mechanisms may include an inactivation of thyroid specific transcription factors.
PKC was found to inhibit nuclear migration of the catalytic subunit of pKA in v-ras
transformed FRTL-5 cells, a rat thyroid epithelial cell line (228). This resulted in an
inactivation of thyroid specific transcription factors that are dependent upon
phosphorylation by pKA (228). However, it should be noted here that TPA is known
as a global activator of protein kinases (207,208) and could potentially have several
unknown effects on thyroid function.
The decreased effectiveness of OAG, in comparison to TPA, in altering T4 release
is not unexpected. In previous reports using dog (30), sheep (29) and pig (31)
thyrocytes, DAG analogs were found to be less effective than TPA in influencing
differentiated thyroid function. Again, this could be due to several possibilities, which
include differences in permeability and differential activation of pKC isoforms.
However, we found that the OAG-induced decrease in T4 release was equivalent to
the decrease observed after treatment with heptanol. It is therefore possible that OAG
causes a reduction of T4 release solely through its effect upon
cell-cell communication.
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In summary, thyrocytes from MRL-lpr/lpr mice with autoimmune thyroiditis have
a significantly higher basal pKC activity than thyrocytes from their non-diseased
counterparts. This increase in pKC activity is responsible for the decreased in Cx43
gap junctional-mediated communication in the thyrocytes from diseased mice.
Furthermore, activation of pKC decreases T4 secretion in thyrocytes from
non-diseased mice. The effect of pKC on T4 secretion is partially mediated through
its effect on intercellular communication. This can further explain the low serum T4
levels associated with the autoimmune thyroiditis in MRL-lpr/lpr mice.

E. Thyrocytes from Mice with Spontaneous Autoimmune Thyroiditis Produce
The Soluble Form of the 55Kd TNF-a Receptor

It has been speculated that soluble TNF-a receptors could protect cells from the
effects of TNF-a by competitive binding. In support of this, increased serum levels
of soluble TNF-a receptors are found associated with increased serum concentrations
of TNF-a (144,145). Upon initial examination, it would appear that increased levels
of soluble TNF-a receptors would be beneficial. In actuality, the inhibitory nature of
soluble TNF-a receptors could be beneficial or detrimental, depending on the disease
state. For example, production of soluble TNF-a receptors could be potentially
detrimental when associated with malignancies since soluble receptors could protect
tumor cells from cytotoxicity. However, in autoimmune diseases, soluble TNF-a
receptors could have a beneficial role by protecting the target tissue.
T-cells cloned from patients with Hashimoto's thyroiditis have been shown to
produce TNF-a (151). This is significant since TNF-a has been shown to adversely

208
effect thyroid function (decreased iodide organification and thyroid hormone release)
(153,154). In the preceding pages, we have documented development of spontaneous
autoimmune thyroiditis in MRL-lpr/lpr mice. Furthermore, we have detected
increased serum levels of TNF-a in these mice. Therefore, the focus of this study
was to determine if autoimmune diseased thyrocytes from MRL-lpr/lpr mice were
producing soluble TNF-a receptors in an attempt to protect themselves from the
potentially detrimental effects of increased TNF-a levels.
To accomplish this, it was first necessary to identify the type of TNF-a receptor
(TNF-R55 or TNF-R75) present on murine thyrocytes. The two TNF-a receptors
have less than 25% homology with each other and possibly mediate different cellular
responses (129). We found that murine thyrocytes possess only TNF-R55. This was
not unexpected since TNF-R55 is found on a variety of cell types whereas TNF-R75
appears to be restricted to hematopoietic cells (229,230).
Soluble TNF-a receptor production has been shown to be accompanied by
decreases in plasma membrane receptor levels (147,148). Therefore, we compared cell
surface TNF-R55 levels on diseased thyrocytes with levels on non-diseased thyroid
cells. We found that the density of plasma membrane-associated TNF-R55 was lower
on diseased thyrocytes when compared to non-diseased thyrocytes. It was therefore
possible that the diseased thyrocytes were producing soluble TNF-R55.
Given the above results, we next examined production of soluble TNF-R55 by
non-diseased and diseased thyrocytes in vitro. We found that diseased thyrocytes
produced 80% more soluble TNF-R55 than non-diseased thyrocytes, which produced
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barely detectable levels. Furthermore, the stimulus for soluble TNF-R55 production
could be intrinsic to the diseased thyrocytes since these experiments were done
in vitro, where lymphocytes and their soluble mediators were removed.
Soluble TNF-a receptor production has been shown to be induced by activation of
pKC (140,146-148). We have reported elevated pKC activity in our diseased
thyrocytes. Therefore, we speculated that the enhanced pKC activity in the diseased
thyrocytes could be involved in their increased production of soluble TNF-R55.
To test this, we decreased pKC activity in diseased thyrocytes by treatment with
Calphostin C, a pKC inhibitor. Inhibition of pKC caused soluble receptor production
to drop below detectable levels. This indicated that soluble TNF-R55 production by
diseased thyrocytes was associated with their elevated pKC activity.
To further confirm the effects of pKC on soluble TNF-R55 production by murine
thyrocytes, we activated pKC in non-diseased thyroid cells by treatments with either
TPA or OAG and assessed soluble TNF-R55 levels. Activation of pKC with TPA
resulted in increased production of soluble TNF-R55 by non-diseased thyrocytes.
These results, combined with decreased soluble receptor production by diseased
thyrocytes after pKC inhibition, strongly suggest a regulatory role for pKC in the
production of soluble TNF-R55 by murine thyrocytes.
Unlike TPA, when pKC in non-diseased thyrocytes was activated with OAG, no
soluble TNF-R55 production was detected. There are several possible explanations
for the inability of OAG to influence soluble TNF-R55 production. These
explanations include differences between TPA and OAG in permeability, stability
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within the membrane and differential activation of pKC isoforms. To help clarify
which is occurring, we measured pKC activity in non-diseased thyrocytes after
treatment with TPA or OAG. We found that both activators increase pKC activity
within the same time frame (30 minutes) and the maximum level of activation attained
was nearly equivalent. However, activity stimulated by OAG dropped to untreated
levels relatively quickly, whereas TPA maintained pKC activation. It is therefore
possible that the inability of OAG to sustain pKC activation could be partially
responsible for its inability to increase TNF-R55 production.
Another factor that could be contributing to the ineffectiveness of OAG in
stimulating soluble receptor production is the inability of OAG to activate all isoforms
of pKC. Diacylglycerol analogs (like OAG) have been shown to selectively activate
certain pKC isoforms, such as Betaj and Betan (11). TPA activates all isoforms, with
the exception of sigma. It is possible that only certain isoforms influence TNF-R55
production by thyrocytes. Clearly, further studies are needed in this area.
There are two mechanisms by which soluble cytokine receptors are produced;
proteolytic cleavage of the extracellular domain of the cell surface receptor or by
secretion of truncated versions (3). Production of soluble TNF-a receptors by cells of
lymphoid origin has been demonstrated to be the result of proteolytic cleavage or
"shedding" (140-149). When shedding of the receptor occurs, there is a concomitant
loss of functional plasma membrane-associated receptors. In this study, we have seen
that diseased thyrocytes have a lower level of cell surface TNF-R55 than
non-diseased thyrocytes. Therefore, we attempted to confirm that TNF-R55

211
production by murine thyrocytes was through receptor shedding. This was done by
examining thyrocyte cell-surface TNF-R55 density after modulating pKC activity.
Our findings surprised us. When pKC activity was decreased in diseased thyrocytes
by treatment with Calphostin C, no change was observed in TNF-R55 cell-surface
density when compared to untreated diseased cells. We observed similar results in
TNF-R55 cell-surface levels of non-diseased thyrocytes after increasing pKC activity
with TPA. These results raised the intriguing possibility that the soluble form of
TNF-R55 may be secreted by murine thyrocytes instead of shed.
If murine thyrocytes were secreting the soluble form of TNF-R55, then this
soluble form should be present in the intracellular membranes (eg. endoplasmic
reticulum, Golgi, vesicles). We found such a form in the intracellular membranes of
diseased thyrocytes. When the intracellular membranes from diseased thyrocytes were
immunoprecipitated with anti-murine TNF-R55 and Western blotted, we found a
28kDa form which corresponded to the soluble form of TNF-R55. We also found a
SlkDa form, which could be the 28kDa form with a leader peptide attached. A leader
peptide would be necessary for passage through the endoplasmic reticulum and Golgi
apparatus (211). Additionally, a 45kDa form and a 41kDa form were seen. In normal
human urine two forms of soluble TNF-R55 have been reported, a 31--33kDa form
and a 48kDa form (231). The 48kDa form was found to be a minor constituent
(less than 5%) of the total soluble TNF-R55 isolated from urine. This larger form
was found to contain additional glycosylation (231). Therefore, it is possible that the
41kDa form we isolated from the intracellular membranes of diseased thyrocytes is
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also a more heavily glycosylated form of soluble TNF-R55. Though we have not
been able to detect this form in thyrocyte culture supernatants, it remains possible that
this from may be present but below detectable levels since the 45kDa form we
observed may be the 41kDa form with a leader peptide.
The presence of these truncated forms of TNF-R55 in the intracellular membranes
of diseased thyrocytes lend support to the conclusion that murine thyrocytes are
secreting the soluble form of TNF-R55. There is precedence for a single soluble
cytokine receptor being produced by both mechanisms. The soluble interleukin-6
(IL-6) receptor has been shown to be produced by proteolytic cleavage in COS-7
cells (232). However, in myeloma cells, soluble IL-6 receptors are synthesized from
a truncated version of the mRNA encoding the receptor's extracellular domain and
then subsequently secreted (141).
The possibility that soluble TNF-R55 is being secreted and not shed from the
cell-surface receptor has left us with the unanswered question of why plasma
membrane-associated TNF-R55 is reduced in diseased thyrocytes. We do not know if
this reduction is the result of decreased protein synthesis or an increase in plasma
membrane receptor turnover and degradation. Furthermore, membrane and secretory
proteins are sorted by entirely different pathways within the cell so they can be
influenced and controlled by different mechanisms. Our data indicates that the
enhanced pKC activity of diseased thyrocytes is not responsible for their decreased
plasma membrane TNF-R55 levels since modulating pKC activity did not alter
cell-surface receptor density. Therefore, other mechanisms must be involved.
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Tyrosine kinase activation may be a plausible mechanism since IL-6 has been
reported to alter TNF-a receptor protein and mRNA levels (233).
The final aspect of this study involves the sensitivity of diseased thyrocytes to the
cytotoxic action of TNF-a. TNF-a is cytotoxic to the rat thyroid epithelial cell line,
FRTL-5 (157). However, cultured thyrocytes from patients with Hashimoto's
thyroiditis were insensitive to its cytotoxic effects (158). It was possible that these
disparate reports could be the result of soluble TNF-a receptor production. Therefore,
in our study we minimized interference from soluble TNF-R55 by changing the media
before the addition of TNF-a to the cells. Regardless of these precautions, we found
that TNF-a was not cytotoxic to diseased and non-diseased murine thyrocytes.
This may be attributed to the presence of only one TNF-a receptor on murine thyroid
cells. It has been suggested that both receptors are necessary for cytotoxicity (134).
In addition, it should be noted that these results do not exclude the possible
necessity for synergism between TNF-a and other cytokines. These cytokines could
include interferon-gamma and IL-6, which have been known to act synergistically
with TNF-a (2,156).
The sensitivity of FRTL-5 cells could be explained by the use of Actinomycin D
to prevent cell division. Actinomycin D has been shown to enhance TNF-a
cytotoxicity, possibly through a synergistic activation of Phospholipase A2 (234).
We did not use such an agent in our studies for two reasons. First, we found that
Mitomycin C (an inhibitor of cell division like Actinomycin D) was toxic to our cells.
Second, we felt that results obtained through the use of these agents would have little
bearing on the in vivo situation.
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In summary, we have found that autoimmune-diseased thyroid cells from
MRL-lpr/lpr mice produce soluble TNF-R55. The production of soluble TNF-R55 is
related to the enhanced pKC activity in the diseased thyrocytes. Furthermore,
the production of soluble TNF-R55 was not due to proteolytic cleavage of the
cell-surface receptor (shedding) but through secretion of a truncated version
of the receptor.

CHAPTERS
CONCLUSIONS

We have clearly established MRL-lpr/lpr mice as a model of spontaneous
autoimmune thyroiditis. In fact, these mice develop an autoimmune thyroiditis that is
strikingly similar to human Hashimoto's thyroiditis, making these mice an excellent
model for use in the studies that comprise this dissertation. As expected, we began
our work with an hypothesis. Our original hypothesis was: physical disruption during
autoimmune disease (thyroiditis) causes a loss of cell-cell communication which
results in tissue destruction through an increased sensitivity to the cytotoxic actions of
TNF-a. The first part of this hypothesis was supported. We did find reduced
Cx43-mediated intercellular communication in autoimmune-diseased thyrocytes.
Cx43 is the principle Cx found in monolayers of cultured thyrocytes. However, this
loss of communication was not due to physical disruption since it also persisted in
culture, wherein physical contact was re-established. Additionally, we saw disruption
of communication in thyroids from 5 month old MRL-lpr/lpr mice. At this age, the
thyroids have extensive lymphocytic infiltration but little, if any, fibrosis. This led
us to look for other possible mechanisms which could explain the decreased
cell-cell communication.
The search ended with the observation that diseased thyroid cells appear to have
accelerated growth relative to non-diseased cells. Though we have yet to fully
document this observation, it did suggest an answer since pKC is a stimulator of
thyroid cell division (201). Moreover, pKC has also been shown by us and others to
down-regulate Cx43-mediated cell-cell communication (113,166,191,199).
215
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We have shown that pKC affects Cx43-mediated communication at several levels.
PKC closes existing channels in the plasma membrane, which results in eventual
turnover of the protein. Furthermore, no new Cx43 gap junctions are inserted into the
plasma membrane. We speculate that this is the result of pKC-induced
conformational changes that prohibit insertion. Additionally, activation of pKC
reduces Cx43 mRNA levels which could lead to a reduction in protein levels.
Therefore, we measured pKC activity in non-diseased and diseased thyrocytes and
found it to be increased in diseased thyroid cells. We found that the elevated pKC
activity in diseased thyrocytes was responsible for their reduced Cx43-mediated
communication. We also found that pKC could decrease T4 release. The mechanism
by which pKC accomplishes this decrease involves cell-cell communication.
These findings are significant since they suggest that the diseased thyrocytes have
been altered and this alteration persists under conditions where lymphocytes are absent
(culture). Therefore once these changes are initiated by immune components, these
components are no longer necessary to reduce thyroid function (decreased T4 release).
This is contrary to the accepted model for reduced thyroid function during thyroiditis
(34). In the accepted model, altered thyroid function, as indicated by reduced thyroid
hormone secretion, is,the result of tissue destruction by components of the immune
response (34). Under this model the tissue is assumed to be otherwise normal (1,34).
After successfully demonstrating decreased intercellular communication in diseased
thyrocytes, we progressed to the second half of the hypothesis. This part of the
hypothesis involved increased sensitivity to TNF-a-induced cytotoxicity due to
decreased cell-cell communication. This part of the hypothesis could not be
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substantiated. TNF-a was found not to be directly cytotoxic to diseased thyrocytes,
regardless of their loss of intercellular communication. This may be due to the
presence of only one TNF-a receptor, TNF-R55, on thyrocytes. It has been
suggested that both receptors are required for cytotoxicity to occur (134).
Though not directly cytotoxic, TNF-a may be a contributor in the initial
development of hypothyroidism during autoimmune thyroiditis since it has been
reported to adversely effect thyroid function (decrease T4 release) (153,154).
However, it is unlikely that TNF-a is contributing latter in the disease. There are two
reasons for this conclusion. First, the increased pKC activity in the diseased
thyrocytes appears to be sufficient to decrease T4 release. Second, we have found that
diseased thyrocytes produce soluble TNF-a receptors (the soluble form of TNF-R55)
which could potentially inhibit TNF-a activity through competitive binding.
The discovery of the production of soluble TNF-a receptors by diseased
thyrocytes proved interesting since it was linked to the aberrant pKC activity.
We have found that the increased pKC activity in the diseased thyrocytes is
responsible for the increased production of soluble TNF-R55 by these cells. This was
expected since pKC has previously been reported to increase soluble TNF-a receptor
production (140,146-148). What was unexpected, and a surprising discovery, was the
mechanism by which the soluble TNF-R55 was being produced by thyrocytes.
Soluble TNF-a receptor production has generally been believed to be by proteolytic
cleavage of the cell-surface receptor. The studies that have led to this conclusion
have utilized mostly cells and cell lines of lymphoid origin (140,146-148).
We, however, have evidence that suggests that murine thyrocytes may be secreting the
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soluble form of TNF-R55 instead of shedding it. To the best of our knowledge, we
are the first to report this.

A. Significance

The findings presented in this dissertation are significant in that they have
important implications for potential treatment modalities. Currently, treatment for
autoimmune thyroiditis involves obstruction of the autoimmune response, in order to
prevent further tissue destruction, and/or the administration of exogenous thyroid
hormones (34). It is generally believed that if tissue destruction could be stopped and
inflammatory mediators removed or inhibited then thyroid function would be restored.
However, our finding indicate that this would not be sufficient since the cause of the
decrease in thyroid function is intrinsic to the diseased thyrocytes (increased pKC
activity) and no longer dependent upon the immune response. Therefore, in order to
restore thyroid function it would be necessary to reverse the aberrancies within the
diseased thyrocytes, ie. decrease the elevated pKC activity.
The use of pKC inhibitors as a treatment for disease is not completely novel.
Currently, several pKC inhibitors are either being considered or are in clinical trials as
treatments for several types of carcinomas (235-239). It is possible that these
inhibitors could be adapted for use in the treatment of autoimmune thyroiditis.
Research will be needed to find a delivery system for these drugs that will target
specifically the thyroid and also be easily administered. Additionally, treatment for
autoimmune thyroiditis will still need to include anti-inflammatory agents to
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prevent or slow the fibrosis that occurs as the disease progresses. By combining
anti-inflammatory drugs with pKC inhibitors it may be possible to successfully restore
normal function to autoimmune-diseased thyroids.

B. Future Investigations

Future work that will extend from this dissertation will involve the mechanisms
responsible for the increased pKC activity in the thyrocytes from the diseased mice.
We have already found increased protein levels of several pKC isoforms in Lewis rats
with adjuvant-thyroglobulin induced thyroiditis (manuscript in preparation). We are
in the process of determining if these isoforms are also elevated in diseased mouse
thyroids. The cause of the elevation in pKC protein levels will also be investigated.
At this time we do not know if there is an increase in protein stability or an actual
increase in pKC isoform protein synthesis. Future investigations will be done to
determine which is occurring.
Investigations designed to isolate the secretory pathway(s) used for soluble
TNF-R55 secretion will also be conducted. In endocrine cells, dense core granules
(DCGs) store secretory proteins, peptides and small molecules (240). Therefore,
investigations will begin with the isolation of DCGs and the analysis of their content
to determine if the soluble form of TNF-R55 is present. Additionally, we will search
for a truncated TNF-R55 mRNA which encodes the soluble form of TNF-R55 in the
diseased murine thyrocytes. Future investigations will also be concerned with
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unraveling the mechanisms responsible for the decreased level of plasma
membrane-associated TNF-R55 on these cells.
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